Note: Descriptions are shown in the official language in which they were submitted.
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
Field of the Invention
The present invention relates to compositions and methods useful for the
diagnosis and treatment of
immune related diseases.
Background of the Invention
Immune related and inflammatory diseases are the mmifestation or consequence
of fairly complex,
often multiple interconnected biological pathways which in normal physiology
are critical to respond to
insult or injury, initiate repair from insult or injury, and mount innate and
acquired defense against foreign
organisms. Disease or pathology occurs when these normal physiological
pathways cause additional insult
or injury either as directly related to the intensity of the response, as a
consequence of abnormal regulation
or excessive stimulation, as a reaction to self, or as a combination of these.
Though the genesis of these diseases often involves multistep pathways and
often multiple different
biological systems/pathways, intervention at critical points in one or more of
these pathways can have an
ameliorative or therapeutic effect. Therapeutic intervention can occur by
either antagonism of a detrimental
process/pathway or stimulation of a beneficial process/pathway.
Many immune related diseases are known and have been extensively studied. Such
diseases
include immune-mediated inflammatory diseases, non-immune-mediated
inflammatory diseases, infectious
diseases, immunodeficiency diseases, neoplasia, etc.
T lymphocytes (T cells) are an important component of a mammalian immune
response. T cells
recognize antigens which are associated with a self molecule encoded by genes
within the major
histocompatibility complex (MHC). The antigen may be displayed together with
MHC molecules on the
surface of antigen presenting cells, virus infected cells, cancer cells,
grafts, etc. The T cell system eliminates
these altered cells which pose a health threat to the host mammal. T cells
include helper T cells and
cytotoxic T cells. Helper T cells proliferate extensively following
recognition of an antigen -MHC complex
on an antigen presenting cell. Helper T cells also secrete a variety of
cytokines, i.e., lymphokines, which
play a central role in the activation of B cells, cytotoxic T cells and a
variety of other cells which participate
in the immune response.
A central event in both humoral and cell mediated immune responses is the
activation and clonal
expansion of helper T cells. Helper T cell activation is initiated by the
interaction of the T cell receptor
(TCR) - CD28 complex with an antigen-MHC on the surface of an antigen
presenting cell. This interaction
mediates a cascade of biochemical events that induce the resting helper T cell
to enter a cell cycle (the GO to
G1 transition) and results in the expression of a high affinity receptor for
IL-2 and sometimes IL-4. The
activated T cell progresses through the cycle proliferating and
differentiating into memory cells or effector
cells.
In addition to the signals mediated through CD28 [Carreno et al., (2002) Annu
Rev Immunol 20:
29-53], the molecule SLAM is also able to provide the second signal for co-
stimulation of T cells necessary
1
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
for proliferation [Aversa et al., (1997) J Immunol 158(9): 4036-4044, Aversa
et al., (1997) Immunol Cell
B_iol 75(2): 202-205]. SLAM is a member of the family of molecules that
contain extracelluar Ig-like
repeats and also contain a SAP intracellular binding site characterized by the
motif TxYxxV/I. Tyrosine
phosphorylation of this motif greatly increases the binding of SAP with SLAM.
As SAP is associated with
X-linked lymphoproliferative disease, a greater understanding of the SAP/SLAM
interaction may lead to
further insights into treatment of this disease [Howie et al, (2002) Blood
99(3): 957-965, Latour et al., 2001,
Nat Immuno 2(8): 681-690, Morra et al. 2001 J Biol Chem 276(39): 36809-36816,
Nichols et al., 2001 Nat
Immnol 2(8): 665-666].
SLAM has been implicated in Thl cell response, suggesting that this molecule
may play a role in
inflammation and autoimmune diseases [Cocks et al., (1995) Nature 376 (6537):
260-263, Aversa et al.,
(1997) Immunol Cell Bio 75(2): 202-205]. SLAM and CD3 crosslinking on the
surface of T cells induces
proliferation of T cells and an increase in Interferon gamma (IFN-y)
production. The reasons above lead to
the search and discovery of a new member of the SLAM family, PR020080. It is
shown herein, that
PR020080 has homology to SLAM, and like SLAM, has expression in B cells, T
cells and memory T cells.
PRO20080 is upregulated on activated T cells, exhibits homotypic binding,
contains SAP binding motifs and
interacts with SAP in T cells. PR020080 plus CD3 co-stimulation induces the
proliferation of T cells and
increases the production and secretion of IFN-y. Evidence is also shown for
PR020080 in the Thl mediated
delayed-type hypersensitivity response, thus making PR020080 a potential
target for treatement of
inflammation and Thl mediated autoimmune diseases.
Summary of the Invention
A. Embodiments
The present invention concerns compositions and methods useful for the
diagnosis and treatment of
immune related disease in mammals, including humans. The present invention is
based on the identification
of PRO20080 (including agonist and antagonist antibodies) which either
stimulate or inhibit the immune
response in mammals. Immune related diseases can be treated by suppressing or
enhancing the immune
response. Molecules that enhance the immune response stimulate or potentiate
the immune response to an
antigen. Molecules which stimulate the immune response can be used
therapeutically where enhancement of
the immune response would be beneficial. Alternatively, molecules that
suppress the immune response
attenuate or reduce the immune response to an antigen (e.g., neutralizing
antibodies) can be used
therapeutically where attenuation of the immune response would be beneficial
(e.g., inflammation).
Accordingly, the PR020080 polypeptides, agonists and antagonists thereof are
also useful to prepare
medicines and medicaments for the treatment of immune-related and inflammatory
diseases. In a specific
aspect, such medicines and medicaments comprise a therapeutically effective
amount of a PR020080
polypeptide, agonist or antagonist thereof with a pharmaceutically acceptable
carrier. Preferably, the
admixture is sterile.
In a further embodiment, the invention concerns a method of identifying
agonists or antagonists to a
PR020080 polypeptide which comprises contacting the PRO20080 polypeptide with
a candidate molecule
and monitoring a biological activity mediated by said PRO20080 polypeptide.
Preferably, the PRO20080
polypeptide is a native sequence PR020080 polypeptide. In a specific aspect,
the PR020080 agonist or
2
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
antagonist is an anti-PR020080 antibody.
In another embodiment, the invention concerns a composition of matter
comprising a PR020080
polypeptide or an agonist or antagonist antibody which binds the polypeptide
in admixture with a carrier or
excipient. In one aspect, the composition comprises a therapeutically
effective amount of the polypeptide or
antibody. In another aspect, when the composition comprises an immune
stimulating molecule, the
composition is useful for: (a) stimulating or enhancing an immune response in
a mammal in need thereof,
(b) increasing the proliferation of T-lymphocytes in a mammal in need thereof
in response to an antigen, (c)
stimulating the activity of T-lymphocytes (d) production of INF-'y. In another
aspect, the composition
comprises a further active ingredient, which may, for example, be a further
antibody or a cytotoxic or
chemotherapeutic agent. Preferably, the composition is sterile.
In another embodiment, the invention concerns a method of treating an immune
related disorder in
a mammal in need thereof, comprising administering to the mammal an effective
amount of a PR020080
polypeptide, an agonist thereof, or an antagonist thereto. In a preferred
aspect, the immune related disorder
is selected from the group consisting of: systemic lupus erythematosis,
rheumatoid arthritis, osteoarthritis,
juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
idiopathic inflammatory myopathies,
Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic
anemia, autoimmune
thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal
disease, demyelinating diseases of
the central and peripheral nervous systems such as multiple sclerosis,
idiopathic demyelinating
polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
demyelinating polyneuropathy,
hepatobiliary diseases such as infectious, autoimmune chronic active
hepatitis, primary biliary cirrhosis,
granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel
disease, gluten-sensitive
enteropathy, and Whipple's disease, autoimmune or immune-mediated skin
diseases including bullous skin
diseases, erythema multiforme and contact dermatitis, psoriasis, allergic
diseases such as asthma, allergic
rhinitis, atopic dermatitis, food hypersensitivity and urticaria, immunologic
diseases of the lung such as
eosinophilic pneumonias, idiopathic pulmonary fibrosis and hypersensitivity
pneumonitis, transplantation
associated diseases including graft rejection and graft -versus-host-disease.
In another embodiment, the invention provides an antibody which specifically
binds to any of the
above or below described polypeptides. Optionally, the antibody is a
monoclonal antibody, humanized
antibody, antibody fragment or single-chain antibody. In one aspect, the
present invention concerns an
isolated antibody which binds a PRO20080 polypeptide. In another aspect, the
antibody mimics the activity
of a PR020080 polypeptide (an agonist antibody) or conversely the antibody
inhibits or neutralizes the
activity of a PR020080 polypeptide (an antagonist antibody). In another
aspect, the antibody is a
monoclonal antibody, which preferably has nonhuman complementarity determining
region (CDR) residues
and human framework region (FR) residues. The antibody may be labeled and may
be immobilized on a
solid support. In a further aspect, the antibody is an antibody fragment, a
monoclonal antibody, a single-
chain antibody, or an anti-idiotypic antibody.
In yet another embodiment, the present invention provides a composition
comprising an anti-
PR020080 antibody in admixture with a pharmaceutically acceptable carrier. In
one aspect, the
composition comprises a therapeutically effective amount of the antibody.
Preferably, the composition is
sterile. The composition may be administered in the form of a liquid
pharmaceutical formulation, which
3
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
may be preserved to achieve extended storage stability. Alternatively, the
antibody is a monoclonal
antibody, an antibody fragment, a humanized antibody, or a single-chain
antibody.
In a further embodiment, the invention concerns an article of manufacture,
comprising:
(a) a composition of matter comprising a PR020080 polypeptide or agonist or
antagonist
thereof;
(b) a container containing said composition; and
(c) a label affixed to said container, or a package insert included in said
container referring to
the use of said PR020080 polypeptide or agonist or antagonist thereof in the
treatment of an immune related
disease. The composition may comprise a therapeutically effective amount of
the PR020080 polypeptide or
the agonist or antagonist thereof.
In yet another embodiment, the present invention concerns a method of
diagnosing an immune
related disease in a mammal, comprising detecting the level of expression of a
gene encoding a PR020080
polypeptide (a) in a test sample of tissue cells obtained from the mammal, and
(b) in a control sample of
known normal tissue cells of the same cell type, wherein a higher or lower
expression level in the test
sample as compared to the control sample indicates the presence of immune
related disease in the mammal
from which the test tissue cells were obtained.
In another embodiment, the present invention concerns a method of diagnosing
an immune disease
in a mammal, comprising (a) contacting an anti-PR020080 antibody with a test
sample of tissue cells
obtained from the mammal, and (b) detecting the formation of a complex between
the antibody and a
PR020080 polypeptide, in the test sample; wherein the formation of said
complex is indicative of the
presence or absence of said disease. The detection may be qualitative or
quantitative, and may be performed
in comparison with monitoring the complex formation in a control sample of
known normal tissue cells of
the same cell type. A larger quantity of complexes formed in the test sample
indicates the presence or
absence of an immune disease in the mammal from which the test tissue cells
were obtained. The antibody
preferably carries a detectable label. Complex formation can be monitored, for
example, by light
microscopy, flow cytometry, fluorimetry, or other techniques known in the art.
The test sample is usually
obtained from an individual suspected of having a deficiency or abnormality of
the immune system.
In another embodiment, the invention provides a method for determining the
presence of a
PRO20080 polypeptide in a sample comprising exposing a test sample of cells
suspected of containing the
PR020080 polypeptide to an anti-PR020080 antibody and determining the binding
of said antibody to said
cell sample. In a specific aspect, the sample comprises a cell suspected of
containing the PR020080
polypeptide and the antibody binds to the cell. The antibody is preferably
detectably labeled and/or bound to
a solid support.
In another embodiment, the present invention concerns an immune-related
disease diagnostic kit,
comprising an anti-PR020080 antibody and a carrier in suitable packaging. The
kit preferably contains
instructions for using the antibody to detect the presence of the PR020080
polypeptide. Preferably the
carrier is pharmaceutically acceptable.
In another embodiment, the present invention concerns a diagnostic kit,
containing an anti-
PR020080 antibody in suitable packaging. The kit preferably contains
instructions for using the antibody to
detect the PR020080 polypeptide.
4
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
In another embodiment, the invention provides a method of diagnosing an immune-
related disease
in a mammal which comprises detecting the presence or absence or a PR020080
polypeptide in a test
sample of tissue cells obtained from said mammal, wherein the presence or
absence of the PR020080
polypeptide in said test sample is indicative of the presence of an immune-
related disease in said mammal.
In another embodiment, the present invention concerns a method for identifying
an agonist of a
PR020080 polypeptide comprising:
(a) contacting cells and a test compound to be screened under conditions
suitable for the induction
of a cellular response normally induced by a PR020080 polypeptide; and
(b) determining the induction of said cellular response to determine if the
test compound is an
effective agonist, wherein the induction of said cellular response is
indicative of said test compound being an
effective agonist.
In another embodiment, the invention concerns a method for identifying a
compound capable of
inhibiting the activity of a PR020080 polypeptide comprising contacting a
candidate compound with a
PR020080 polypeptide under conditions and for a time sufficient to allow these
two components to interact
and determining whether the activity of the PRO20080 polypeptide is inhibited.
In a specific aspect, either
the candidate compound or the PR020080 polypeptide is immobilized on a solid
support. In another aspect,
the non-immobilized component carries a detectable label. In a preferred
aspect, this .method comprises the
steps of:
(a) contacting cells and a test compound to be screened in the presence of a
PR020080 polypeptide
under conditions suitable for the induction of a cellular response normally
induced by a PR020080
polypeptide; and
(b) determining the induction of said cellular response to determine if the
test compound is an
effective antagonist.
In another embodiment, the invention provides a method for identifying a
compound that inhibits
the expression of a PR020080 polypeptide in cells that normally express the
polypeptide, wherein the
method comprises contacting the cells with a test compound and determining
whether the expression of the
PR020080 polypeptide is inhibited. In a preferred aspect, this method
comprises the steps of:
(a) contacting cells and a test compound to be screened under conditions
suitable for allowing
expression of the PR020080 polypeptide; and
(b) determining the inhibition of expression of said polypeptide.
In yet another embodiment, the present invention concerns a method for
treating an immune-related
disorder in a mammal that suffers therefrom comprising administering to the
mammal a nucleic acid
molecule that codes for either (a) a PR020080 polypeptide, (b) an agonist of a
PR020080 polypeptide or (c)
an antagonist of a PR020080 polypeptide, wherein said agonist or antagonist
may be an anti-PRO20080
antibody. In a preferred embodiment, the mammal is human. In another preferred
embodiment, the nucleic
acid is administered via ex vivo gene therapy. In a further preferred
embodiment, the nucleic acid is
comprised within a vector, more preferably an adenoviral, adeno-associated
viral, lentiviral or retroviral
vector.
In yet another aspect, the invention provides a recombinant viral particle
comprising a viral vector
consisting essentially of a promoter, nucleic acid encoding (a) a PR020080
polypeptide, (b) an agonist
5
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
polypeptide of a PR020080 polypeptide, or (c) an antagonist polypeptide of a
PR020080 polypeptide, and a
signal sequence for cellular secretion of the polypeptide, wherein the viral
vector is in association with viral
structural proteins. Preferably, the signal sequence is from a mammal, such as
from a native PR020080
polypeptide.
In a still further embodiment, the invention concerns an ex vivo producer cell
comprising a nucleic
acid construct that expresses retroviral structural proteins and also
comprises a retroviral vector consisting
essentially of a promoter, nucleic acid encoding (a) a PR020080 polypeptide,
(b) an agonist polypeptide of a
PR020080 polypeptide or (c) an antagonist polypeptide of a PRO20080
polypeptide, and a signal sequence
for cellular secretion of the polypeptide, wherein said producer cell packages
the retroviral vector in
association with the structural proteins to produce recombinant retroviral
particles.
In a still further embodiment, the invention provides a method of increasing
the activity of T-
lymphocytes in a mammal comprising administering to said mammal (a) a PR020080
polypeptide, (b) an
agonist of a PR020080 polypeptide, whey ein the activity of T-lymphocytes in
the mammal is increased.
In a still further embodiment, the invention provides a method of decreasing
the activity of T
lymphocytes in a mammal comprising administering to said mammal an antagonist
of a PR020080
polypeptide, wherein the activity of T-lymphocytes in the mammal is decreased.
In a still further embodiment, the invention provides a method of increasing
the proliferation of T-
lymphocytes in a mammal comprising administering to said mammal (a) a PR020080
polypeptide, (b) an
agonist of a PR020080 polypeptide, wherein the proliferation of T-lymphocytes
in the mammal is increased.
In a still further embodiment, the invention provides a method of decreasing
the proliferation of T-
lymphocytes in a mammal comprising administering to said mammal an antagonist
of a PR020080
polypeptide, wherein the proliferation of T-lymphocytes in the mammal is
decreased.
In a still further embodiment, the invention provides a method of decreasing
the Thl mediated
delayed type hypersensitive response in a mammal comprising administering to
said mammal an mtagonist
of a PR020080 polypeptide, wherein the Thl mediated delayed type
hypersensitive response is decreased.
In a still further embodiment, the invention provides a method of inhibiting
the inflammatory
immune response, said method comprising contacting a T cell line containing a
reporter construct with a
PR020080 antagonist thereof, wherein said inflammatory immune response is
inhibited and measured.
B. Additional Embodiments
In other embodiments of the present invention, the invention provides vectors
comprising DNA
encoding any of the herein described polypeptides. Host cell comprising any
such vector are also provided.
By way of example, the host cells may be CHO cells, E. coli, or yeast. A
process for producing any of the
herein described polypeptides is further provided and comprises culturing host
cells under conditions
suitable for expression of the desired polypeptide and recovering the desired
polypeptide from the cell
culture.
In other embodiments, the invention provides chimeric molecules comprising any
of the herein
described polypeptides fused to a heterologous polypeptide or amino acid
sequence. Example of such
chimeric molecules comprise any of the herein described polypeptides fused to
an epitope tag sequence or a
Fc region of an immunoglobulin.
6
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
In another embodiment, the invention provides an antibody which specifically
binds to any of the
above or below described polypeptides. Optionally, the antibody is a
monoclonal antibody, humanized
antibody, antibody fragment or single-chain antibody.
In yet other embodiments, the invention provides oligonucleotide probes useful
for isolating
genomic and cDNA nucleotide sequences or as antisense probes, wherein those
probes may be derived from
any of the above or below described nucleotide sequences.
In other embodiments, the invention provides an isolated nucleic acid molecule
comprising a
nucleotide sequence that encodes a PR020080 polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nucleotide
sequence having at least
about 80% nucleic acid sequence identity, alternatively at least about 81%
nucleic acid sequence identity,
alternatively at least about 82% nucleic acid sequence identity, alternatively
at least about 83% nucleic acid
sequence identity, alternatively at least about 84% nucleic acid sequence
identity, alternatively at least about
85% nucleic acid sequence identity, alternatively at least about 86% nucleic
acid sequence identity,
alternatively at least about 87% nucleic acid sequence identity, alternatively
at least about 88% nucleic acid
sequence identity, alternatively at least about 89% nucleic acid sequence
identity, alternatively at least about
90% nucleic acid sequence identity, alternatively at least about 91% nucleic
acid sequence identity,
alternatively at least about 92% nucleic acid sequence identity, alternatively
at least about 93% nucleic acid
sequence identity, alternatively at least about 94% nucleic acid sequence
identity, alternatively at least about
95% nucleic acid sequence identity, alternatively at least about 96% nucleic
acid sequence identity,
alternatively at least about 97% nucleic acid sequence identity, alternatively
at least about 98% nucleic acid
sequence identity and alternatively at least about 99% nucleic acid sequence
identity to (a) a DNA molecule
encoding a PR020080 polypeptide having a full-length amino acid sequence as
disclosed herein, an amino
acid sequence lacking the signal peptide as disclosed herein, an extracellular
domain of a transmembrane
protein, with or without the signal peptide, as disclosed herein or any other
specifically defined fragment of
the full-length amino acid sequence as disclosed herein, or (b) the complement
of the DNA molecule of (a).
In other aspects, the isolated nucleic acid molecule comprises a nucleotide
sequence having at least
about 80% nucleic acid sequence identity, alternatively at least about 81%
nucleic acid sequence identity,
alternatively at least about 82% nucleic acid sequence identity, alternatively
at least about 83% nucleic acid
sequence identity, alternatively at least about 84% nucleic acid sequence
identity, alternatively at least about
85% nucleic acid sequence identity, alternatively at least about 86% nucleic
acid sequence identity,
alternatively at least about 87% nucleic acid sequence identity, alternatively
at least about 88% nucleic acid
sequence identity, alternatively at least about 89% nucleic acid sequence
identity, alternatively at least about
90% nucleic acid sequence identity, alternatively at least about 91% nucleic
acid sequence identity,
alternatively at least about 92% nucleic acid sequence identity, alternatively
at least about 93% nucleic acid
sequence identity, alternatively at least about 94% nucleic acid sequence
identity, alternatively at least about
95% nucleic acid sequence identity, alternatively at least about 96% nucleic
acid sequence identity,
alternatively at least about 97% nucleic acid sequence identity, alternatively
at least about 98% nucleic acid
sequence identity and alternatively at least about 99% nucleic acid sequence
identity to (a) a DNA molecule
comprising the coding sequence of a full-length PRO20080 polypeptide cDNA as
disclosed herein, the
coding sequence of a PR020080 polypeptide lacking the signal peptide as
disclosed herein, the coding
7
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
sequence of an extracellular domain of a transmembrane PR020080 polypeptide,
with or without the signal
peptide, as disclosed herein or the coding sequence of any other specifically
defined fragment of the full-
length amino acid sequence as disclosed herein, or (b) the complement of the
DNA molecule of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule
comprising a
nucleotide sequence having at least about 80% nucleic acid sequence identity,
alternatively at least about
81% nucleic acid sequence identity, alternatively at least about 82% nucleic
acid sequence identity,
alternatively at least about 83% nucleic acid sequence identity, alternatively
at least about 84% nucleic acid
sequence identity, alternatively at least about 85% nucleic acid sequence
identity, alternatively at least about
86% nucleic acid sequence identity, alternatively at least about 87% nucleic
acid sequence identity,
alternatively at least about 88% nucleic acid sequence identity, alternatively
at least about 89% nucleic acid
sequence identity, alternatively at least about 90% nucleic acid sequence
identity, alternatively at least about
91% nucleic acid sequence identity, alternatively at least about 92% nucleic
acid sequence identity,
alternatively at least about 93% nucleic acid sequence identity, alternatively
at least about 94% nucleic acid
sequence identity, alternatively at least about 95% nucleic acid sequence
identity, alternatively at least about
96% nucleic acid sequence identity, alternatively at least about 97% nucleic
acid sequence identity,
alternatively at least about 98% nucleic acid sequence identity and
alternatively at least about 99% nucleic
acid sequence identity to (a) a DNA molecule that encodes the same mature
polypeptide encoded by any of
the human protein cDNAs deposited with the ATCC as disclosed herein, or (b)
the complement of the DNA
molecule of (a).
Another aspect the invention provides an isolated nucleic acid molecule
comprising a nucleotide
sequence encoding a PR020080 polypeptide which is either transmembrane domain-
deleted or
transmembrane domain-inactivated, or is complementary to such encoding
nucleotide sequence, wherein the
transmembrane domains) of such polypeptide are disclosed herein. Therefore,
soluble extracellular
domains of the herein described PR020080 polypeptides are contemplated.
Another embodiment is directed to fragments of a PR020080 polypeptide coding
sequence, or the
complement thereof, that may find use as, for example, hybridization probes,
for encoding fragments of a
PR020080 polypeptide that may optionally encode a polypeptide comprising a
binding site for an anti-
PR020080 antibody or as antisense oligonucleotide probes. Such nucleic acid
fragments are usually at least
about 20 nucleotides in length, alternatively at least about 30 nucleotides in
length, alternatively at least
about 40 nucleotides in length, alternatively at least about 50 nucleotides in
length, alternatively at least
about 60 nucleotides in length, alternatively at least about 70 nucleotides in
length, alternatively at least
about 80 nucleotides in length, alternatively at least about 90 nucleotides in
length, alternatively at least
about 100 nucleotides in length, alternatively at least about 110 nucleotides
in length, alternatively at least
about 120 nucleotides in length, alternatively at least about 130 nucleotides
in length, alternatively at least
about 140 nucleotides in length, alternatively at least about 150 nucleotides
in length, alternatively at least
about 160 nucleotides in length, alternatively at least about 170 nucleotides
in length, alternatively at least
about 180 nucleotides in length, alternatively at least about 190 nucleotides
in length, alternatively at least
about 200 nucleotides in length, alternatively at least about 250 nucleotides
in length, alternatively at least
about 300 nucleotides in length, alternatively at least about 350 nucleotides
in length, alternatively at least
about 400 nucleotides in length, alternatively at least about 450 nucleotides
in length, alternatively at least
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
about 500 nucleotides in length, alternatively at least about 600 nucleotides
in length, alternatively at least
about 700 nucleotides in length, alternatively at least about 800 nucleotides
in length, alternatively at least
about 900 nucleotides in length and alternatively at least about 1000
nucleotides in length, wherein in this
context the term "about" means the referenced nucleotide sequence length plus
or minus 10% of that
referenced length. It is noted that novel fragments of a PR020080 polypeptide-
encoding nucleotide
sequence may be determined in a routine manner by aligning the PR020080
polypeptide-encoding
nucleotide sequence with other known nucleotide sequences using any of a
number of well known sequence
alignment programs and determining which PR020080 polypeptide-encoding
nucleotide sequence
fragments) are novel. All of such PR020080 polypeptide-encoding nucleotide
sequences are contemplated
herein. Also contemplated are the PR020080 polypeptide fragments encoded by
these nucleotide molecule
fragments, preferably those PR020080 polypeptide fragments that comprise a
binding site for an anti-
PR020080 antibody.
In another embodiment, the invention provides isolated PR020080 polypeptide
encoded by any of
the isolated nucleic acid sequences herein above identified.
In a certain aspect, the invention concerns an isolated PR020080 polypeptide,
comprising an amino
acid sequence having at least about 80% amino acid sequence identity,
alternatively at least about 81%
amino acid sequence identity, alternatively at least about 82% amino acid
sequence identity, alternatively at
least about 83% amino acid sequence identity, alternatively at least about 84%
amino acid sequence identity,
alternatively at least about 85% amino acid sequence identity, alternatively
at least about 86% amino acid
sequence identity, alternatively at least about 87% amino acid sequence
identity, alternatively at least about
88% amino acid sequence identity, alternatively at least about 89% amino acid
sequence identity,
alternatively at least about 90% amino acid sequence identity, alternatively
at least about 91% amino acid
sequence identity, alternatively at least about 92% amino acid sequence
identity, alternatively at least about
93% amino acid sequence identity, alternatively at least about 94% amino acid
sequence identity,
alternatively at least about 95% amino acid 'sequence identity, alternatively
at least about 96% amino acid
sequence identity, alternatively at least about 97% amino acid sequence
identity, alternatively at least about
98% amino acid sequence identity and alternatively at least about 99% amino
acid sequence identity to a
PR020080 polypeptide having a full-length amino acid sequence as disclosed
herein, an amino acid
sequence lacking the signal peptide as disclosed herein, an extracellular
domain of a transmembrane protein,
with or without the signal peptide, as disclosed herein or any other
specifically defined fragment of the full-
length amino acid sequence as disclosed herein.
In a further aspect, the invention concerns an isolated PR020080 polypeptide
comprising an amino
acid sequence having at least about 80% amino acid sequence identity,
alternatively at least about 81%
amino acid sequence identity, alternatively at least about 82% amino acid
sequence identity, alternatively at
least about 83% amino acid sequence identity, alternatively at least about 84%
amino acid sequence identity,
alternatively at least about 85% amino acid sequence identity, alternatively
at least about 86% amino acid
sequence identity, alternatively at least about 87% amino acid sequence
identity, alternatively at least about
88% amino acid sequence identity, alternatively at least about 89% amino acid
sequence identity,
alternatively at least about 90% amino acid sequence identity, alternatively
at least about 91% amino acid
sequence identity, alternatively at least about 92% amino acid sequence
identity, alternatively at least about
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
93% amino acid sequence identity, alternatively at least about 94% amino acid
sequence identity,
alternatively at least about 95% amino acid sequence identity, alternatively
at least about 96% amino acid
sequence identity, alternatively at least about 97% amino acid sequence
identity, alternatively at least about
98% amino acid sequence identity and alternatively at least about 99% amino
acid sequence identity to an
amino acid sequence encoded by any of the human protein cDNAs deposited with
the ATCC as disclosed
herein.
In a specific aspect, the invention provides an isolated PR020080 polypeptide
without the N-
terminal signal sequence and/or the initiating methionine and is encoded by a
nucleotide sequence that
encodes such an amino acid sequence as herein before described. Processes for
producing the same are also
herein described, wherein those processes comprise culturing a host cell
comprising a vector which
comprises the appropriate encoding nucleic acid molecule under conditions
suitable for expression of the
PR020080 polypeptide and recovering the PRO20080 polypeptide from the cell
culture.
Another aspect the invention provides an isolated PR020080 polypeptide which
is either
transmembrane domain-deleted or transmembrane domain-inactivated. Processes
for producing the same
are also herein described, wherein those processes comprise culturing a host
cell comprising a vector which
comprises the appropriate encoding nucleic acid molecule under conditions
suitable for expression of the
PR020080 polypeptide and recovering the PR020080 polypeptide from the cell
culture.
In yet another embodiment, the invention concerns agonists and antagonists of
a native PR020080
polypeptide as defined herein. In a particular embodiment, the agonist or
antagonist is an anti-PRO20080
antibody or a small molecule.
In a further embodiment, the invention concerns a method of identifying
agonists or antagonists to a
PR020080 polypeptide which comprise contacting the PR020080 polypeptide with a
candidate molecule
and monitoring a biological activity mediated by said PR020080 polypeptide.
Preferably, the PRO20080
polypeptide is a native PR020080 polypeptide.
In a still further embodiment, the invention concerns a composition of matter
comprising a
PR020080 polypeptide, or an agonist or antagonist of a PR020080 polypeptide as
herein described, or an
anti-PR020080 antibody, in combination with a carrier. Optionally, the carrier
is a pharmaceutically
acceptable carrier.
Another embodiment of the present invention is directed to the use of a
PR020080 polypeptide, or
an agonist or antagonist thereof as herein before described, or an anti-
PRO20080 antibody, for the
preparation of a medicament useful in the treatment of a condition which is
responsive to the PR020080
polypeptide, an agonist or antagonist thereof or an anti-PRO20080 antibody.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence
PR020080 cDNA,
wherein SEQ ID NO:l is a clone designated herein as "DNA161000-2896".
Figure 2 shows the amino acid sequence (SEQ ID N0:2) derived from the coding
sequence of SEQ
ID NO:1 shown in Figure 1.
Figure 3 shows a Northern Blot analysis of the expression of PR020080.
Figure 4 shows the expression of PR020080 in a panel of cell lines.
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Figure Sa shows the expression of PR020080 on human peripheral T cells.
Figure Sb shows high expression of PR020080 on CD4+ CD45R0+ memory Tcells.
Figure 6 shows an ELISA assay showing that labeled PR020080 can bind to bound
PR020080.
Figure 7 shows homotypic binding of PR020080 at the cell surface by
immunofluoresence.
Figure 8a shows the proliferation of T-cells and the production of INF-y when
T cells are
stimulated with anti-PR020080 antibody and anti-CD3 antibody.
Figure 8b shows the proliferation of T-cells and the production of INF-y when
T cells are
stimulated with PR020080-Fc fusion molecule.
Figure 9a shows the phosphorylated state of PR020080 and its association with
SAP.
Figure 9b shows a time course of phosphorylation of PR020080 upon co-
stimulation treatment and
addition of a cross linking antibody.
Figure 9c shows the phosphorylated state of PR020080 and its association with
SAP upon co-
stimulation.
Figure 10a shows the effect of the murine homologue of PR020080 on T cell
proliferation in vivo.
Figure l Ob shows the effect of the murine homologue of PR020080 on INF-'y
production in vivo.
Figure lOc shows the effect of murine homologue of PR020080 in a delayed-type
hypersensitivity
response as measured by ear swelling.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. Definitions
The terms "PR020080 polypeptide" and "PRO20080" as used herein encompass
native sequence
polypeptides and polypeptide variants (which are further defined herein). The
PR020080 polypeptides
described herein may be isolated from a variety of sources, such as from human
tissue types or from another
source, or prepared by recombinant or synthetic methods. The teen "PR020080
polypeptide" refers to each
individual PR020080/number polypeptide disclosed herein. All disclosures in
this specification which refer
to the "PR020080 polypeptide" refer to each of the polypeptides individually
as well as jointly. For
example, descriptions of the preparation of, purification of, derivation of,
formation of antibodies to or
against, administration of, compositions containing, treatment of a disease
with, etc., pertain to each
polypeptide of the invention individually. The term "PR020080 polypeptide"
also includes variants of the
PR020080 polypeptides disclosed herein.
A "native sequence PR020080 polypeptide" comprises a polypeptide having the
same amino acid
sequence as the corresponding PR020080 polypeptide derived from nature. Such
native sequence
PR020080 polypeptides can be isolated from nature or can be produced by
recombinant or synthetic means.
The term "native sequence PR020080 polypeptide" specifically encompasses
naturally-occurring'truncated
or secreted forms of the specific PR020080 polypeptide (e.g., an extracellular
domain sequence), naturally-
occurring variant forms (e.g., alternatively spliced forms) and naturally-
occurring allelic variants of the
polypeptide. In various embodiments of the invention, the native sequence
PRO20080 polypeptides
disclosed herein are mature or full-length native sequence polypeptides
comprising the full-length amino
acids sequences shown in the accompanying figures. Start and stop codons are
shown in bold font and
underlined in the figures. However, while the PR020080 polypeptide disclosed
in the accompanying figures
11
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
are shown to begin with methionine residues designated herein as amino acid
position 1 in the figures, it is
conceivable and possible that other methionine residues located either
upstream or downstream from the
amino acid position 1 in the figures may be employed as the starting amino
acid residue for the PRO20080
polypeptides.
The PRO20080 polypeptide "extracellular domain" or "ECD" refers to a form of
the PR020080
polypeptide which is essentially free of the transmembrane and cytoplasmic
domains. Ordinarily, a
PR020080 polypeptide ECD will have less than 1% of such transmembrane and/or
cytoplasmic domains
and preferably, will have less than 0.5% of such domains. It will be
understood that any transmembrane
domains identified for the PR020080 polypeptides of the present invention are
identified pursuant to criteria
routinely employed in the art for identifying that type of hydrophobic domain.
The exact boundaries of a
transmembrane domain may vary but most likely by no more than about 5 amino
acids at either end of the
domain as initially identified herein. Optionally, therefore, an extracellular
domain of a PR020080
polypeptide may contain from about 5 or fewer amino acids on either side of
the transmembrane
domain/extracellular domain boundary as identified in the Examples or
specification and such polypeptides,
with or without the associated signal peptide, and nucleic acid encoding them,
are contemplated by the
present invention.
The approximate location of the "signal peptides" of the various PR020080
polypeptides disclosed
herein are shown in the present specification and/or the accompanying figures.
It is noted, however, that the
C-terminal boundary of a signal peptide may vary, but most likely by no more
than about 5 amino acids on
either side of the signal peptide C-terminal boundary as initially identified
herein, wherein the C-terminal
boundary of the signal peptide may be identified pursuant to criteria
routinely employed in the art for
identifying that type of amino acid sequence element (e.g., Nielsen et al.,
Prot. Eng. 10:1-6 (1997) and von
Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also
recognized that, in some cases,
cleavage of a signal sequence from a secreted polypeptide is not entirely
uniform, resulting in more than one
secreted species. These mature polypeptides, where the signal peptide is
cleaved within no more than about
5 amino acids on either side of the C-terminal boundary of the signal peptide
as identified herein, and the
polynucleotides encoding them, are contemplated by the present invention.
"PR020080 polypeptide variant" means an active PR020080 polypeptide as defined
above or
below having at least about 80% amino acid sequence identity with a full-
length native sequence PR020080
polypeptide sequence as disclosed herein, a PR020080 polypeptide sequence
lacking the signal peptide as
disclosed herein, an extracellular domain of a PR020080 polypeptide, with or
without the signal peptide, as
disclosed herein or any other fragment of a full-length PR020080 polypeptide
sequence as disclosed herein.
Such PR020080 polypeptide variants include, for instance, PR020080
polypeptides wherein one or more
amino acid residues are added, or deleted, at the N- or C-terminus of the full-
length native amino acid
sequence. Ordinarily, a PR020080 polypeptide variant will have at least about
80% amino acid sequence
identity, alternatively at least about 81% amino acid sequence identity,
alternatively at least about 82%
amino acid sequence identity, alternatively at least about 83% amino acid
sequence identity, alternatively at
least about 84% amino acid sequence identity, alternatively at least about 85%
amino acid sequence identity,
alternatively at least about 86% amino acid sequence identity, alternatively
at least about 87% amino acid
sequence identity, alternatively at least about 88% amino acid sequence
identity, alternatively at least about
12
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
89% amino acid sequence identity, alternatively at least about 90% amino acid
sequence identity,
alternatively at least about 91% amino acid sequence identity, alternatively
at least about 92% amino acid
sequence identity, alternatively at least about 93% amino acid sequence
identity, alternatively at least about
94% amino acid sequence identity, alternatively at least about 95% amino acid
sequence identity,
alternatively at least about 96% amino acid sequence identity, alternatively
at least about 97% amino acid
sequence identity, alternatively at least about 98% amino acid sequence
identity and alternatively at least
about 99% amino acid sequence identity to a full-length native sequence
PR020080 polypeptide sequence as
disclosed herein, a PR020080 polypeptide sequence lacking the signal peptide
as disclosed herein, an
extracellular domain of a PRO20080 polypeptide, with or without the signal
peptide, as disclosed herein or
any other specifically defined fragment of a full-length PR020080 polypeptide
sequence as disclosed herein.
Ordinarily, PR020080 variant polypeptides are at least about 10 amino acids in
length, alternatively at least
about 20 amino acids in length, alternatively at least about 30 amino acids in
length, alternatively at least
about 40 amino acids in length, alternatively at least about 50 amino acids in
length, alternatively at least
about 60 amino acids in length, alternatively at least about 70 amino acids in
length, alternatively at least
about 80 amino acids in length, alternatively at least about 90 amino acids in
length, alternatively at least
about 100 amino acids in length, alternatively at least about 150 amino acids
in length, alternatively at least
about 200 amino acids in length, alternatively at least about 300 amino acids
in length, or more.
"Percent (%) amino acid sequence identity" with respect to the PR020080
polypeptide sequences
identified herein is defined as the percentage of amino acid residues in a
candidate sequence that are
identical with the amino acid residues in the specific PR020080 polypeptide
sequence, after aligning the
sequences and introducing gaps, if necessary, to achieve the maximum percent
sequence identity, and not
considering any conservative substitutions as part of the sequence identity.
Alignment for purposes of
determining percent amino acid sequence identity can be achieved in various
ways that are within the skill in
the art, for instance, using publicly available computer software such as
BLAST, BLAST-2, ALIGN or
Megalign (DNASTAR) software. Those skilled in the art can determine
appropriate parameters for
measuring alignment, including any algorithms needed to achieve maximal
alignment over the full length of
the sequences being compared. For purposes herein, however, % amino acid
sequence identity values are
generated using the sequence comparison computer program ALIGN-2, wherein the
complete source code
for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence
comparison computer
program was authored by Genentech, Inc. and the source code shown in Table 1
below has been filed with
user documentation in the U.S. Copyright Office, Washington D.C., 20559, where
it is registered under U.S.
Copyright Registration No. TXUS 10087. The ALIGN-2 program is publicly
available through Genentech,
Inc., South San Francisco, California or may be compiled from the source code
provided in Table 1 below.
The ALIGN-2 program should be compiled for use on a UNIX operating system,
preferably digital UNIX
V4.OD. All sequence comparison parameters are set by the ALIGN-2 program and
do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons,
the % amino acid
sequence identity of a given amino acid sequence A to, with, or against a
given amino acid sequence B
(which can alternatively be phrased as a given amino acid sequence A that has
or comprises a certain
amino acid sequence identity to, with, or against a given amino acid sequence
B) is calculated as follows:
13
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by
the sequence alignment
program ALIGN-2 in that program's alignment of A and B, and where Y is the
total number of amino acid
residues in B. It will be appreciated that where the length of amino acid
sequence A is not equal to the
length of amino acid sequence B, the % amino acid sequence identity of A to B
will not equal the % amino
acid sequence identity of B to A. As examples of % amino acid sequence
identity calculations using this
method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence
identity of the amino acid
sequence designated "Comparison Protein" to the amino acid sequence designated
"PR020080", wherein
"PR020080" represents the amino acid sequence of a hypothetical PR020080
polypeptide of interest,
"Comparison Protein" represents the amino acid sequence of a polypeptide
against which the "PR020080"
polypeptide of interest is being compared, and "X, "Y" and "Z" each represent
different hypothetical amino
acid residues.
Unless specifically stated otherwise, all % amino acid sequence identity
values used herein are
obtained as described in the immediately preceding paragraph using the ALIGN-2
computer program.
However, % amino acid sequence identity values may also be obtained as
described below by using the WU-
BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480
(1996)). Most of the
WLT-BLAST-2 search parameters are set to the default values. Those not set to
default values, i.e., the
adjustable parameters, are set with the following values: overlap span = 1,
overlap fraction = 0.125, word
threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is
employed, a % amino acid
sequence identity value is determined by dividing (a) the number of matching
identical amino acid residues
between the amino acid sequence of the PR020080 polypeptide of interest having
a sequence derived from
the native PR020080 polypeptide and the comparison amino acid sequence of
interest (i.e., the sequence
against which the PR020080 polypeptide of interest is being compared which may
be a PR020080 variant
polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid
residues of the
PR020080 polypeptide of interest. For example, in the statement "a polypeptide
comprising an the amino
acid sequence A which has or having at least 80% amino acid sequence identity
to the amino acid sequence
B", the amino acid sequence A is the comparison amino acid sequence of
interest and the amino acid
sequence B is the amino acid sequence of the PRO20080 polypeptide of interest.
Percent amino acid sequence identity may also be determined using the sequence
comparison
program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
The NCBI-BLAST2
sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov
or otherwise obtained
from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several
search parameters,
wherein all of those search parameters are set to default values including,
for example, unmask = yes, strand
= all, expected occurrences = 10, minimum low complexity length = 15/5, mufti-
pass e-value = 0.01,
constant for mufti-pass = 25, dropoff for final gapped aligmnent = 25 and
scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for amino acid sequence
comparisons, the
amino acid sequence identity of a given amino acid sequence A to, with, or
against a given amino acid
sequence B (which can alternatively be phrased as a given amino acid sequence
A that has or comprises a
14
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
certain % amino acid sequence identity to, with, or against a given amino acid
sequence B) is calculated as
follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by
the sequence alignment
program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the
total number of amino
acid residues in B. It will be appreciated that where the length of amino acid
sequence A is not equal to the
length of amino acid sequence B, the % amino acid sequence identity of A to B
will not equal the % amino
acid sequence identity of B to A.
"PR020080 variant polynucleotide" or "PR020080 variant nucleic acid sequence"
means a nucleic
acid molecule which encodes an active PR020080 polypeptide as defined below
and which has at least
about 80% nucleic acid sequence identity with a nucleotide acid sequence
encoding a full-length native
sequence PR020080 polypeptide sequence as disclosed herein, a full-length
native sequence PR020080
polypeptide sequence lacking the signal peptide as disclosed herein, an
extracellular domain of a PR020080
polypeptide, with or without the signal peptide, as disclosed herein or any
other fragment of a full-length
PR020080 polypeptide sequence as disclosed herein. Ordinarily, a PR020080
variant polynucleotide will
have at least about 80% nucleic acid sequence identity, alternatively at least
about 81% nucleic acid
sequence identity, alternatively at least about 82% nucleic acid sequence
identity, alternatively at least about
83% nucleic acid sequence identity, alternatively at least about 84% nucleic
acid sequence identity,
alternatively at least about 85% nucleic acid sequence identity, alternatively
at least about 86% nucleic acid
sequence identity, alternatively at least about 87% nucleic acid sequence
identity, alternatively at least about
88% nucleic acid sequence identity, alternatively at least about 89% nucleic
acid sequence identity,
alternatively at least about 90% nucleic acid sequence identity, alternatively
at least about 91% nucleic acid
sequence identity, alternatively at least about 92% nucleic acid sequence
identity, alternatively at least about
93% nucleic acid sequence identity, alternatively at least about 94% nucleic
acid sequence identity,
alternatively at least about 95% nucleic acid sequence identity, alternatively
at least about 96% nucleic acid
sequence identity, alternatively at least about 97% nucleic acid sequence
identity, alternatively at least about
98% nucleic acid sequence identity and alternatively at least about 99%
nucleic acid sequence identity with a
nucleic acid sequence encoding a full-length native sequence PR020080
polypeptide sequence as disclosed
herein, a full-length native sequence PR020080 polypeptide sequence lacking
the signal peptide as disclosed
herein, an extracellular domain of a PR020080 polypeptide, with or without the
signal sequence, as
disclosed herein or any other fragment of a full-length PR020080 polypeptide
sequence as disclosed herein.
Variants do not encompass the native nucleotide sequence.
Ordinarily, PR020080 variant polynucleotides are at least about 30 nucleotides
in length,
alternatively at least about 60 nucleotides in length, alternatively at least
about 90 nucleotides in length,
alternatively at least about 120 nucleotides in length, alternatively at least
about 150 nucleotides in length,
alternatively at least about 180 nucleotides in length, alternatively at least
about 210 nucleotides in length,
alternatively at least about 240 nucleotides in length, alternatively at least
about 270 nucleotides in length,
alternatively at least about 300 nucleotides in length, alternatively at least
about 450 nucleotides in length,
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
alternatively at least about 600 nucleotides in length, alternatively at least
about 900 nucleotides in length, or
more.
"Percent (%) nucleic acid sequence identity" with respect to PR020080-encoding
nucleic acid
sequences identified herein is defined as the percentage of nucleotides in a
candidate sequence that are
identical with the nucleotides in the PR020080 nucleic acid sequence of
interest, after aligning the
sequences and introducing gaps, if necessary, to achieve the maximum percent
sequence identity.
Alignment for purposes of determining percent nucleic acid sequence identity
can be achieved in various
ways that are within the skill in the art, for instance, using publicly
available computer software such as
BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein,
however, % nucleic
acid sequence identity values are generated using the sequence comparison
computer program ALIGN-2,
wherein the complete source code for the ALIGN-2 program is provided in Table
1 below. The ALIGN-2
sequence comparison computer program was authored by Genentech, Inc. and the
source code shown in
Table 1 below has been filed with user documentation in the U.S. Copyright
Office, Washington D.C.,
20559, where it is registered under U.S. Copyright Registration No. TXU510087.
The ALIGN-2 program is
publicly available through Genentech, Inc., South San Francisco, California or
may be compiled from the
source code provided in Table 1 below. The ALIGN-2 program should be compiled
for use on a UNIX
operating system, preferably digital UNIX V4.OD. All sequence comparison
parameters are set by the
ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for nucleic acid sequence comparisons,
the % nucleic
acid sequence identity of a given nucleic acid sequence C to, with, or against
a given nucleic acid sequence
D (which can alternatively be phrased as a given nucleic acid sequence C that
has or comprises a certain
nucleic acid sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows:
100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by the
sequence alignment program
ALIGN-2 in that program's alignment of C and D, and where Z is the total
number of nucleotides in D. It
will be appreciated that where the length of nucleic acid sequence C is not
equal to the length of nucleic acid
sequence D, the % nucleic acid sequence identity of C to D will not equal the
% nucleic acid sequence
identity of D to C. As examples of % nucleic acid sequence identity
calculations, Tables 4 and 5,
demonstrate how to calculate the % nucleic acid sequence identity of the
nucleic acid sequence designated
"Comparison DNA" to the nucleic acid sequence designated "PR020080-DNA",
wherein "PR020080-
DNA" represents a hypothetical PR020080-encoding nucleic acid sequence of
interest, "Comparison DNA"
represents the nucleotide sequence of a nucleic acid molecule against which
the "PR020080-DNA" nucleic
acid molecule of interest is being compared, and "N", "L" and "V" each
represent different hypothetical
nucleotides.
Unless specifically stated otherwise, all % nucleic acid sequence identity
values used herein are
obtained as described in the immediately preceding paragraph using the ALIGN-2
computer program.
However, % nucleic acid sequence identity values may also be obtained as
described below by using the
WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-
480 (1996)). Most of
16
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
the WU-BLAST-2 search parameters are set to the default values. Those not set
to default values, i.e., the
adjustable parameters, are set with the following values: overlap span = 1,
overlap fraction = 0.125, word
threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is
employed, a % nucleic acid
sequence identity value is determined by dividing (a) the number of matching
identical nucleotides between
the nucleic acid sequence of the PR020080 polypeptide-encoding nucleic acid
molecule of interest having a
sequence derived from the native sequence PR020080 polypeptide-encoding
nucleic acid and the
comparison nucleic acid molecule of interest (i.e., the sequence against which
the PRO20080 polypeptide-
encoding nucleic acid molecule of interest is being compared which may be a
variant PR020080
polynucleotide) as determined by WU-BLAST-2 by (b) the total number of
nucleotides of the PR020080
polypeptide-encoding nucleic acid molecule of interest. For example, in the
statement "an isolated nucleic
acid molecule comprising a nucleic acid sequence A which has or having at
least 80% nucleic acid sequence
identity to the nucleic acid sequence B", the nucleic acid sequence A is the
comparison nucleic acid
molecule of interest and the nucleic acid sequence B is the nucleic acid
sequence of the PR020080
polypeptide-encoding nucleic acid molecule of interest.
Percent nucleic acid sequence identity may also be deternined using the
sequence comparison
program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)).
The NCBI-BLAST2
sequence comparison program may be downloaded from
http://www.ncbi.nlin.nih.gov or. otherwise obtained
from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several
search parameters,
wherein all of those search parameters are set to default values including,
for example, unmask = yes, strand
= all, expected occurrences = 10, minimum low complexity length = 15/5, mufti-
pass e-value = 0.01,
constant for mufti-pass = 25, dropoff for final gapped alignment = 25 and
scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for sequence comparisons, the %
nucleic acid
sequence identity of a given nucleic acid sequence C to, with, or against a
given nucleic acid sequence D
(which can alternatively be phrased as a given nucleic acid sequence C that
has or comprises a certain
nucleic acid sequence identity to, with, or against a given nucleic acid
sequence D) is calculated as follows:
100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by the
sequence alignment program
NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total
number of nucleotides in
D. It will be appreciated that where the length of nucleic acid sequence C is
not equal to the length of
nucleic acid sequence D, the % nucleic acid sequence identity of C to D will
not equal the % nucleic acid
sequence identity of D to C.
In other embodiments, PR020080 variant polynucleotides are nucleic acid
molecules that encode
an active PR020080 polypeptide and which are capable of hybridizing,
preferably under stringent
hybridization and wash conditions, to nucleotide sequences encoding a full-
length PR020080 polypeptide as
disclosed herein. PRO20080 variant polypeptides may be those that are encoded
by a PRO20080 variant
polynucleotide.
"Isolated," when used to describe the various polypeptides disclosed herein,
means polypeptide that
has been identified and separated and/or recovered from a component of its
natural environment.
17
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Contaminant components of its natural environment are materials that would
typically interfere with
diagnostic or therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other
proteinaceous or non-proteinaceous solutes. In preferred embodiments, the
polypeptide will be purified (1)
to a degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a
spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing
or reducing conditions
using Coomassie blue or, preferably, silver stain. Isolated polypeptide
includes polypeptide in situ within
recombinant cells, since at least one component of the PRO20080 polypeptide
natural environment will not
be present. Ordinarily, however, isolated polypeptide will be prepared by at
least one purification step.
An "isolated" PRO20080 polypeptide-encoding nucleic acid or other polypeptide-
encoding nucleic
acid is a nucleic acid molecule that is identified and separated from at least
one contaminant nucleic acid
molecule with which it is ordinarily associated in the natural source of the
polypeptide-encoding nucleic
acid. An isolated polypeptide-encoding nucleic acid molecule is other than ui
the form or setting in which it
is found in nature. Isolated polypeptide-encoding nucleic acid molecules
therefore are distinguished from
the specific polypeptide-encoding nucleic acid molecule as it exists in
natural cells. However, an isolated
polypeptide-encoding nucleic acid molecule includes polypeptide-encoding
nucleic acid molecules
contained in cells that ordinarily express the polypeptide where, for example,
the nucleic acid molecule is in
a chromosomal location different from that of natural cells.
The term "control sequences" refers to DNA sequences necessary for the
expression of an operably
linked coding sequence in a particular host organism. The control sequences
that are suitable for
prokaryotes, for example, include a promoter, optionally an operator sequence,
and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation signals, and
enhancers.
Nucleic acid is "operably linked" when it is placed into a functional
relationship with another
nucleic acid sequence. For example, DNA for a presequence or secretory leader
is operably linked to DNA
for a polypeptide if it is expressed as a preprotein that participates in the
secretion of the polypeptide; a
promoter or enhancer is operably linked to a coding sequence if it affects the
transcription of the sequence;
or a ribosome binding site is operably linked to a coding sequence if it is
positioned so as to facilitate
translation. Generally, "operably linked" means that the DNA sequences being
linked are contiguous, and,
in the case of a secretory leader, contiguous and in reading phase. However,
enhancers do not have to be
contiguous. Linking is accomplished by ligation at convenient restriction
sites. If such sites do not exist, the
synthetic oligonucleotide adaptors or linkers are used in accordance with
conventional practice.
The term "antibody" is used in the broadest sense and specifically covers, for
example, single anti-
PR020080 monoclonal antibodies (including agonist, antagonist, and
neutralizing antibodies), anti-
PRO20080 antibody compositions with polyepitopic specificity, single chain
anti-PR020080 antibodies, and
fragments of anti-PR020080 antibodies (see below). The term "monoclonal
antibody" as used herein refers
to an antibody obtained from a population of substantially homogeneous
antibodies, i.e., the individual
antibodies comprising the population are identical except for possible
naturally-occurring mutations that
may be present in minor amounts.
"Stringency" of hybridization reactions is readily determinable by one of
ordinary skill in the art,
and generally is an empirical calculation dependent upon probe length, washing
temperature, and salt
concentration. In general, longer probes require higher temperatures for
proper annealing, while shorter
18
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
probes need lower temperatures. Hybridization generally depends on the ability
of denatured DNA to
reanneal when complementary strands are present in an environment below their
melting temperature. 'The
higher the degree of desired homology between the probe and hybridizable
sequence, the higher the relative
temperature which can be used. As a result, it follows that higher relative
temperatures would tend to make
the reaction conditions more stringent, while lower temperatures less so. For
additional details and
explanation of stringency of hybridization reactions, see Ausubel et al.,
Current Protocols in Molecular
Biolo , Wiley Interscience Publishers, (1995).
"Stringent conditions" or "high stringency conditions", as defined herein, may
be identified by those
that: (1) employ low ionic strength and high temperature for washing, for
example 0.015 M sodium
chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C;
(2) employ during hybridization a
denaturing agent, such as formamide, for example, 50% (v/v) formamide with
0.1% bovine serum
albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/SOmM sodium phosphate buffer at
pH 6.5 with 750 mM
sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50%
formamide, 5 x SSC (0.75 M NaCI,
0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium
pyrophosphate, 5 x Denhardt's
solution, sonicated salmon sperm DNA (50 pglml), 0.1% SDS, and 10% dextran
sulfate at 42°C, with
washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50%
formamide at 55°C, followed by a
high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.
"Moderately stringent conditions" may be identified as described by Sambrook
et al., Molecular
Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and
include the use of washing
solution and hybridization conditions (e.g., temperature, ionic strength and
%SDS) less stringent that those
described above. An example of moderately stringent conditions is overnight
incubation at 37°C in a
solution comprising: 20% formamide, 5 x SSC (150 mM NaCI, 15 mM trisodium
citrate), 50 mM sodium
phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml
denatured sheared salmon
sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
The skilled artisan will recognize
how to adjust the temperature, ionic strength, etc. as necessary to
accommodate factors such as probe length
and the like.
The term "epitope tagged" when used herein refers to a chimeric polypeptide
comprising a
PR020080 polypeptide fused to a "tag polypeptide". The tag polypeptide has
enough residues to provide an
epitope against which an antibody can be made, yet is short enough such that
it does not interfere with
activity of the polypeptide to which it is fused. The tag polypeptide
preferably also is fairly unique so that
the antibody does not substantially cross-react with other epitopes. Suitable
tag polypeptides generally have
at least six amino acid residues and usually between about 8 and 50 amino acid
residues (preferably,
between about 10 and 20 amino acid residues).
As used herein, the term "immunoadhesin" designates antibody-like molecules
which combine the
binding specificity of a heterologous protein (an "adhesin") with the effector
functions of immunoglobulin
constant domains. Structurally, the immunoadhesins comprise a fusion of an
amino acid sequence with the
desired binding specificity which is other than the antigen recognition and
binding site of an antibody (i.e., is
"heterologous"), and an immunoglobulin constant domain sequence. The adhesin
part of an immunoadhesin
molecule typically is a contiguous amino acid sequence comprising at least the
binding site of a receptor or a
ligand. The immunoglobulin constant domain sequence in the immunoadhesin may
be obtained from any
19
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including
IgA-1 and IgA-2), IgE,
IgD or IgM.
"Active" or "activity" for the purposes herein refers to forms) of a PR020080
polypeptide which
retain a biological and/or an immunological activity of native or naturally-
occurring PR020080, wherein
"biological" activity refers to a biological function (either inhibitory or
stimulatory) caused by a native or
naturally-occurring PR020080 other than the ability to induce the production
of an antibody against an
antigenic epitope possessed by a native or naturally-occurring PRO20080 and an
"immunological" activity
refers to the ability to induce the production of an antibody against an
antigenic epitope possessed by a
native or naturally-occurring PR020080.
The term "antagonist" is used in the broadest sense, and includes any molecule
that partially or fully
blocks, inhibits, or neutralizes a biological activity of a native PR020080
polypeptide disclosed herein. In a
similar manner, the term "agonist" is used in the broadest sense and includes
any molecule that mimics a
biological activity of a native PRO20080 polypeptide disclosed herein.
Suitable agonist or antagonist
molecules specifically include agonist or antagonist antibodies or antibody
fragments, fragments or amino
acid sequence variants of native PR020080 polypeptides, peptides, antisense
oligonucleotides, small organic
molecules, etc. Methods for identifying agonists or antagonists of a PRO20080
polypeptide may comprise
contacting a PR020080 polypeptide with a candidate agonist or antagonist
molecule and measuring a
detectable change in one or more biological activities normally associated
with the PRO20080 polypeptide.
"Treatment" refers to both therapeutic treatment and prophylactic or
preventative measures,
wherein the object is to prevent or slow down (lessen) the targeted pathologic
condition or disorder. Those
in need of treatment include those already with the disorder as well as those
prone to have the disorder or
those in whom the disorder is to be prevented.
"Chronic" administration refers to administration of the agents) in a
continuous mode as opposed
to an acute mode, so as to maintain the initial therapeutic effect (activity)
for an extended period of time.
"Intermittent" administration is treatment that is not consecutively done
without interruption, but rather is
cyclic in nature.
"Mammal" for purposes of treatment refers to any animal classified as a
mammal, including
humans, domestic and farm animals, and zoo, sports, or pet animals, such as
dogs, cats, cattle, horses, sheep,
pigs, goats, rabbits, etc. Preferably, the mammal is human.
Administration "in combination with" one or more further, therapeutic agents
includes simultaneous
(concurrent) and consecutive administration in any order.
"Carriers" as used herein include pharmaceutically acceptable carriers,
excipients, or stabilizers
which are nontoxic to the cell or mammal being exposed thereto at the dosages
and concentrations
employed. Often the physiologically acceptable carrier is an aqueous pH
buffered solution. Examples of
physiologically acceptable carriers include buffers such as phosphate,
citrate, and other organic acids;
antioxidants including ascorbic acid; low molecular weight (less than about 10
residues) polypeptide;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic
polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine,
arginine or lysine;
monosaccharides, disaccharides, and other carbohydrates including glucose,
mannose, or dextrins; chelating
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming
counterions such as sodium;
and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and
PLURONICSTM.
"Antibody fragments" comprise a portion of an intact antibody, preferably the
antigen binding or
variable region of the intact antibody. Examples of antibody fragments include
Fab, Fab', F(ab')2, and Fv
fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10):
1057-1062 [1995]); single-chain
antibody molecules; and multispecific antibodies formed from antibody
fragments.
Papain digestion of antibodies produces two identical antigen-binding
fragments, called "Fab"
fragments, each with a single antigen-binding site, and a residual "Fc"
fragment, a designation reflecting the
ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment
that has two antigen-combining
sites and is still capable of cross-linking antigen.
"Fv" is the minimum antibody fragment which contains a complete antigen-
recognition and -
binding site. This region consists of a dimer of one heavy- and one light-
chain variable domain in tight, non-
covalent association. It is in this configuration that the three CDRs of each
variable domain interact to
define an antigen-binding site on the surface of the VH-VL dimer.
Collectively, the six CDRs confer antigen-
binding specificity to the antibody. However, even a single variable domain
(or half of an Fv comprising
only three CDRs specific for an antigen) has the ability to recognize and bind
antigen, although at a lower
affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the
first constant domain
(CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the
addition of a few residues at the
carboxy terminus of the heavy chain CH1 domain including one or more cysteines
from the antibody hinge
region. Fab'-SH is the designation herein for Fab' in which the cysteine
residues) of the constant domains
bear a free thiol group. F(ab')Z antibody fragments originally were produced
as pairs of Fab' fragments
which have hinge cysteines between them. Other chemical couplings of antibody
fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species
can be assigned to
one of two clearly distinct types, called kappa and lambda, based on the amino
acid sequences of their
constant domains.
Depending on the amino acid sequence of the constant domain of their heavy
chains,
immunoglobulins can be assigned to different classes. There are five major
classes of immunoglobulins:
IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into
subclasses (isotypes), e.g.,
IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
"Single-chain Fv" or "sFv" antibody fragments comprise the VH and VL domains
of antibody,
wherein these domains are present in a single polypeptide chain. Preferably,
the Fv polypeptide further
comprises a polypeptide linker between the VH and VL domains which enables the
sFv to form the desired
structure for antigen binding. For a review of sFv, see Pluckthun in The
Pharmacology of Monoclonal
Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp.
269-315 (1994).
The term "diabodies" refers to small antibody fragments with two antigen-
binding sites, which
fragments comprise a heavy-chain variable domain (VH) connected to a light-
chain variable domain (VL) in
the same polypeptide chain (VH-VL). By using a linker that is too short to
allow pairing between the two
domains on the same chain, the domains are forced to pair with the
complementary domains of another chain
21
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
and create two antigen-binding sites. Diabodies are described more fully in,
for example, EP 404,097; WO
93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448
(1993).
An "isolated" antibody is one which has been identified and separated and/or
recovered from a
component of its natural environment. Contaminant components of its natural
environment are materials
which would interfere with diagnostic or therapeutic uses for the antibody,
and may include enzymes,
hormones, and other proteinaceous or nonproteinaceous solutes. In preferred
embodiments, the antibody
will be purified (1) to greater than 95% by weight of antibody as determined
by the Lowry method, and most
preferably more than 99% by weight, (2) to a degree sufficient to obtain at
least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator, or (3) to
homogeneity by SDS-PAGE
under reducing or nonreducing conditions using Coomassie blue or, preferably,
silver stain. Isolated
antibody includes the antibody in situ within recombinant cells since at least
one component of the
antibody's natural environment will not be present. Ordinarily, however,
isolated antibody will be prepared
by at least one purification step.
An antibody that "specifically binds to" or is "specific for" a particular
polypeptide or an epitope on
a particular polypeptide is one that binds to that particular polypeptide or
epitope on a particular polypeptide
without substantially binding to any other polypeptide or polypeptide epitope.
The word "label" when used herein refers to a detectable compound or
composition which is
conjugated directly or indirectly to the antibody so as to generate a
"labeled" antibody. The label may be
detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in
the case of an enzymatic label, may
catalyze chemical alteration of a substrate compound or composition which is
detectable.
By "solid phase" is meant a non-aqueous matrix to which the antibody of the
present invention can
adhere. Examples of solid phases encompassed herein include those formed
partially or entirely of glass
(e.g., controlled pore glass), polysaccharides (e.g., agarose),
polyacrylamides, polystyrene, polyvinyl alcohol
and silicones. In certain embodiments, depending on the context, the solid
phase can comprise the well of an
assay plate; in others it is a purification column (e.g., an affinity
chromatography column). This term also
includes a discontinuous solid phase of discrete particles, such as those
described in U.S. Patent No.
4,275,149.
A "liposome" is a small vesicle composed of various types of lipids,
phospholipids and/or
surfactant which is useful for delivery of a drug (such as a PR020080
polypeptide or antibody thereto) to a
mammal. The components of the liposome are commonly arranged in a bilayer
formation, similar to the
lipid arrangement of biological membranes.
A "small molecule" is defined herein to have a molecular weight below about
500 Daltons.
The term "immune related disease" means a disease in which a component of the
immune system of
a mammal causes, mediates or otherwise contributes to a morbidity in the
mammal. Also included are
diseases in which stimulation or intervention of the immune response has an
ameliorative effect on
progression of the disease. Included within this term are immune-mediated
inflammatory diseases, non-
immune-mediated inflammatory diseases, infectious diseases, immunodeficiency
diseases, neoplasia, etc.
The term "T cell mediated disease" means a disease in which T cells directly
or indirectly mediate
or otherwise contribute to a morbidity in a mammal. The T cell mediated
disease may be associated with
22
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
cell mediated effects, lymphokine mediated effects, etc., and even effects
associated with B cells if the B
cells are stimulated, for example, by the lymphokines secreted by T cells.
Examples of immune-related and inflammatory diseases, some of which are immune
or T cell
mediated, which can be treated according to the invention include systemic
lupus erythematosis, rheumatoid
arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic
sclerosis (scleroderma), idiopathic
inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's syndrome,
systemic vasculitis,
sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal
nocturnal hemoglobinuria),
autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-
mediated
thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis,
juvenile lymphocytic thyroiditis,
atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease
(glomerulonephritis, tubulointerstitial
nephritis), demyelinating diseases of the central and peripheral nervous
systems such as multiple sclerosis,
idiopathic demyelinating polyneuropathy or Guillain-Barre syndrome, and
chronic inflammatory
demyelinating polyneuropathy, hepatobiliary diseases such as infectious
hepatitis (hepatitis A, B, C, D, E
and other non-hepatotropic viruses), autoimmune chronic active hepatitis,
primary biliary cirrhosis,
granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel
disease (ulcerative colitis: Crohn's
disease), gluten-sensitive enteropathy, and Whipple's disease, autoimmune or
immune-mediated skin
diseases including bullous skin diseases, erythema multiforme and contact
dermatitis, psoriasis, allergic
diseases such as asthma, allergic rhinitis, atopic dermatitis, food
hypersensitivity and urticaria, immunologic
diseases of the lung such as eosinophilic pneumonias, idiopathic pulmonary
fibrosis and hypersensitivity
pneumonitis, transplantation associated diseases including graft rejection and
graft -versus-host-disease.
Infectious diseases including viral diseases such as AIDS (HIV infection),
hepatitis A, B, C, D, and E,
herpes, etc., bacterial infections, fungal infections, protozoal infections
and parasitic infections.
The term "effective amount" is a concentration or amount of a PR020080
polypeptide and/or
agonist/antagonist which results in achieving a particular stated purpose. An
"effective amount" of a
PR020080 polypeptide or agonist or antagonist thereof may be determined
empirically. Furthermore, a
"therapeutically effective amount" is a concentration or amount of a PR020080
polypeptide and/or
agonist/antagonist which is effective for achieving a stated therapeutic
effect. This amount may also be
determined empirically.
The teen "cytotoxic agent" as used herein refers to a substance that inhibits
or prevents the function
of cells and/or causes destruction of cells. The term is intended to include
radioactive isotopes (e.g., I'3',
Iizs~ Y~o and Re'$6), chemotherapeutic agents, and toxins such as
enzymatically active toxins of bacterial,
fungal, plant or animal origin, or fragments thereof.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of
cancer. Examples
of chemotherapeutic agents include adriamycin, doxorubicin, epirubicin, 5-
fluorouracil, cytosine arabinoside
("Ara-C"), cyclophosphamide, thiotepa, busulfan, cytoxin, taxoids, e.g.,
paclitaxel (Taxol, Bristol-Myers
Squibb Oncology, Princeton, NJ), and doxetaxel (Taxotere, Rhone-Poulenc Rorer,
Antony, France),
toxotere, methotrexate, cisplatin, melphalan, vinblastine, bleomycin,
etoposide, ifosfamide, mitomycin C,
mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin,
carminomycin, aminopterin,
dactinomycin, mitomycins, esperamicins (see U.S. Pat. No. 4,675,187),
melphalan and other related nitrogen
mustards. Also included in this definition are hormonal agents that act to
regulate or inhibit hormone action
23
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
on tumors such as tamoxifen and onapristone.
A "growth inhibitory agent" when used herein refers to a compound or
composition which inhibits
growth of a cell, especially cancer cell overexpressing any of the genes
identified herein, either in vitro or in
vivo. Thus, the growth inhibitory agent is one which significantly reduces the
percentage of cells
overexpressing such genes in S phase. Examples of growth inhibitory agents
include agents that block cell
cycle progression (at a place other than S phase), such as agents that induce
G1 arrest and M-phase arrest.
Classical M-phase Mockers include the vincas (vincristine and vinblastine),
taxol, and topo II inhibitors such
as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those
agents that arrest G 1 also spill
over into S-phase arrest, for example, DNA alkylating agents such as
tamoxifen, prednisone, dacarbazine,
mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further
information can be found in
The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1,
entitled "Cell cycle regulation,
oncogens, and antineoplastic drugs" by Murakami et al. (WB Saunders:
Philadelphia, 1995), especially p.
13.
The term "cytokine" is a generic term for proteins released by one cell
population which act on
another cell as intercellular mediators. Examples of such cytokines are
lymphokines, monokines, and
traditional polypeptide hormones. Included among the cytokines are growth
hormone such as human growth
hormone, N-methionyl human growth hormone, and bovine growth hormone;
parathyroid hormone;
thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones
such as follicle stimulating
hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone
(LH); hepatic growth factor;
fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-
a and -[3; mullerian-inhibiting
substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular
endothelial growth factor;
integrin; thrombopoietin (TPO); nerve growth factors such as NGF-(3; platelet-
growth factor; transforming
growth factors (TGFs) such as TGF-a and TGF-(3; insulin-like growth factor-I
and -II; erythropoietin (EPO);
osteoinductive factors; interferons such as interferon-a, -(3, and -'y; colony
stimulating factors (CSFs) such as
macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-
CSF (G-CSF);
interleukins (ILs) such as IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-9, IL-11, IL-12; a tumor
necrosis factor such as TNF-a or TNF-(3; and other polypeptide factors
including LIF and kit ligand (KL).
As used herein, the term cytokine includes proteins from natural sources or
from recombinant cell culture
and biologically active equivalents of the native sequence cytokines.
As used herein, the term "immunoadhesin" designates antibody-like molecules
which combine the
binding specificity of a heterologous protein (an "adhesin") with the effector
functions of immunoglobulin
constant domains. Structurally, the immunoadhesins comprise a fusion of an
amino acid sequence with the
desired binding specificity which is other than the antigen recognition and
binding site of an antibody (i.e., is
"heterologous"), and an immunoglobulin constant domain sequence. The adhesin
part of an immunoadhesin
~ molecule typically is a contiguous amino acid sequence comprising at least
the binding site of a receptor or a
ligand. The immunoglobulin constant domain sequence in the immunoadhesin may
be obtained from any
immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including
IgA-1 and IgA-2), IgE,
IgD or IgM.
As used herein, the term "inflammatory cells" designates cells that enhance
the inflammatory
response such as mononuclear cells, eosinophils, macrophages, and
polymorphonuclear neutrophils (PMN).
24
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
As used herein, the term "delayed type hypersensitivity" or "DTH" is an immune
reaction caused
by an antigen and is mediated by the cellular component of the immune system,
specifically, memory T
cells. The hallmark DTH response is is induration, swelling, edema and
monocytic infiltration into the site
of the lesion within 24 to 72 hours. DTH has been classified at Type IV
hypersensitivity by Coombs and
Gell [ Gell et al., (1968) Clinical Aspects in Immunology. Blackwell, Oxford]
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
/*
Table 1
* C-C
increased
from
12 to
15
* Z is erage of EQ
av
* B is erage of ND
av
* match
with
stop
is M;
stop-stop
= 0;
J (joker)
match
= 0
*/
#define M -8 /* value of a match with a stop */
int day[26][26] _ {
/* A _
B C D E F G H I J K L M N O P Q R 5 T
U V W X Y Z */
IS /* A { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2,-1,
*/ O, M, 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, 0},
/* B { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2,
*/ 2, M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, 1},
/* C {-2,-4,15,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4,
*/ M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5},
!* D { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3,
*/ 2, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 2},
/* E { 0, 2,-5, 3, 4,-5, 0, 1,-2, 0, 0,-3,-2,
*/ 1, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 3},
/* F {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2,
*/ 0,-4, M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5},
l* G { 1, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3,
*/ O, M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, 0},
/* H {-1, 1,-3, 1, 1,-2,-2, 6,-2, 0, 0,-2,-2,
*/ 2, M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, 2},
/* I {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2,
*/ 2,-2, M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2},
/* J { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
*/ 0, O, M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0},
/* K {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3,
*/ 0, 1, M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4,
0},
/* L {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6,
*/ 4,-3, M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2},
/* M {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4,
*/ 6,-2, M,-2,-1, 0,-2,-1, 0, 2,-4, 0,-2,-1},
/* N { 0, 2,-4, 2, 1,-4, 0, 2,-2, 0, 1,-3,-2,
*/ 2, M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, 1},
/* O { M, M, M, M, M, M, M, M, M, M, M =M -M
*/ -M,
- _
M,_M,_M,_M,_M,_M,_M,_M},
M,
M,
0,
M,
_ _
_ _
/* P { 1,-1,-3,-1,-1,-5,-1, 0,-2, 0,-1,-3,-2,-1,
*/ M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0},
/* Q { 0, 1,-5, 2, 2,-5,-1, 3,-2, 0, 1,-2,-1,
*/ 1, M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, 3},
/* R {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3,
*/ 0, O, M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4,
0},
/* S { 1, 0, 0, 0, 0,-3, 1,-1,-1, 0, 0,-3,-2,
*/ 1, M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, 0},
/* T { 1, 0,-2, 0, 0,-3, 0,-1, 0, 0, 0,-1,-1,
*/ O, M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, 0},
/* U { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
*/ 0, O, M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0},
/* V { 0,-2,-2,-2,-2,-1,-1,-2, 4, 0,-2, 2,
*/ 2,-2, M,-1,-2,-2,-1, 0, 0, 4,-6, 0,-2,-2},
/* W {-6,-5,-8,-7,-7, 0,-7,-3,-5, 0,-3,-2,-4,-4,
*/ M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6},
/* x { o, o, o, o, o, o, o, o, o, o, o, o,
*/ o, o,_M, o, o, o, o, o, o, o, o, o, o,
o},
l* Y {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2,
*/ M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4},
/* Z { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1,
*/ 1, M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
50
26
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
*/
#include
< stdio.h
>
#include h >
< ctype.
#defineMAXJMP /* max jumps in a diag */
16
#defineMAXGAP /* don't continue to penalize gaps larger than
24 this */
#defineJMPS 1024 /* max jmps in an path */
#defineMX 4 /* save if there's at least MX-1 bases since
last jmp */
#dei'ineDMAT 3 /* value of matching bases */
#defineDMIS 0 /* penalty for mismatched bases */
#defineDINSO 8 /* penalty for a gap */
#deiineDINS1 1 /* penalty per base */
#definePINSO 8 /* penalty for a gap */
#definePINS1 4 /* penalty per residue *!
struct
jmp
{
short n[MAXJ MP]; /* size of jmp (neg for dely) */
unsigned MP]; /* base no. of jmp in seq x */
short
x[MAXJ
}; /* limits seq to 2~ 16 -1 */
struct
diag
{
int score; /* score at last jmp */
long offset; /* offset of prev block */
short ijmp; /* current jmp index */
struct /* list of jmps */
jmp
jp;
struct
path
{
int spc; /* number of leading spaces */
short n[JMPS];
l* size
of jmp
(gap)
*/
int x[JMPS]; jmp (last elem before gap) */
/* loc
of
};
char *ofile; /* output file name */
char *namex[2];/* seq names: getseqsQ */
char *prog; /* prog name for err msgs */
char *seqx[2]; /* seqs: getseqsQ */
int dmax; /* best diag: nwQ */
int dmax0; /* final diag */
int dna; /* set if dna: main() *l
int endgaps; /* set if penalizing end gaps */
int gapx, gapy;/* total gaps in seqs */
int IenO, lent;/* seq lens */
int ngapx, /* total size of gaps */
ngapy;
int smax; /* max score: nw() */
int *xbm; /* bitmap for matching */
long offset; /* current offset in jmp file */
struct ding *dx; /* holds diagonals */
struct path pp[2]; /* holds path for seqs */
char *calloc(),, *index(), *strcpy();
*mallocQ
char *getseqQ, cQ; '
*g callo
27
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
l* Needleman-Wunsch alignment program
usage: progs filet filet
* where filet and filet are two dna or two protein sequences.
* The sequences can be in upper- or lower-case an may contain ambiguity
* Any lines beginning with ';' ' >' or ' <' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
* Output is in the file "align.out"
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/
#include "nw.h"
#include "day.h"
static _dbval[26] _ {
1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};
static _pbval[26] _ {
1, 2 ~ (1 < < ('D'-'A')) ~ (1 < < ('N'-'A')), 4, 8, 16, 32, 64,
128, 256, OxFFFFFFF, 1 < < 10, 1 < < 11, 1 < < 12, 1 < < 13, 1 < < 14,
1«15, 1«16, 1«17, 1«18, 1«19, 1«20, 1«21, 1«22,
1«23, 1«24, 1«25(1«('E'-'A'))~(1«('Q'-'A'))
};
main(ac, av)
main
int ac;
char *av[];
{
prog = av[0];
3 5 if (ac ! = 3) {
fprintf(stderr,"usage: %s filet filet\n", prog);
fprintf(stderr,"where filet and filet are two dna or two protein
sequences.\n");
fprintf(stderr, "The sequences can be in upper- or lower-case\n");
fprintf(stderr,"Any lines beginning with ';' or ' <' are ignored\n");
fprintf(stderr,"Output is in the file \"align.out\"\n");
exit(1);
}
namex[0] = av[1];
namex[1] = av[2];
seqx[0] = getseq(namex[0], &len0);
seqx[1] = getseq(namex[1], &lenl);
xbm = (dna)? dbval : ~bval;
endgaps = 0; /* 1 to penalize endgaps */
ofile = "align.out"; /* output file */
nw(); /* fill in the matrix, get the possible jmps */
readjmpsQ; /* get the actual jmps */
print(); /* print stats, alignment */
}
cleanup(0); /* unlink any tmp files */
28
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/* do the alignment, return best score: main()
* dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
* pro: PAM 250 values
* When scores are equal, we prefer mismatches to any gap, prefer
* a new gap to extending an ongoing gap, and prefer a gap in seqx
* to a gap in seq y.
*/
nwQ
nw
{ char *px, *py; /* seqs and ptrs */
int *ndely, *dely; /* keep track of defy */
int ndelx, delx; /* keep track of delx */
int *tmp; /* for swapping row0, rowl */
int mis; l* score for each type */
int ins0, insl; /* insertion penalties */
register id; /* diagonal index */
register ij; /* jmp index */
register *col0, *coll; /* score for curr, last row */
register xx, yy; /* index into seqs */
dx = (struct diag *)g calloc("to get diags", len0+lenl+1, sizeof(struct
diag));
ndely = (int *)g calloc("to get ndely", lent + 1, sizeof(int));
dely = (int *)g calloc("to get defy", lent+1, sizeof(int));
col0 = (int *)g_calloc("to get col0", lenl+1, sizeof(int));
toll = (int *)g calloc("to get toll", lenl+1, sizeof(int));
ins0 = (dna)? DINSO : PINSO;
insl = (dna)? DINS1 : PINS1;
smax = -10000;
if (endgaps) {
for (col0[0] = dely[0] _ -ins0, yy = 1; yy < = lenl; yy++) {
col0[yy] = defy[yy] = col0[yy-1] - insl;
ndely[yy] = yy;
col0[0] = 0; /* Waterman Bull Math Biol 84 */
else
for (yy = 1; yy < = lent; yy++)
dely[yy] _ -ins0;
/* fill in match matrix
*/
for (px = seqx[0], xx = 1; xx < = IenO; px++, xx++) {
/* initialize first entry in col
*l
if (endgaps) {
if (xx == 1)
toll[0] = delx = -(ins0+insl);
else
toll[0] = delx = col0[0] - insl;
ndelx = xx;
}
else {
col l [0] = 0;
delx = -ins0;
ndelx = 0;
}
29
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
...nw
for (py = seqx[1], yy = 1; yy < = lenl; py++, yy++) {
mis = col0[yy-1];
$ if (dna)
mis +_ (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
else
mis += day[*px-'A'][*py-'A'];
/* update penalty for del in x seq;
* favor new del over ongong del
* ignore MAXGAP if weighting endgaps
*/
if (endgaps ~ ~ ndely[yy] < MAXGAP) {
if (col0[yy] - ins0 > = dely[yy]) {
dely[yy] = col0[yy] - (ins0+insl);
ndely[yy] = 1;
} else {
dely[yy] -= insl;
ndely[yy] + +;
}
} else {
if (col0[yy] - (ins0+insl) > = dely[yy]) {
dely[yy] = col0[yy] - (ins0+insl);
ndely[yy] = 1;
} else
ndely[yy] + +;
}
/* update penalty for del in y seq;
* favor new del over ongong del
*/
if (endgaps ~ ~ ndelx < MAXGAP) {
if (coll[yy-1] - ins0 > = delx) {
delx = colt[yy-1] - (ins0+insl);
ndelx = 1;
} else {
delx -= insl;
ndelx++;
}
} else {
if (colt[yy-1] - (ins0+insl) > = delx) {
delx = colt[yy-1] - (ins0+insl);
ndelx = 1;
} else
ndelx++;
}
/* pick the maximum score; we're favoring
* mis over any del and delx over dely
*!
60
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
...nw
id=xx-yy+lenl-1;
if (mis > = delx && mis > = dely[yy])
col l [yy] = mis;
else if (delx > = dely[yy]) {
col l [yy] = delx;
ij = dx[id].ijmp;
if (dx[id].jp.n[0] && (!dna ~ ~ (ndelx > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO))
{
dx[id] . ijmp+ +;
if (++ij > = MAXJMP) {
writejmps(id);
ij = dx[id].ijmp = 0;
dx[id].offset = offset;
offset += sizeof(struct jmp) + sizeof(offset);
}
}
dx[id].jp.n[ij] = ndelx;
dx[id].jp.x[ij] = xx;
dx[id].score = delx;
}
else {
coil[yy] = dely[yy];
ij = dx[id].ijmp;
if (dx[id].jp.n[0] && (!dna ~ ~ (ndely[yy] > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO))
{
dx[id] . ijmp+ +;
if (++ij > = MAXJMP) {
writejmps(id);
ij = dx[id].ijmp = 0;
dx[id].offset = offset;
offset += sizeof(struct jmp) + sizeof(offset);
}
}
dx[id].jp.n[ij] _ -ndely[yy];
dx[id].jp.x[ij] = xx;
dx[id].score = dely[yy];
}
if (xx == len0 && yy < lenl) {
/* last col
*/
if (endgaps)
colt[yy] -= ins0+insl*(lenl-yy);
if (col l [yy] > smax) {
smax = colt[yy];
dmax = id;
}
}
}
if (endgaps && xx < len0)
coll[yy-1] -= ins0+insl*(len0-xx);
if (coll[yy-1] > smax) {
smax = colt[yy-1];
dmax = id;
}
tmp = col0; col0 = coll; coll = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
(void) free((char *)col0);
(void) free((char *)coll); }
31
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
* printQ -- only routine visible outside this module
*
* static:
* getmatQ -- trace back best path, count matches: printQ
* pr align() -- print alignment of described in array p[ ]: printQ
* dumpblock() -- dump a block of lines with numbers, stars: pr align()
* nums() -- put out a number line: dumpblock()
* putline() -- put out a line (name, [num], seq, [num]): dumpblock()
* stars() - -put a line of stars: dumpblock()
* stripnameQ -- strip any path and prefix from a seqname
*/
#include "nw.h"
#define SPC 3
#define P_LINE 256 /* maximum output line */
#define P SPC 3 /* space between name or num and seq */
extern _day[26][26];
int olen; /* set output line length */
FILE *fx; /* output file */
print()
print
{
int lx, 1y, firstgap, lastgap; /* overlap */
if ((fx = fopen(ofile, "w")) _ = 0) {
fprintf(stderr," % s: can't write % s\n", prog, ofile);
cleanup(1);
fprintf(fx, " <first sequence: %as (length = %d)\n", namex[0], len0);
fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], lenl);
olen = 60;
lx = len0;
1y = lent;
firstgap = lastgap = 0;
if (dmax < lenl - 1) { /* leading gap in x */
pp[0].spc = firstgap = lent - dmax - 1;
1y -= pp[0].spc;
else if (dmax > lenl - 1) { /* leading gap in y */
pp[1].spc = firstgap = dmax - (lenl - 1);
lx -= pp[1].spc;
if (dmax0 < len0 - 1) { /* trailing gap in x */
lastgap = len0 - dmax0 -l;
lx -= lastgap;
else if (dmax0 > len0 - 1) { /* trailing gap in y */
lastgap = dmax0 - (len0 - 1);
1y -= lastgap;
getmat(lx, 1y, firstgap, lastgap);
pr align();
32
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
* trace back the best path, count matches
*/
static
getmat(lx, 1y, firstgap, lastgap) getmat
int Ix, 1y; /* "core" (minus endgaps) */
int firstgap, lastgap; l* leading trailing overlap */
{
int nm, i0, i1, siz0, sizl;
char outx[32];
double pct;
register n0, n1;
register char *p0, *pl;
/* get total matches, score
*/
i0 = i1 = siz0 = sizl = 0;
p0 = seqx[0] + pp[1].spc;
p1 = seqx[1] + pp[0].spc;
n0 = pp[1].spc + 1;
n1 = pp[0].spc + 1;
nm=0;
while ( *p0 && *pl ) {
if (siz0) {
p1++;
n1++;
siz0--;
}
else if (sizl) {
p0++;
n0++;
siz 1--;
}
else {
if (xbm[*p0-'A']&xbm[*pl-'A'])
nm++;
if (n0++ _= pp[0].x[i0])
siz0 = pp[0].n[i0++];
if (n1++ _= pp[1].x[il])
sizl = pp[1].n[il++];
p0++;
p1++;
}
/* pct homology:
* if penalizing endgaps, base is the shorter seq
* else, knock off overhangs and take shorter core
*/
if (endgaps)
lx = (len0 < lenl)? len0 : lent;
else
lx = (lx < 1y)? lx : 1y;
pct = 100. *(double)mn/(double)Ix;
fprintf(fx, "\n");
fprintf(fx, " < %d match% s in an overlap of %d: % .2f percent similarity\n",
~ (~ _= 1)? ..,. : "es,~ Ix, pct);
33
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
fprintf(fx, " < gaps in first sequence: % d", gapx); ...getmat
if (gapx) {
(void) sprintf(outx, " (%ad %s%s)",
ngapx, (dna)? "base":"residue", (ngapx == 1)? "":"s");
fprintf(fx,"%s", outx);
fprintf(fx, ", gaps in second sequence: %ad", gapy);
if (gapy) {
(void) sprintf(outx, " (%d %as%s)",
ngapy, (dna)? "base":"residue", (ngapy == 1)? "":"s");
fprintf(fx,"%s", outx);
if (dna)
fprintf(fx,
"\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
smax, DMAT, DMIS, DINSO, DINSl);
else
fprintf(fx,
"\n < score: % d (Dayhoff PAM 250 matrix, gap penalty
= % d + % d per residue)\n" ,
smax, PINSO, PINSl);
if (endgaps)
fprintf(fx,
2$ " < endgaps penalized. left endgap: %d %s%s, right
endgap: %0d %s%s\n",
firstgap, (dna)? "base" : "residue", (firstgap
== 1)? "" : "s",
lastgap, (dna)? "base" : "residue", (lastgap ==
1)? "" : "s");
else
fprintf(fx, " < endgaps not penalized\n");
}
static nm; /* matches in core -- for checking */
static lmax; /* lengths of stripped file names */
static ij[2]; /* jmp index for a path */
static nc[2]; /* number at start of current line */
static ni[2]; /* current elem number -- for gapping */
static siz[2];
static char *ps[2]; /* ptr to current element */
static char *po[2]; /* ptr to next output char slot */
static char out[2][P LINE]; /* output line */
static char star[P LINE]; /* set by stars() */
1*
* print alignmentof described in struct path pp[ ]
*/
static
pr align U pr align
{
int nn; /* char count */
int more;
register i;
for (i = 0, lmax = 0; i < 2; i++) {
nn = stripname(namex[i]);
if (nn > Imax)
lmax = nn;
nc[i] = 1;
ni[i] = 1;
siz[i] = ij[i] = 0;
ps[i] = seqx[i];
po[i] = out[i]; }
34
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
for (nn = nm = 0, more = 1; more; ) {
...pr align
for (i = more = 0; i < 2; i++) {
/*
* do we have more of this sequence?
*/
if (!*ps[i])
continue;
more++;
if (pp[i].spc) { /* leading space */
*po[i]++ _ ' ';
pp[i].spc--;
else if (siz[i]) { /* in a gap */
*po[i]++ _ ' ';
siz[i]--;
else { /* we're putting a seq element
*/
*po[i] _ *ps[i];
if (islower(*ps[i]))
*ps[i] = toupper(*ps[i]);
po[i]++;
ps[i}++;
30' /*
* are we at next gap for this seq?
*/
if (ni[i] _= pp[i].x[ij[i]]) {
/*
* we need to merge all gaps
* at this location
*!
siz[i] = pp[i].n[ij[i]++];
while (ni[i] _= pp[i].x[ij[i]])
siz[i] += pp[i].n[ij[i]++];
ni[i] + +;
if (++nn == olen ~ ~ !more && nn)
dumpblockQ;
for (i = 0; i < 2; i++)
po[i] = out[i];
nn=0;
}
/*
* dump a block of lines, including numbers, stars: pr alignQ
*/
static
dumpblock()
dumpblock
{
register i;
for (i = 0; i < 2; i++)
*po[i]__ -_ '\0';
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
..dumpblock
(void) putt('\n', fx);
For (i = 0; i < 2; i++) {
if (*out[i] && (*out[i] ! _ ' ' ~ ~ *(po[i]) ! _ ' ')) {
if (i = = 0)
nums(i);
if (i == 0 && *out[1])
starsQ;
putline(i);
if (i == 0 && *out[1])
fprintf(fx, star);
if (i == 1)
nums(i);
/*
* put out a number line: dumpblockQ
*/
static
nums(ix) nums
int ix; /* index in out[ ] holding seq line */
{
char mine[P LINE];
register i>j;
register char *pn, *px, *py;
for (pn = mine, i = 0; i < lmax+P SPC; i++, pn++)
*pn = . .;
for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
if (*py =- ' ' ~ ~ *PY = _ -')
*Pn = >
else {
if (i%a10 == 0 ~ ~ (i == 1 && nc[ix] != 1)) {
j = (i < 0)? -i : i;
for (px = pn; j; j /= 10, px--)
*px = j%10 + '0';
if (i < 0)
*px = . , .
else
*Pn =
i++;
*pn = '\0';
nc[ixj = i;
for (pn = mine; *pn; pn++)
(void) putt(*pn, fx);
(void) putt('\n', fx);
/*
* put out a line (name, [num], seq, [num]): dumpblock()
*/
static
putline(ix) putline
int ix;
36
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
...putline
int i;
register char *px;
for (px = namex[ix], i = 0; *px && *px ! _ '''; px++, i++)
(void) putt(*px, fx);
for (; i < lmax+P SPC; i++)
(void) putt(' ', fx);
/* these count from 1:
* ni( ] is current element (from 1)
* nc[ ] is number at start of current line
*/
for (px = out[ix]; *px; px++)
(void) putt(*px&Ox7F, fx);
(void) putt('\n', fx);
}
l*
* put a line of stars (seqs always in out[0], out[1]): dumpblock()
*!
static
stars()
stars
int i;
register char *p0, *pl, cx, *px;
if (! *out[0] ~ ~ (*out[0] _ - ' ' && *(po[0]) _ - ' ')
!*out[1] ~ ~ (*out[1] _- ' ' && *(po[1]) _- ' '))
return;
. px = star;
for (i = lmax+P SPC; i; i--)
*px++ _ ' ';
for (p0 = out[0], p1 = out[1]; *p0 && *pl; p0++, p1++) {
if (isalpha(*p0) && isalpha(*p1)) {
if (xbm[*p0-'A']&xbm[*pl-'A']) ~
cx = '*';
nm++;
}
else if (!dna && day[*p0-'A'][*pl-'A'] > 0)
cx = ";
else
cx = ";
}
else
cx = ";
*px++ = cx;
*px++ _ '\n';
*px = '\0';
37
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
* strip path or prefix from pn, return len: pr align()
*/
static
stripname(pn) stripname
char *pn; /* file name (may be path) *!
register char *px, *py;
PY=0>
for (px = pn; *px; px++)
if (*px =_ 'l')
py=px+1;
if (py)
(void) strcpy(pn, py);
return(strlen(pn));
25
35
45
55
38
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
* cleanup() -- cleanup any tmp file
* getseqQ -- read in seq, set dna, len, maxlen
* g callocQ -- callocQ with error checkin
* readjmps() -- get the good jmps, from tmp file if necessary
* writejmpsQ -- write a filled array of jmps to a tmp file: nwQ
*/
#include "nw.h"
#include < sys/file.h >
char *jname = "/tmp/homgXXXXXX"; l* tmp file for jmps */
FILE *fj;
int cleanup(); /* cleanup tmp file */
long lseek();
l*
* remove any tmp file if we blow
*/
cleanup(i) cleanup
int i;
{
if (fj)
(void) unlink(jname);
exit(i); '
/*
* read, return ptr to seq, set dna, len, maxlen
* skip lines starting with ';', ' <', or ' >'
* seq in upper or lower case
*/
char
getseq(file, len) getseq
char *file; /* file name */
int *len; /* seq len */
{
char line[1024], *pseq;
register char *px, *py;
int natgc, tlen;
FILE *fp;
if ((fp = fopen(file, "r")) _ = 0) {
fprintf(stderr," % s: can't read % s\n", prog, file);
exit(1);
tlen = natgc = 0;
while (fgets(line, 1024, fp)) {
if (*line =- '~' ~ ~ *line =- ' <' ~ ~ *line =- ' >')
continue;
for (px = line; *px ! _ '\n'; px++)
if (isupper(*px) ~ ~ islower(*px))
tlen++;
}
if ((pseq = malloc((unsigned)(tlen+6))) _ = 0) {
fprintf(stderr,"%s: mallocQ failed to get %d bytes for %s\n", prog, tlen+6,
file);
exit(1);
pseq[0] = pseq[1] = pseq[2] = pseq[3] _ '\0';
39
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
...getseq
py = pseq + 4;
*len = tlen;
rewind(fp);
while (fgets(line, 1024, fp)) {
if (*line =- ''' ~ ~ *line =- ' <' ~ ~ *line =- ' >')
continue;
for (px = line; *px ! _ '\n'; px++) {
if (isupper(*px))
*py++ _ *px;
else if (islower(*px))
*py++ = toupper(*px);
if (index("ATGCU",*(py-1)))
natgc+ +;
*py + + _ '\0';
*PY = ~\0~;
(void) fclose(fp);
dna = natgc > (tlen/3);
return(pseq+4);
char
g calloc(msg, nx, sz) g-calloc
char *msg; /* program, calling routine */
int nx, sz; /* number and size of elements *!
{
char *px, *calloc();
if ((px = calloc((unsigned)nx, (unsigned)sz)) _ = 0) {
if (*msg) {
fprintf(stderr, "% s: g callocQ failed % s (n= % d, sz= %d)\n", prog, msg, nx,
sz);
exit(1);
return(px);
/*
* get anal jmps from dx[ ] or tmp file, set pp[ ], reset dmax: main()
*!
readjmpsQ readjmps
{
int fd = -1;
int siz, i0, i1;
register i, j, xx;
if (fj) {
(void) fclose(fj);
if ((fd = open(jname, O_RDONLY, 0)) < 0) {
fprintf(stderr, "%s: can't open() %s\n", prog, jname);
cleanup(1);
for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; ; i++) {
while (1) {
for (j = dx[dmax].ijmp; j > = 0 && dx[dmax].jp.x[j] > = xx; j--)
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
...readjmps
if (j < 0 && dx[dmax].offset && fj) {
(void) lseek(fd, dx[dmax].offset, 0);
(void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
(void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
dx[dmax].ijmp = MAXJMP-1;
else
break;
if (i > = JMPS) {
fprintf(stderr, "%s: too many gaps in alignment\n", prog);
cleanup(1);
if (j > = o) {
siz = dx[dmax].jp.n(j];
xx = dx[dmax].jp.x[j];
dmax + = siz;
if (siz < 0) { /* gap in second seq *!
pp[1].n[il] _ -siz;
xx + = siz;
/*id=xx-yy+lenl-1
*!
pp[1].x[il] = xx - dmax + lenl - 1;
gapy+ +;
ngapy -= siz;
/* ignore MAXGAP when doing endgaps *!
siz = (-siz < MAXGAP ~ ~ endgaps)? -siz : MAXGAP;
i1++;
else if (siz > 0) { l* gap in first seq */
pp[0].n(i0] = siz;
pp[0].x[i0] = xx;
gapx++;
ngapx += siz;
/* ignore MAXGAP when doing endgaps */
siz = (siz < MAXGAP ~ ~ endgaps)? siz : MAXGAP;
i0++;
}
else
break;
/* reverse the order of jmps
*/
for (j = 0, i0--; j < i0; j++, i0--) {
i = pp[0].n(j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[O].x[i0] = i;
for (j = 0, i1--; j < i1; j++, i1--) {
i = pp[1].n[j]; pp[1].n[j] = pp[1].n[il]; pp[1].n[il] = i;
i = pp[1].x[j]; pp[1].x[j] = pp[1].x[il]; pp[1].x[il] = i;
if (fd > = 0)
(void) close(fd);
if (fj) {
(void) unlink(jname);
~ = 0;
offset = 0;
41
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 1 (cony)
/*
* write a filled jmp struct offset of the prev one (if any): nwQ
*/
writejmps(ix) writejmps
int ix;
char *mktempQ;
if (!~) ~
if (mktemp(jname) < 0) {
fprintf(stderr, "%s: can't mktempQ %s\n", prog, jname);
cleanup(1);
} "
if ((fj = fopen(jname, "w")) _= 0) {
fprintf(stderr, "%s: can't write %s\n", prog, jname);
exit(1);
(void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
(void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
42
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 2
PR020080 XXXXXXXXXXXXXXX (Length = 15 amino acids)
Comparison Protein XXXXXYYYYYYY (Length = 12 amino acids)
% amino acid sequence identity =
(the number of identically matching amino acid residues between the two
polypeptide sequences as
determined by ALIGN-2) divided by (the total number of amino acid residues of
the PR020080
polypeptide) _
5 divided by 15 = 33.3
Table 3
PR020080 XXXXXXXXXX (Length = 10 amino acids)
Comparison Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids)
amino acid sequence identity =
(the number of identically matching amino acid residues between the two
polypeptide sequences as
determined by ALIGN-2) divided by (the total number of amino acid residues of
the PR020080
polypeptide) _
5 divided by 10 = 50
Table 4
PR020080-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides)
Comparison DNA NNNNNNLLLLLLLLLL (Length = 16 nucleotides)
% nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid
sequences as determined by
ALIGN-2) divided by (the total number of nucleotides of the PR020080-DNA
nucleic acid sequence) _
43
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
6 divided by 14 = 42.9
Table 5
PR020080-DNA NNNNNNNNNNNN (Length = 12 nucleotides)
Comparison DNA NNNNLLLVV (Length = 9 nucleotides)
% nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid
sequences as determined by
ALIGN-2) divided by (the total number of nucleotides of the PR020080-DNA
nucleic acid sequence) _
4 divided by 12 = 33.3
II. Compositions and Methods of the Invention
A. Full-Length PR020080 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding
polypeptides referred to in the present application as PR020080 polypeptides.
In particular, cDNAs
encoding various PR020080 polypeptides have been identified and isolated, as
disclosed in further detail
in the Examples below. It is noted that proteins produced in separate
expression rounds may be given
different PR020080 numbers but the UNQ number is unique for any given DNA and
the encoded protein,
and will not be changed. However, for sake of simplicity, in the present
specification the protein encoded
by the full length native nucleic acid molecules disclosed herein as well as
all further native homologues
and variants included in the foregoing definition of PR020080, will be
referred to as
"PR020080/number", regardless of their origin or mode of preparation.
As disclosed in the Examples below, various cDNA clones have been deposited
with the ATCC.
The actual nucleotide sequences of those clones can readily be determined by
the skilled artisan by
sequencing of the deposited clone using routine methods in the art. The
predicted amino acid sequence
can be determined from the nucleotide sequence using routine skill. For the
PR020080 polypeptides and
encoding nucleic acids described herein, Applicants have identified what is
believed to be the reading
frame best identifiable with the sequence information available at the time.
B. PR020080 Polypeptide Variants
In addition to the full-length native sequence PR020080 polypeptides described
herein, it is
contemplated that PR020080 variants can be prepared. PR020080 variants can be
prepared by
introducing appropriate nucleotide changes into the PR020080 DNA, and/or by
synthesis of the desired
PR020080 polypeptide. Those skilled in the art will appreciate that amino acid
changes may alter post-
44
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
translational processes of the PR020080, such as changing the number or
position of glycosylation sites or
altering the membrane anchoring characteristics.
Variations in the native full-length sequence PRO20080 or in various domains
of the PR020080
described herein, can be made, for example, using any of the techniques and
guidelines for conservative
and non-conservative mutations set forth, for instance, in U.S. Patent No.
5,364,934. Variations may be
a substitution, deletion or insertion of one or more codons encoding the
PR020080 that results in a change
in the amino acid sequence of the PR020080 as compared with the native
sequence PR020080.
Optionally, the variation is by substitution of at least one amino acid with
any other amino acid in one or
more of the domains of the PR020080. Guidance in determining which amino acid
residue may be
inserted, substituted or deleted without adversely affecting the desired
activity may be found by comparing
the sequence of the PR020080 with that of homologous known protein molecules
and minimizing the
number of amino acid sequence changes made in regions of high homology. Amino
acid substitutions can
be the result of replacing one amino acid with another amino acid having
similar structural and/or
chemical properties, such as the replacement of a leucine with a serine, i.e.,
conservative amino acid
replacements. Insertions or deletions may optionally be in the range of about
1 to 5 amino acids. The
variation allowed may be determined by systematically making insertions,
deletions or substitutions of
amino acids in the sequence and.testing the resulting variants for activity
exhibited by the full-length or
mature native sequence.
PR020080 polypeptide fragments are provided herein. Such fragments may be
truncated at the
N-terminus or C-terminus, or may lack internal residues, for example, when
compared with a full length
native protein. Certain fragments lack amino acid residues that are not
essential for a desired biological
activity of the PR020080 polypeptide.
PR020080 fragments may be prepared by any of a number of conventional
techniques. Desired
peptide fragments may be chemically synthesized. An alternative approach
involves generating PR020080
fragments by enzymatic digestion, e.g., by treating the protein with an enzyme
known to cleave proteins at
sites defined by particular amino acid residues, or by digesting the DNA with
suitable restriction enzymes
and isolating the desired fragment. Yet another suitable technique involves
isolating and amplifying a
DNA fragment encoding a desired polypeptide fragment, by polymerase chain
reaction (PCR).
Oligonucleotides that define the desired termini of the DNA fragment are
employed at the 5' and 3'
primers in the PCR. Preferably, PR020080 polypeptide fragments share at least
one biological and/or
immunological activity with the native PR020080 polypeptide disclosed herein.
In particular embodiments, conservative substitutions of interest are shown in
Table 6 under the
heading of preferred substitutions. If such substitutions result in a change
in biological activity, then more
substantial changes, denominated exemplary substitutions in Table 6, or as
further described below in
reference to amino acid classes, are introduced and the products screened.
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Table 6
Original Exemplary Preferred
Residue Substitutions Substitutions
Ala (A) val; leu; ile
Arg (R) lys; gln; asn lys
Asn (N) gln; his; lys; arg gln
Asp (D) glu glu
Cys (C) ser ser
Gln (Q) asn
asn
Glu (E) asp asp
Gly (G) pro; ala ala
His (H) asn; gln; lys; arg arg
Ile (I) leu; val; met; ala; phe;
norleucine leu
Leu (L) norleucine; ile; val;
met; ala; phe ile
Lys (K) arg; gln; asn arg
Met (M) leu; phe; ile leu
Phe (F) leu; val; ile; ala; tyr leu
ala
Pro (P) . ala
~r
Ser (S) thr
Thr (T) ser ser
Trp (W) tYr; Phe n'r
Tyr (Y) trp; phe; thr; ser phe
Val (V) ile; leu; met; phe;
ala; norleucine leu
Substantial modifications in function or immunological identity of the
PR020080 polypeptide are
accomplished by selecting substitutions that differ significantly in their
effect on maintaining (a) the
structure of the polypeptide backbone in the area of the substitution, for
example, as a sheet or helical
conformation, (b) the charge or hydrophobicity of the molecule at the target
site, or (c) the bulk of the side
chain. Naturally occurring residues are divided into groups based on common
side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and
(6) aromatic: trp, tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these
classes for
another class. Such substituted residues also may be introduced into the
conservative substitution sites or,
more preferably, into the remaining (non-conserved) sites.
The variations can be made using methods known in the art such as
oligonucleotide-mediated
(site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-
directed mutagenesis lc:arter et
al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res.,
10:6487 (1987)], cassette
mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection
mutagenesis [Wells et al., Philos.
46
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be
performed on the cloned
DNA to produce the PR020080 variant DNA.
Scanning amino acid analysis can also be employed to identify one or more
amino acids along a
contiguous sequence. Among the preferred scanning amino acids are relatively
small, neutral amino
acids. Such amino acids include alanine, glycine, serine, and cysteine.
Alanine is typically a preferred
scanning amino acid among this group because it eliminates the side-chain
beyond the beta-carbon and is
less likely to alter the main-chain conformation of the variant [Cunningham
and Wells, Science, 244:
1081-1085 (1989)]. Alanine is also typically preferred because it is the most
common amino acid.
Further, it is frequently found in both buried and exposed positions
[Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine
substitution does not yield
adequate amounts of variant, an isoteric amino acid can be used.
C. Modifications of PR020080
Covalent modifications of PR020080 are included within the scope of this
invention. One type of
covalent modification includes reacting targeted amino acid residues of a
PR020080 polypeptide with an
organic derivatizing agent that is capable of reacting with selected side
chains or the N- or C- terminal
residues of the PR020080. Derivatization with bifunctional agents is useful,
for instance, for crosslinking
PR020080 to a water-insoluble support matrix or surface for use in the method
for purifying anti-
PR020080 antibodies, and vice-versa. Commonly used crosslinking agents
include, e.g., 1,1-
bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters,
for example, esters with 4-
azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl
esters such as 3,3'-
dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-
maleimido-1,8-octane and agents
such as methyl-3-[(p-azidophenyl)dithio]propioimidate.
Other modifications include deamidation of glutaminyl and asparaginyl residues
to the
corresponding glutamyl and aspartyl residues, respectively, hydroxylation of
proline and lysine,
phosphorylation of hydroxyl groups of Beryl or threonyl residues, methylation
of the a-amino groups of
lysine, arginine, and histidine side chains [T.E. Creighton, Proteins:
Structure and Molecular Properties,
W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-
terminal amine, and
amidation of any C-terminal carboxyl group.
Another type of covalent modification of the PR020080 polypeptide included
within the scope of
this invention comprises altering the native glycosylation pattern of the
polypeptide. "Altering the native
glycosylation pattern" is intended for purposes herein to mean deleting one or
more carbohydrate moieties
found in native sequence PR020080 (either by removing the underlying
glycosylation site or by deleting
the glycosylation by chemical and/or enzymatic means), and/or adding one or
more glycosylation sites that
are not present in the native sequence PR020080. In addition, the phrase
includes qualitative changes in
the glycosylation of the native proteins, involving a change in the nature and
proportions of the various
carbohydrate moieties present.
Addition of glycosylation sites to the PR020080 polypeptide may be
accomplished by altering the
amino acid sequence. The alteration may be made, for example, by the addition
of, or substitution by,
47
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
one or more serine or threonine residues to the native sequence PR020080 (for
O-linked glycosylation
sites). The PR020080 amino acid sequence may optionally be altered through
changes at the DNA level,
particularly by mutating the DNA encoding the PR020080 polypeptide at
preselected bases such that
codons are generated that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties on the
PR020080 polypeptide
is by chemical or enzymatic coupling of glycosides to the polypeptide. Such
methods are described in the
art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and
Wriston, CRC Crit. Rev.
Biochem., pp. 259-306 (1981).
Removal of carbohydrate moieties present on the PR020080 polypeptide may be
accomplished
chemically or enzymatically or by mutational substitution of codons encoding
for amino acid residues that
serve as targets for glycosylation. Chemical deglycosylation techniques are
known in the art and
described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys.,
259:52 (1987) and by Edge et
al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate
moieties on polypeptides can
be achieved by the use of a variety of endo- and exo-glycosidases as described
by Thotakura et al., Meth.
Enzymol., 138:350 (1987).
Another type of covalent modification of PR020080 comprises linking the
PR020080 polypeptide
to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol
(PEG), polypropylene glycol,
or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835;
4,496,689; 4,301,144;
4,670,417; 4,791,192 or 4,179,337.
The PR020080 of the present invention may also be modified in a way to form a
chimeric
molecule comprising PR020080 fused to another, heterologous polypeptide or
amino acid sequence.
In one embodiment, such a chimeric molecule comprises a fusion of the PR020080
with a tag
polypeptide which provides an epitope to which an anti-tag antibody can
selectively bind. The epitope tag
is generally placed at the amino- or carboxyl- terminus of the PR020080. The
presence of such epitope-
tagged forms of the PR020080 can be detected using an antibody against the tag
polypeptide. Also,
provision of the epitope tag enables the PR020080 to be readily purified by
affinity purification using an
anti-tag antibody or another type of affinity matrix that binds to the epitope
tag. Various tag polypeptides
and their respective antibodies are well known in the art. Examples include
poly-histidine (poly-his) or
poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its
antibody 12CA5 [Field et al.,
Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10,
G4, B7 and 9E10
antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616
(1985)]; and the Herpes
Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al.,
Protein Engineering, 3(6):547-
553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al.,
BioTechnology, 6:1204-1210
(1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)];
an alpha-tubulin epitope
peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7
gene 10 protein peptide tag
[Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].
In an alternative embodiment, the chimeric molecule may comprise a fusion of
the PR020080
with an irnmunoglobulin or a particular region of an immunoglobulin. For a
bivalent form of the chimeric
48
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
molecule (also referred to as an "immunoadhesin"), such a fusion could be to
the Fc region of an IgG
molecule. The Ig fusions preferably include the substitution of a soluble
(transmembrane domain deleted
or inactivated) form of a PR020080 polypeptide in place of at least one
variable region within an Ig
molecule. In a particularly preferred embodiment, the immunoglobulin fusion
includes the hinge, CH2
and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgGl molecule. For the
production of
immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.
D. Preparation of PR020080
The description below relates primarily to production of PR020080 by culturing
cells
transformed or transfected with a vector containing PR020080 nucleic acid. It
is, of course, contemplated
that alternative methods, which are well known in the art, may be employed to
prepare PR020080. For
instance, the PR020080 sequence, or portions thereof, may be produced by
direct peptide synthesis using
solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide
Synthesis, W.H. Freeman Co., San
Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In
vitro protein synthesis
may be performed using manual techniques or by automation. Automated synthesis
may be accomplished,
for instance, using an Applied Biosystems Peptide Synthesizer (Foster City,
CA) using manufacturer's
instructions. Various portions of the PR020080 may be chemically synthesized
separately and combined
using chemical or enzymatic methods to produce the full-length PR020080.
1. Isolation of DNA Encoding PR020080
DNA encoding PR020080 may be obtained from a cDNA library prepared from tissue
believed
to possess the PR020080~mRNA and to express it at a detectable level.
Accordingly, human PR020080
DNA can be conveniently obtained from a cDNA library prepared from human
tissue, such as described
in the Examples. The PR020080-encoding gene may also be obtained from a
genomic library or by
known synthetic procedures (e.g., automated nucleic acid synthesis).
Libraries can be screened with probes (such as antibodies to the PR020080 ox
oligonucleotides of
at least about 20-80 bases) designed to identify the gene of interest or the
protein encoded by it. Screening
the cDNA or genomic library with the selected probe may be conducted using
standard procedures, such
as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New
York: Cold Spring
Harbor Laboratory Press, 1989). An alternative means to isolate the gene
encoding PR020080 is to use
PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A
Laboratory Manual (Cold
Spring Harbor Laboratory Press, 1995)].
The Examples below describe techniques for screening a cDNA library. The
oligonucleotide
sequences selected as probes should be of sufficient length and sufficiently
unambiguous that false
positives are minimized. The oligonucleotide is preferably labeled such that
it can be detected upon
hybridization to DNA in the library being screened. Methods of labeling are
well known in the art, and
include the use of radiolabels like 3zP-labeled ATP, biotinylation or enzyme
labeling. Hybridization
conditions, including moderate stringency and high stringency, are provided in
Sambrook et al., supra.
Sequences identified in such library screening methods can be compared and
aligned to other
known sequences deposited and available in public databases such as GenBank or
other private sequence
49
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
databases. Sequence identity (at either the amino acid or nucleotide level)
within defined regions of the
molecule or across the full-length sequence can be determined using methods
known in the art and as
described herein.
Nucleic acid having protein coding sequence may be obtained by screening
selected cDNA or
genomic libraries using the deduced amino acid sequence disclosed herein for
the first time, and, if
necessary, using conventional primer extension procedures as described in
Sambrook et al., supra, to
detect precursors and processing intermediates of mRNA that may not have been
reverse-transcribed into
cDNA.
2. Selection and Transformation of Host Cells
Host cells are transfected or transformed with expression or cloning vectors
described herein for
PR020080 production and cultured in conventional nutrient media modified as
appropriate for inducing
promoters, selecting transformants, or amplifying the genes encoding the
desired sequences. The culture
conditions, such as media, temperature, pH and the like, can be selected by
the skilled artisan without
undue experimentation. In general, principles, protocols, and practical
techniques for maximizing the
productivity of cell cultures can be found in Mammalian Cell Biotechnology: a
Practical Approach, M.
Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.
Methods of eukaryotic cell transfection and prokaryotic cell transformation
are known to the
ordinarily skilled artisan, for example, CaCl2, CaP04, liposome-mediated and
electroporation. Depending
on the host cell used, transformation is performed using standard techniques
appropriate to such cells.
The calcium treatment employing calcium chloride, as described in Sambrook et
al., supra, or
electroporation is generally used for prokaryotes. Infection with
Agrobacterium tumefaciens is used for
transformation of certain plant cells, as described by Shaw et al., Gene,
23:315 (1983) and WO 89/05859
published 29 June 1989. For mammalian cells without such cell walls, the
calcium phosphate precipitation
method of Graham and van der Eb, Virolo , 52:456-457 (1978) can be employed.
General aspects.of
mammalian cell host system transfections have been described in U.S. Patent
No. 4,399,216.
Transformations into yeast are typically carried out according to the method
of Van Solingen et al., J.
Bact., _130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829
(1979). However, other
methods for introducing DNA into cells, such as by nuclear microinjection,
electroporation, bacterial
protoplast fusion with intact cells, or polycations, e.g., polybrene,
polyornithine, may also be used. For
various techniques for transforming mammalian cells, see Keown et al., Methods
in Enzymology,
185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
Suitable host cells for cloning or expressing the DNA in the vectors herein
include prokaryote,
yeast, or higher eukaryote cells. Suitable prokaryotes include but are not
limited to eubacteria, such as
Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such
as E. coli. Various E.
coli strains are publicly available, such as E. coli K12 strain MM294 (ATCC
31,446); E. coli X1776
(ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and KS 772 (ATCC 53,635).
Other suitable
prokaryotic host cells include Enterobacteriaceae such as Esclaericlaia, e.g.,
E. coli, Eraterobacter,
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Erwinia, Klebsiella, Proteus, Sahnotzella, e.g., Salznottella typhimuriutn,
Serratia, e.g., Serratia
znarcescans, and Shigella, as well as Bacilli such as B. subtilis and B.
licheniformis (e.g., B. licheniformis
41P disclosed in DD 266,710 published 12 April 1989), Pseudornonas such as P.
aerugitzosa, and
Streptomyces. These examples are illustrative rather than limiting. Strain
W3110 is one particularly
preferred host or parent host because it is a common host strain for
recombinant DNA product
fermentations. Preferably, the host cell secretes minimal amounts of
proteolytic enzymes. For example,
strain W3110 may be modified to effect a genetic mutation in the genes
encoding proteins endogenous to
the host, with examples of such hosts including E. coli W3110 strain 1A2,
which has the complete
genotype tonA ; E. coli W3110 strain 9E4, which has the complete genotype tonA
ptr3; E. coli W3110
strain 27C7 (ATCC 55,244), which has the complete genotype totzA ptr3 phoA EIS
(argF lac)169 degP
ontpT kan'; E. coli W3110 strain 37D6, which has the complete genotype tonA
ptr3 phoA E15 (argF
lac)169 degP ontpT rbs7 ilvG kanr; E. coli W3110 strain 40B4, which is strain
37D6 with a non
kanamycin resistant degP deletion mutation; and an E. coli strain having
mutant periplasmic protease
disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, in
vitro methods of cloning,
e.g., PCR or other nucleic acid polymerase reactions, are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or
yeast are suitable
cloning or expression hosts for PR020080-encoding vectors. Saccharomyces
cerevisiae is a commonly
used lower eukaryotic host microorganism. Others include Schizosaccharornyces
potnbe (Beach and
Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985);
Kluyverotnyces hosts (U.S. Patent
No. 4,943,529; Fleer et al., Bio/Teclmology, 9:968-975 (1991)) such as, e.g.,
K. lactis (MW98-8C,
CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), K.
fragilis (ATCC 12,424),
K. bulgaricus (ATCC 16,045), K. wickeratnii (ATCC 24,178), K. waltii (ATCC
56,500), K.
drosophilaruzn (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135
(1990)), K. tltermotolerans,
and K. matxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070;
Sreekrishna et al., J. Basic
Microbiol., 28:265-278 [1988]); Candida; Trichoderma reesia (EP 244,234);
Neurospora crassa (Case et
al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); Schwanniomyces such as
Schwarzrtiotnyces
occidetttalis (EP 394,538 published 31 October 1990); and filamentous fungi
such as, e.g., Neurospora,
Penicilliutn, Tolypocladium (WO 91/00357 published 10 January 1991), and
Aspergillus hosts such as A.
nidulazzs (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289
[1983]; Tilburn et al., Gene,
26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474
[1984]) and A. niger (Kelly
and Hynes, EMBO J., 4:475-479 [1985]). Methylotropic yeasts are suitable
herein and include, but are
not limited to, yeast capable of growth on methanol selected from the genera
consisting of Hatzsettula,
Cartdida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodototula. A
list of specific species that
are exemplary of this class of yeasts may be found in C. Anthony, The
Biochemistry of Methylotrophs,
269 (1982).
Suitable host cells for the expression of glycosylated PR020080 are derived
from multicellular
organisms. Examples of invertebrate cells include insect cells such as
Drosophila S2 and Spodoptera Sf9,
as well as plant cells. Examples of useful mammalian host cell lines include
Chinese hamster ovary
51
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
(CHO) and COS cells. More specific examples include monkey kidney CVl line
transformed by SV40
(COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells
subcloned for growth in
suspension culture, Graham et al., J. Gen Virol., 36:59 (1977)); Chinese
hamster ovary cells/-DHFR
(CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse
sertoli cells (TM4,
Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL
75); human liver cells
(Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The
selection of the
appropriate host cell is deemed to be within the skill in the art.
3. Selection and Use of a Replicable Vector
The nucleic acid (e.g., cDNA or genomic DNA) encoding PR020080 may be inserted
into a
replicable vector for cloning (amplification of the DNA) or for expression.
Various vectors are publicly
available. The vector may, for example, be in the form of a plasmid, cosmid,
viral particle, or phage.
The appropriate nucleic acid sequence may be inserted into the vector by a
variety of procedures. In
y~ general, DNA is inserted into an appropriate restriction endonuclease
sites) using techniques known in the
art. Vector components generally include, but are not limited to, one or more
of a signal sequence, an
origin of replication, one or more marker genes, an enhancer element, a
promoter, and a transcription
termination sequence. Construction of suitable vectors containing one or more
of these components
employs standard ligation techniques which are known to the skilled artisan.
The PRO20080 may be produced recombinantly not only directly, but also as a
fusion
polypeptide with a heterologous polypeptide, which may be a signal sequence or
other polypeptide having
a specific cleavage site at the N-terminus of the mature protein or
polypeptide. In general, the signal
sequence may be a component of the vector, or it may be a part of the PR020080-
encoding DNA that is
inserted into the vector. The signal sequence may be a prokaryotic signal
sequence selected, for example,
from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable
enterotoxin II leaders. For
yeast secretion the signal sequence may be, e.g., the yeast invertase leader,
alpha factor leader (including
Saccharornyces and Kluyveromyces a-factor leaders, the latter described in
U.S. Patent No. 5,010,182), or
acid phosphatase leader, the C. albicaras glucoamylase leader (EP 362,179
published 4 April 1990), or the
signal described in WO 90/13646 published 15 November 1990. In mammalian cell
expression,
mammalian signal sequences may be used to direct secretion of the protein,
such as signal sequences from
secreted polypeptides of the same or related species, as well as viral
secretory leaders.
Both expression and cloning vectors contain a nucleic acid sequence that
enables the vector to
replicate in one or more selected host cells. Such sequences are well known
for a variety of bacteria,
yeast, and viruses. The origin of replication from the plasmid pBR322 is
suitable for most Gram-negative
bacteria, the 2~, plasmid origin is suitable for yeast, and various viral
origins (SV40, polyoma, adenovirus,
VSV or BPV) are useful for cloning vectors in mammalian cells.
Expression and cloning vectors will typically contain a selection gene, also
termed a selectable
marker. Typical selection genes encode proteins that (a) confer resistance to
antibiotics or other toxins,
e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement
auxotrophic deficiencies, or (c)
52
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
supply critical nutrients not available from complex media, e.g., the gene
encoding D-alanine racemase
for Bacilli.
An example of suitable selectable markers for mammalian cells are those that
enable the
identification of cells competent to take up the PR020080-encoding nucleic
acid, such as DHFR or
thymidine kinase. An appropriate host cell when wild-type DHFR is employed is
the CHO cell line
deficient in DHFR activity, prepared and propagated as described by Urlaub et
al., Proc. Natl. Acad. Sci.
USA, 77:4216 (1980). A suitable selection gene for use in yeast is the trill
gene present in the yeast
plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene,
7:141 (1979);
Tschemper et al., Gene, 10:157 (1980)]. The trill gene provides a selection
marker for a mutant strain of
yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076
or PEP4-1 [Jones,
Genetics, 85:12 ( 1977)] .
Expression and cloning vectors usually contain a promoter operably linked to
the PR020080-
encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized
by a variety of potential
host cells are well known. Promoters suitable for use with prokaryotic hosts
include the (3-lactamase and
lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et
al., Nature, 281:544 (1979)],
alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic
Acids Res., 8:4057 (1980);
EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al.,
Proc. Natl. Acad. Sci. USA,
80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a
Shine-Dalgarno (S.D.)
sequence operably linked to the DNA encoding PR020080.
Examples of suitable promoting sequences for use with yeast hosts include the
promoters for 3
phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or
other glycolytic enzymes
[Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry,
17:4900 (1978)], such as
enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase,
phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase,
pyruvate kinase,
triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional
advantage of
transcription controlled by growth conditions, are the promoter regions for
alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, degradative enzymes associated with
nitrogen metabolism,
metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes
responsible for maltose and
galactose utilization. Suitable vectors and promoters for use in yeast
expression are further described in
EP 73,657.
PR020080 transcription from vectors in mammalian host cells is controlled, for
example, by
promoters obtained from the genomes of viruses such as polyoma virus, fowlpox
virus (UK 2,211,504
published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma
virus, avian sarcoma virus,
cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40),
from heterologous
mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter,
and from heat-shock
promoters, provided such promoters are compatible with the host cell systems.
53
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Transcription of a DNA encoding the PR020080 by higher eukaryotes may be
increased by
inserting an enhancer sequence into the vector. Enhancers are cis-acting
elements of DNA, usually about
from 10 to 300 bp, that act on a promoter to increase its transcription. Many
enhancer sequences are now
known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and
insulin). Typically,
however, one will use an enhancer from a eukaryotic cell virus. Examples
include the SV40 enhancer on
the late side of the replication origin (bp 100-270), the cytomegalovirus
early promoter enhancer, the
polyoma enhancer on the late side of the replication origin, and adenovirus
enhancers. The enhancer may
be spliced into the vector at a position 5' or 3' to the PR020080 coding
sequence, but is preferably located
at a site 5' from the promoter.
Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant,
animal, human, or
nucleated cells from other multicellular organisms) will also contain
sequences necessary for the
termination of transcription and for stabilizing the mRNA. Such sequences are
commonly available from
the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs
or cDNAs. These regions
contain nucleotide segments transcribed as polyadenylated fragments in the
untranslated portion of the
mRNA encoding PR020080. ,
Still other methods, vectors, and host cells suitable for adaptation to the
synthesis of PR020080
in recombinant vertebrate cell culture are described in Gething et al.,
Nature, 293:620-625 (1981); Mantei
et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.
4. Detecting Gene Amplification/Expression
Gene amplification and/or expression may be measured in a sample directly, for
example, by
conventional Southern blotting, Northern blotting to quantitate the
transcription of mRNA [Thomas, Proc.
Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or in
situ hybridization, using
an appropriately labeled probe, based on the sequences provided herein.
Alternatively, antibodies may be
employed that can recognize specific duplexes, including DNA duplexes, RNA
duplexes, and DNA-RNA
hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled
and the assay may be
carried out where the duplex is bound to a surface, so that upon the formation
of duplex on the surface,
the presence of antibody bound to the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such
as
immunohistochemical staining of cells or tissue sections and assay of cell
culture or body fluids, to
quantitate directly the expression of gene product. Antibodies useful for
immunohistochemical staining
and/or assay of sample fluids may be either monoclonal or polyclonal, and may
be prepared in any
mammal. Conveniently, the antibodies may be prepared against a native sequence
PRO20080 polypeptide
or against a synthetic peptide based on the DNA sequences provided herein or
against exogenous sequence
fused to PR020080 DNA and encoding a specific antibody epitope.
5. Purification of Polvnentide
Forms of PR020080 may be recovered from culture medium or from host cell
lysates. If
membrane-bound, it can be released from the membrane using a suitable
detergent solution (e.g. Triton-X
100) or by enzymatic cleavage. Cells employed in expression of PR020080 can be
disrupted by various
54
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
physical or chemical means, such as freeze-thaw cycling, sonication,
mechanical disruption, or cell lysing
agents.
It may be desired to purify PR020080 from recombinant cell proteins or
polypeptides. The
following procedures are exemplary of suitable purification procedures: by
fractionation on an ion-
s exchange column; ethanol precipitation; reverse phase HPLC; chromatography
on silica or on a cation-
exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate
precipitation; gel
filtration using, for example, Sephadex G-75; protein A Sepharose columns to
remove contaminants such
as IgG; and metal chelating columns to bind epitope-tagged forms of the
PR020080. Various methods of
protein purification may be employed and such methods are known in the art and
described for example in
Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification:
Principles and Practice,
Springer-Verlag, New York (1982). The purification steps) selected will
depend, for example, on the
nature of the production process used and the particular PR020080 produced.
E. Tissue Distribution
The location of tissues expressing the PR020080 can be identified by
determining mRNA
expression in various human tissues. The location of such genes provides
information about which tissues
are most likely to be affected by the stimulating and inhibiting activities of
the PR020080 polypeptides.
The location of a gene in a specific tissue also provides sample tissue for
the activity blocking assays
discussed below.
As noted before, gene expression in various tissues may be measured by
conventional Southern
blotting, Northern blotting to quantitate the transcription of mRNA (Thomas,
Proc. Natl. Acad. Sci. USA,
_77:5201-5205 [1980]), dot blotting (DNA analysis), or ira situ hybridization,
using an appropriately labeled
probe, based on the sequences provided herein. Alternatively, antibodies may
be employed that can
recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA
hybrid duplexes or
DNA-protein duplexes.
Gene expression in various tissues, alternatively, may be measured by
immunological methods,
such as immunohistochemical staining of tissue sections and assay of cell
culture or body fluids, to
quantitate directly the expression of gene product. Antibodies useful for
immunohistochemical staining
and/or assay of sample fluids may be either monoclonal or polyclonal, and may
be prepared in any
mammal. Conveniently, the antibodies may be prepared against a native sequence
of a PR020080
polypeptide or against a synthetic peptide based on the DNA sequences encoding
the PR020080
polypeptide or against an exogenous sequence fused to a DNA encoding a
PR020080 polypeptide and
encoding a specific antibody epitope. General techniques for generating
antibodies, and special protocols
for Northern blotting and ira situ hybridization are provided below.
F. Antibody Binding Studies
The activity of the PR020080 polypeptides can be further verified by antibody
binding studies, in
which the ability of anti-PR020080 antibodies to inhibit the effect of the
PR020080 polypeptides,
respectively, on tissue cells is tested. Exemplary antibodies include
polyclonal, monoclonal, humanized,
bispecific, and heteroconjugate antibodies, the preparation of which will be
described hereinbelow.
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Antibody binding studies may be carried out in any known assay method, such as
competitive
binding assays, direct and indirect sandwich assays, and immunoprecipitation
assays. Zola, Monoclonal
Antibodies: A Maraual of Techniques, pp.147-158 (CRC Press, Inc., 1987).
Competitive binding assays rely on the ability of a labeled standard to
compete with the test
sample analyte for binding with a limited amount of antibody. The amount of
target protein in the test
sample is inversely proportional to the amount of standard that becomes bound
to the antibodies. To
facilitate determining the amount of standard that becomes bound, the
antibodies preferably are
insolubilized before or after the competition, so that the standard and
analyte that are bound to the
antibodies may conveniently be separated from the standard and analyte which
remain unbound.
Sandwich assays involve the use of two antibodies, each capable of binding to
a different
immunogenic portion, or epitope, of the protein to be detected. In a sandwich
assay, the test sample
analyte is bound by a first antibody which is immobilized on a solid support,
and thereafter a second
antibody binds to the analyte, thus forming an insoluble three-part complex.
See, e.g., US Pat No.
4,376,110. The second antibody may itself be labeled with a detectable moiety
(direct sandwich assays) or
may be measured using an anti-immunoglobulin antibody that is labeled with a
detectable moiety (indirect
sandwich assay). For example, one type of sandwich assay is an ELISA assay, in
which case the
detectable moiety is an enzyme.
For immunohistochemistry, the tissue sample may be fresh or frozen or may be
embedded in
paraffin and fixed with a preservative such as formalin, for example.
G. Cell-Based Assays
Cell-based assays and animal models for immune related diseases can be used to
further
understand the relationship between the genes and polypeptides identified
herein and the development and
pathogenesis of immune related disease.
In a different approach, cells of a cell type known to be involved in a
particular immune related
disease are transfected with the cDNAs described herein, and the ability of
these cDNAs to stimulate or
inhibit immune function is analyzed. Suitable cells can be transfected with
the desired gene, and
monitored for immune function activity. Such transfected cell lines can then
be used to test the ability of
poly- or monoclonal antibodies or antibody compositions to inhibit or
stimulate immune function, for
example to modulate T-cell proliferation or inflammatory cell infiltration.
Cells transfected with the
coding sequences of the genes identified herein can further be used to
identify drug candidates for the
treatment of immune related diseases.
In addition, primary cultures derived from transgenic animals (as described
below) can be used in
the cell-based assays herein, although stable cell lines are preferred.
Techniques to derive continuous cell
lines from transgenic _animals are well known in the art (see, e.g., Small et
al., Mol. Cell. Biol. 5: 642
648 [1985]).
One suitable cell based assay is the mixed lymphocyte reaction (MLR). Current
Protocols in
Immunology, unit 3.12; edited by J E Coligan, A M Kruisbeek, D H Marglies, E M
Shevach, W Strober,
National Institutes of Health, Published by John Wiley & Sons, Inc. In this
assay, the ability of a test
56
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
compound to stimulate or inhibit the proliferation of activated T cells is
assayed. A suspension of
responder T cells is cultured with allogeneic stimulator cells and the
proliferation of T cells is measured by
uptake of tritiated thymidine. This assay is a general measure of T cell
reactivity. Since the majority of T
cells respond to and produce IL-2 upon activation, differences in
responsiveness in this assay in part
reflect differences in IL-2 production by the responding cells. The MLR
results can be verified by a
standard lymphokine (IL-2) detection assay. Current Protocols in Lmmunology,
above, ~. m, 6.3.
A proliferative T cell response in an MLR assay may be due to direct mitogenic
properties of an
assayed molecule or to external antigen induced activation. Additional
verification of the T cell
stimulatory activity of the PR020080 polypeptides can be obtained by a
costimulation assay. T cell
activation requires an antigen specific signal mediated through the T-cell
receptor (TCR) and a
costimulatory signal mediated through a second ligand binding interaction, for
example, the B7 (CD80,
CD86)/CD28 binding interaction. CD28 crosslinking increases lymphokine
secretion by activated T cells.
T cell activation has both negative and positive controls through the binding
of ligands which have a
negative or positive effect. CD28 and CTLA-4 are related glycoproteins in the
Ig superfamily which bind
to B7. CD28 binding to B7 has a positive costimulation effect of T cell
activation; conversely, CTLA-4
binding to B7 has a T cell deactivating effect. Chambers, C. A. and Allison,
J. P., Curr. Opin. Immunol.
(1997) 9:396. Schwartz, R. H., Cell (1992) 71:1065; Linsey, P. S. and
Ledbetter, J. A., Aranu. Rev.
Irnrnunol. (1993) 11:191; June, C. H. et al, InZmuraol. Today (1994) 15:321;
Jenkins, M. I~., Irnrnuniry
(1994) 1:405. In a costimulation assay, the P1ZUZUU~U polypephaes are assayea
ror i ceu cosummawry
or inhibitory activity.
PR020080 polypeptides, as well as other compounds of the invention, which are
stimulators
(costimulators) of T cell proliferation and agonists, e.g., agonist
antibodies, thereto as determined by
MLR and costimulation assays, for example, are useful in treating immune
related diseases characterized
by poor, suboptimal or inadequate immune function. These diseases are treated
by stimulating the
proliferation and activation of T cells (and T cell mediated immunity) and-
enhancing the immune response
in a mammal through administration of a stimulatory compound, such as the
stimulating PR020080
polypeptides. The stimulating polypeptide may, for example, be a PR020080
polypeptide or an agonist
antibody thereof.
Direct use of a stimulating compound as in the invention has been validated in
experiments with
4-1BB glycoprotein, a member of the tumor necrosis factor receptor family,
which binds to a ligand (4-
1BBL) expressed on primed T cells and signals T cell activation and growth.
Alderson, M. E. et al., J.
Irnrnunol. (1994) 24:2219.
The use of an agonist stimulating compound has also been validated
experimentally. Activation
of 4-1BB by treatment with an agonist anti-4-1BB antibody enhances eradication
of tumors. Hellstrom, I.
and Hellstrom, K. E., Crit. Rev. Irnmuraol. (1998) 18:1. Immunoadjuvant
therapy for treatment of
tumors, described in more detail below, is another example of the use of the
stimulating compounds of
the invention.
57
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
An immune stimulating or enhancing effect can also be achieved by antagonizing
or blocking the
activity of a PR020080 which has been found to be inhibiting in the MLR assay.
Negating the inhibitory
activity of the compound produces a net stimulatory effect. Suitable
antagonists/blocking compounds are
antibodies or fragments thereof which recognize and bind to the inhibitory
protein, thereby blocking the
effective interaction of the protein with its receptor and inhibiting
signaling through the receptor. This
effect has been validated in experiments using anti-CTLA-4 antibodies which
enhance T cell proliferation,
presumably by removal of the inhibitory signal caused by CTLA-4 binding.
Walunas, T. L. et al,
Immunity (1994) 1:405.
On the other hand, PR020080 polypeptides, as well as other compounds of the
invention, which
are direct inhibitors of T cell proliferation/activation or lymphokine
secretion, can be directly used to
suppress the immune response. These compounds are useful to reduce the degree
of the immune response
and to treat immune related diseases characterized by a hyperactive,
superoptimal, or autoimmune
response. This use of the compounds of the invention has been validated by the
experiments described
above in which CTLA-4 binding to receptor B7 deactivates T cells. The direct
inhibitory compounds of
. the invention function in an analogous manner. The use of compound which
suppress vascular
permeability would be expected to reduce inflammation. Such uses would be
beneficial in treating
conditions associated with excessive inflammation.
Alternatively, compounds, e.g., antibodies, which bind to stimulating PR020080
polypeptides
and block the stimulating effect of these molecules produce a net inhibitory
effect and can be used to
suppress the T cell mediated immune response by inhibiting T cell
proliferation/activation and/or
lymphokine secretion. Blocking the stimulating effect of the polypeptides
suppresses the immune response
of the mammal. This use has been validated in experiments using an anti-IL2
antibody. In these
experiments, the antibody binds to IL2 and blocks binding of IL2 to its
receptor thereby achieving a T cell
inhibitory effect.
H. Animal Models
The results of the cell based in vitro assays can be further verified using in
vivo animal models
and assays for T-cell function. A variety of well known animal models can be
used to further understand
the role of the genes identified herein in the development and pathogenesis of
immune related disease, and
to test the efficacy of candidate therapeutic agents, including antibodies,
and other antagonists of the native
polypeptides, including small molecule antagonists. The in vivo nature of such
models makes them
predictive of responses in human patients. Animal models of immune related
diseases include both non-
recombinant and recombinant (transgenic) animals. Non-recombinant animal
models include, for
example, rodent, e.g., marine models. Such models can be generated by
introducing cells into syngeneic
mice using standard techniques, e.g., subcutaneous injection, tail vein
injection, spleen implantation,
intraperitoneal implantation, implantation under the renal capsule, etc.
Graft-versus-host disease occurs when immunocompetent cells are transplanted
into
immunosuppressed or tolerant patients. The donor cells recognize and respond
to host antigens. The
58
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
response can vary from life threatening severe inflammation to mild cases of
diarrhea and weight loss.
Graft-versus-host disease models provide a means of assessing T cell
reactivity against MHC antigens and
minor transplant antigens. A suitable procedure is described in detail in
Current Protocols in
Immunology, above, unit 4.3.
An animal model for skin allograft rejection is a means of testing the ability
of T cells to mediate
in vivo tissue destruction and a measure of their role in transplant
rejection. The most common and
accepted models use murine tail-skin grafts. Repeated experiments have shown
that skin allograft
rejection is mediated by T cells, helper T cells and killer-effector T cells,
and not antibodies.
Auchincloss, H. Jr. and Sachs, D. H., Fundatneratal Immunology, 2nd ed., W. E.
Paul ed., Raven Press,
NY, 1989, 889-992. A suitable procedure is described in detail in Crtrrerat
Protocols in Immunology,
above, unit 4.4. Other transplant rejection models which can be used to test
the compounds of the
invention are the allogeneic heart transplant models described by Tanabe, M.
et al, Transplantation (1994)
58:23 and Tinubu, S. A. et al, J. Irnrnuraol. (1994) 4330-4338.
Animal models for delayed type hypersensitivity provides an assay of cell
mediated immune
function as well. Delayed type hypersensitivity reactions are a T cell
mediated ira vivo immune response
characterized by inflammation which does not reach a peak until after a period
of time has elapsed after
challenge with an antigen. These reactions also occur in tissue specific
autoimmune diseases such as
multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE, a
model for MS). A
suitable procedure is described in detail in Current Protocols in
Irnrnunology, above, unit 4.5.
EAE is a T cell mediated autoimmune disease characterized by T cell and
mononuclear cell
inflammation and subsequent demyelination of axons in the central nervous
system. EAE is generally
considered to be a relevant animal model for MS in humans. Bolton, C.,
Multiple Sclerosis (1995) 1:143.
Both acute and relapsing-remitting models have been developed. The compounds
of the invention can be
tested for T cell stimulatory or inhibitory activity against immune mediated
demyelinating disease using
the protocol described in Current Protocols in Imrnunology, above, units 15.1
and 15.2. See also the
models for myelin disease in which oligodendrocytes or Schwann cells are
grafted into the central nervous
system as described in Duncan, I. D. et al, Molec. Med. Today (1997) 554-561.
Contact hypersensitivity is a simple delayed type hypersensitivity in vivo
assay of cell mediated
immune function. In this procedure, cutaneous exposure to exogenous haptens
which gives rise to a
delayed type hypersensitivity reaction which is measured and quantitated.
Contact sensitivity involves an
initial sensitizing phase followed by an elicitation phase. The elicitation
phase occurs when the T
lymphocytes encounter an antigen to which they have had previous contact.
Swelling and inflammation
occur, making this an excellent model of human allergic contact dermatitis. A
suitable procedure is
described in detail in Current Protocols ira Immunology, Eds. J. E. Cologan,
A. M. I~ruisbeek, D. H.
Margulies, E. M. Shevach and W. Strober, John Wiley & Sons, Inc., 1994, unit
4.2. See also Grabbe, S.
and Schwarz, T, Irr2mura. Today 19 (1): 37-44 (1998) .
An animal model for arthritis is collagen-induced arthritis. This model shares
clinical,
histological and immunological characteristics of human autoimmune rheumatoid
arthritis and is an
59
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
acceptable model for human autoimmune arthritis. Mouse and rat models are
characterized by synovitis,
erosion of cartilage and subchondral bone. The compounds of the invention can
be tested for activity
against autoimmune arthritis using the protocols described in Current
Protocols in Imrnuraology, above,
units 15.5. See also the model using a monoclonal antibody to CD18 and VLA-4
integrins described in
Issekutz, A.C. et al., Immunology (1996) 88:569.
A model of asthma has been described in which antigen-induced airway hyper-
reactivity,
pulmonary eosinophilia and inflammation are induced by sensitizing an animal
with ovalbumin and then
challenging the animal with the same protein delivered by aerosol. Several
animal models (guinea pig,
rat, non-human primate) show symptoms similar to atopic asthma in humans upon
challenge with aerosol
antigens. Murine models have many of the features of human asthma. Suitable
procedures to test the
compounds of the invention for activity and effectiveness in the treatment of
asthma are described by
Wolyniec, W. W. et al, Arn. J. Respir. Cell Mol. Biol. (1998) 18:777 and the
references cited therein.
Additionally, the compounds of the invention can be tested on animal models
for psoriasis like
diseases. Evidence suggests a T cell pathogenesis for psoriasis. The compounds
of the invention can be
tested in the scid/scid _mouse model described by Schon, M. P. et al, Nat.
Med. (1997) 3:183, in which
the mice demonstrate histopathologic skin lesions resembling psoriasis.
Another suitable model is the
human skin/scid mouse chimera prepared as described by Nickoloff, B. J. et al,
Am. J. Path. (1995)
_146:580.
Recombinant (transgenic) animal models can be engineered by introducing the
coding portion of
the genes identified herein into the genome of animals of interest, using
standard techniques for producing
transgenic animals. Animals that can serve as a target for transgenic
manipulation include, without
limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-
human primates, e.g., baboons,
chimpanzees and monkeys. Techniques known in the art to introduce a transgene
into such animals
include pronucleic microinjection (Hoppe and Wanger, U.S. Patent No.
4,873,191); retrovirus-mediated
gene transfer into germ lines (e.g., Van der Putten et al., Proc. Natl. Acad.
Sci. USA 82, 6148-615
[1985]); gene targeting in embryonic stem cells (Thompson et al., Cell 56, 313-
321 [1989]);
electroporation of embryos (Lo, Mol. Cel. Biol. 3, 1803-1814 [1983]); sperm-
mediated gene transfer
(Lavitrano et al., Cell 57, 717-73 [1989]). For review, see, for example, U.S.
Patent No. 4,736,866.
For the purpose of the present invention, transgenic animals include those
that carry the transgene
only in part of their cells ("mosaic animals"). The transgene can be
integrated either as a single transgene,
or in concatamers, e.g., head-to-head or head-to-tail tandems. Selective
introduction of a transgene into a
particular cell type is also possible by following, for example, the technique
of Lasko et al., Proc. Natl.
Acad. Sci. USA 89, 6232-636 (1992).
The expression of the transgene in transgenic animals can be monitored by
standard techniques.
For example, Southern blot analysis or PCR amplification can be used to verify
the integration of the
transgene. The level of mRNA expression can then be analyzed using techniques
such as in situ
hybridization, Northern blot analysis, PCR, or immunocytochemistry.
The animals may be further examined for signs of immune disease pathology, for
example by
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
histological examination to determine infiltration of immune cells into
specific tissues. Blocking
experiments can also be performed in which the transgenic animals are treated
with the compounds of the
invention to determine the extent of the T cell proliferation stimulation or
inhibition of the compounds. In
these experiments, blocking antibodies which bind to the PR020080 polypeptide,
prepared as described
above, are administered to the animal and the effect on immune function is
determined.
Alternatively, "knock out" animals can be constructed which have a defective
or altered gene
encoding a polypeptide identified herein, as a result of homologous
recombination between the endogenous
gene encoding the polypeptide and altered genomic DNA encoding the same
polypeptide introduced into
an embryonic cell of the animal. For example, cDNA encoding a particular
polypeptide can be used to
clone genomic DNA encoding that polypeptide in accordance with established
techniques. A portion of
the genomic DNA encoding a particular polypeptide can be deleted or replaced
with another gene, such as
a gene encoding a selectable marker which can be used to monitor integration.
Typically, several
kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included
in the vector [see e.g.,
Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous
recombination vectors]. The
vector is introduced into an embryonic stem cell line (e.g., by
electroporation) and cells in which the
introduced DNA has homologously recombined with the endogenous DNA are
selected [see e. g., Li et al. ,
Cell, _69:915 (1992)]. The selected cells are then injected into a blastocyst
of an animal (e.g., a mouse or
rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcitzomas and
Embryonic Stem Cells: A
Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A
chimeric embryo can
then be implanted into a suitable pseudopregnant female foster animal and the
embryo brought to term to
create a "knock out" animal. Progeny harboring the homologously recombined DNA
in their germ cells
can be identified by standard techniques and used to breed animals in which
all cells of the animal contain
the homologously recombined DNA. Knockout animals can be characterized for
instance, for their ability
to defend against certain pathological conditions and for their development of
pathological conditions due
to absence of the polypeptide.
I. _ImmunoAdjuvant Therapy
In one embodiment, the immunostimulating compounds of the invention can be
used in
immunoadjuvant therapy for the treatment of tumors (cancer). It is now well
established that T cells
recognize human tumor specific antigens. One group of tumor antigens, encoded
by the MAGE, BAGE
and GAGE families of genes, are silent in all adult normal tissues , but are
expressed in significant
amounts in tumors, such as melanomas, lung tumors, head and neck tumors, and
bladder carcinomas.
DeSmet, C. et al., (1996) Proc. Natl. Acad. Sci. USA, 93:7149. It has been
shown that costimulation of
T cells induces tumor regression and an antitumor response both in vitro and
in vivo. Melero, I. et al.,
Nature Medicirte -(1997) 3:682; Kwon, E. D. et al., Proc. Natl. Acad. Sci. USA
(1997) 94: 8099; Lynch,
D. H. et al, Nature Medicine (1997) 3:625; Finn, O. J. and Lotze, M. T., J.
Immunol. (1998) 21:114.
The stimulatory compounds of the invention can be administered as adjuvants,
alone or together with a
growth regulating agent, cytotoxic agent or chemotherapeutic agent, to
stimulate T cell
proliferation/activation and an antitumor response to tumor antigens. The
growth regulating, cytotoxic, or
61
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
chemotherapeutic agent may be administered in conventional amounts using known
administration
regimes. Immunostimulating activity by the compounds of the invention allows
reduced amounts of the
growth regulating, cytotoxic, or chemotherapeutic agents thereby potentially
lowering the toxicity to the
patient.
J. Screening Assays for Drug Candidates
Screening assays for drug candidates are designed to identify compounds that
bind to or complex
with the polypeptides encoded by the genes identified herein or a biologically
active fragment thereof, or
otherwise interfere with the interaction of the encoded polypeptides with
other cellular proteins. Such
screening assays will include assays amenable to high-throughput screening of
chemical libraries, making
them particularly suitable for identifying small molecule drug candidates.
Small molecules contemplated
include synthetic organic or inorganic compounds, including peptides,
preferably soluble peptides,
(poly)peptide-immunoglobulin fusions, and, in particular, antibodies
including, without limitation, poly-
and monoclonal antibodies and antibody fragments, single-chain antibodies,
anti-idiotypic antibodies, and
chimeric or humanized versions of such antibodies or fragments, as well as
human antibodies and antibody
fragments. The assays can be performed in a variety of formats, including
protein-protein binding assays,
biochemical screening assays, immunoassays and cell based assays, which are
well characterized in the
art. All assays are common in that they call for contacting the drug candidate
with a polypeptide encoded
by a nucleic acid identified herein under conditions and for a time sufficient
to allow these two
components to interact.
In binding assays, the interaction is binding and the complex formed can be
isolated or detected in
the reaction mixture. In a particular embodiment, the polypeptide encoded by
the gene identified herein or
the drug candidate is immobilized on a solid phase, e.g., on a microtiter
plate, by covalent or non-covalent
attachments. Non-covalent attachment generally is accomplished by coating the
solid surface with a
solution of the polypeptide and drying. Alternatively, an immobilized
antibody, e.g., a monoclonal
antibody, specific for the polypeptide to be immobilized can be used to anchor
it to a solid surface. The
assay is performed by adding the non-immobilized component, which may be
labeled by a detectable
label, to the immobilized component, e.g., the coated surface containing the
anchored component. When
the reaction is complete, the non-reacted components are removed, e.g., by
washing, and complexes
anchored on the solid surface are detected. When the originally non-
immobilized component carries a
detectable label, the detection of label immobilized on the surface indicates
that complexing occurred.
Where the originally non-immobilized component does not carry a label,
complexing can be detected, for
example, by using a labelled antibody specifically binding the immobilized
complex.
If the candidate compound interacts with but does not bind to a particular
protein encoded by a
gene identified herein, its interaction with that protein can be assayed by
methods well known for detecting
protein-protein interactions. Such assays include traditional approaches, such
as, cross-linking, co-
immunoprecipitation, and co-purification through gradients or chromatographic
columns. In addition,
protein-protein interactions can be monitored by using a yeast-based genetic
system described by Fields
and co-workers [Fields and Song, Nature (Londora) 340, 245-246 (1989); Chien
et al., Proc. Natl. Acad.
62
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Sci. USA 88, 9578-9582 (1991)] as disclosed by Chevray and Nathans, Proc.
Natl. Acad. Sci. USA 89,
5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist
of two physically
discrete modular domains, one acting as the DNA-binding domain, while the
other one functioning as the
transcription activation domain. The yeast expression system described in the
foregoing publications
(generally referred to as the "two-hybrid system") takes advantage of this
property, and employs two
hybrid proteins, one in which the target protein is fused to the DNA-binding
domain of GAL4, and
another, in which candidate activating proteins are fused to the activation
domain. The expression of a
GALL-lacZ reporter gene under control of a GAL4-activated promoter depends on
reconstitution of GAL4
activity via protein-protein interaction. Colonies containing interacting
polypeptides are detected with a
chromogenic substrate for [3-galactosidase. A complete kit (MATCHMAKERTM) for
identifying protein-
protein interactions between two specific proteins using the two-hybrid
technique is commercially
available from Clontech. This system can also be extended to map protein
domains involved in specific
protein interactions as well as to pinpoint amino acid residues that are
crucial for these interactions.
In order to find compounds that interfere with the interaction of a gene
identified herein and other
intra- or extracellular components can be tested, a reaction mixture is
usually prepared containing the
product of the gene and the intra- or extracellular component under conditions
and for a time allowing for
the interaction and binding of the two products. To test the ability of a test
compound to inhibit binding,
the reaction is run in the absence and in the presence of the test compound.
In addition, a placebo may be
added to a third reaction mixture, to serve as positive control. The binding
(complex formation) between
the test compound and the intra- or extracellular component present in the
mixture is monitored as
described above. The formation of a complex in the control reactions) but not
in the reaction mixture
containing the test compound indicates that the test compound interferes with
the interaction of the test
compound and its reaction partner.
K. Compositions and Methods for the Treatment of Immune Related Diseases
The compositions useful in the treatment of immune related diseases include,
without limitation,
proteins, antibodies, small organic molecules, peptides, phosphopeptides,
antisense and ribozyme
molecules, triple helix molecules, etc. that inhibit or stimulate immune
function, for example, T cell
proliferation/activation, lymphokine release, or immune cell infiltration.
For example, antisense RNA and RNA molecules act to directly block the
translation of mRNA
by hybridizing to targeted mRNA and preventing protein translation. When
antisense DNA is used,
oligodeoxyribonucleotides derived from the translation initiation site, e.g.,
between about -10 and +10
positions of the target gene nucleotide sequence, are preferred.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific
cleavage of RNA.
Ribozymes act by sequence-specific hybridization to the complementary target
RNA, followed by
endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential
RNA target can be identified
by known techniques. For further details see, e.g., Rossi, Current Biology 4,
469-471 (1994), and PCT
publication No. WO 97/33551 (published September 18, 1997).
Nucleic acid molecules in triple helix formation used to inhibit transcription
should be single-
63
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
stranded and composed of deoxynucleotides. The base composition of these
oligonucleotides is designed
such that it promotes triple helix formation via Hoogsteen base pairing rules,
which generally require
sizeable stretches of purines or pyrimidines on one strand of a duplex. For
further details see, e.g., PCT
publication No. WO 97/33551, supra.
These molecules can be identified by any or any combination of the screening
assays discussed
above and/or by any other screening techniques well known for those skilled in
the art.
L. Anti-PR020080 Antibodies
The present invention further provides anti-PR020080 antibodies. Exemplary
antibodies include
polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.
1. Polyclonal Antibodies
The anti-PR020080 antibodies may comprise polyclonal antibodies. Methods of
preparing
polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies
can be raised in a mammal,
for example, by one or more injections of an immunizing agent and, if desired,
an adjuvant. Typically,
the immunizing agent and/or adjuvant will be injected in the mammal by
multiple subcutaneous or
intraperitoneal injections. The immunizing agent may include the PR020080
polypeptide or a fusion
protein thereof. It may be useful to conjugate the immunizing agent to a
protein known to be
immunogenic in the mammal being immunized. Examples of such immunogenic
proteins include but are
not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin,
and soybean trypsin
inhibitor. Examples of adjuvants which may be employed include Freund's
complete adjuvant and MPL-
TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
The immunization
protocol may be selected by one skilled in the art without undue
experimentation.
2. Monoclonal Antibodies
The anti-PR020080 antibodies may, alternatively, be monoclonal antibodies.
Monoclonal
antibodies may be prepared using hybridoma methods, such as those described by
Kohler and Milstein,
Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other
appropriate host animal, is
typically immunized with an immunizing agent to elicit lymphocytes that
produce or are capable of
producing antibodies that will specifically bind to the immunizing agent.
Alternatively, the lymphocytes
may be immunized in vitro.
The immunizing agent will typically include the PR020080 polypeptide or a
fusion protein
thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if
cells of human origin are
desired, or spleen cells or lymph node cells are used if non-human mammalian
sources are desired. The
lymphocytes are then fused with an immortalized cell line using a suitable
fusing agent, such as
polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies:
Principles and Practice,
Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually
transformed mammalian cells,
particularly myeloma cells of rodent, bovine and human origin. Usually, rat or
mouse myeloma cell lines
are employed. The hybridoma cells may be cultured in a suitable culture medium
that preferably contains
one or more substances that inhibit the growth or survival of the unfused,
immortalized cells. For
64
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT
or HPRT), the culture medium for the hybridomas typically will include
hypoxanthine, aminopterin, and
thymidine ("HAT medium"), which substances prevent the growth of HGPRT-
deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support
stable high level
expression of antibody by the selected antibody-producing cells, and are
sensitive to a medium such as
HAT medium. More preferred immortalized cell lines are marine myeloma lines,
which can be obtained,
for instance, from the Salk Institute Cell Distribution Center, San Diego,
California and the American
Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human
heteromyeloma cell
lines also have been described for the production of human monoclonal
antibodies [I~ozbor, J. Immunol.,
133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and
Applications, Marcel
Dekker, Inc., New York, (1987) pp. 51-63].
The culture medium in which the hybridoma cells are cultured can then be
assayed for the
presence of monoclonal antibodies directed against PR020080. Preferably, the
binding specificity of
monoclonal antibodies produced by the hybridoma cells is determined by
immunoprecipitation or by an in
vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked
immunoabsorbent assay (ELISA).
Such techniques and assays are known in the art. The binding affinity of the
monoclonal antibody can,
for example, be determined by the Scatchard analysis of Munson and Pollard,
Anal. Biochem., 107:220
(1980).
After the desired hybridoma cells are identified, the clones may be subcloned
by limiting dilution
procedures and grown by standard methods [Goding, su ra . Suitable culture
media for this purpose
include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.
Alternatively, the
hybridoma cells may be grown in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclones may be isolated or
purified from the culture
medium or ascites fluid by conventional immunoglobulin purification procedures
such as, for example,
protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis,
dialysis, or affinity
chromatography.
The monoclonal antibodies may also be made by recombinant DNA methods, such as
those
described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies
of the invention can
be readily isolated and sequenced using conventional procedures (e.g., by
using oligonucleotide probes
that are capable of binding specifically to genes encoding the heavy and light
chains of marine antibodies).
The hybridoma cells of the invention serve as a preferred source of such DNA.
Once isolated, the DNA
may be placed into expression vectors, which are then transfected into host
cells such as simian COS cells,
Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise
produce immunoglobulin
protein, to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. The DNA also
may be modified, for example, by substituting the coding sequence for human
heavy and light chain
constant domains in place of the homologous marine sequences [U.S. Patent No.
4,816,567; Morrison et
al., su ra or by covalently joining to the immunoglobulin coding sequence all
or part of the coding
sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin
polypeptide can be
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
substituted for the constant domains of an antibody of the invention, or can
be substituted for the variable
domains of one antigen-combining site of an antibody of the invention to
create a chimeric bivalent
antibody.
The antibodies may be monovalent antibodies. Methods for preparing monovalent
antibodies are
well known in the art. For example, one method involves recombinant expression
of immunoglobulin
light chain and modified heavy chain. The heavy chain is truncated generally
at any point in the Fc region
so as to prevent heavy chain crosslinking. Alternatively, the relevant
cysteine residues are substituted with
another amino acid residue or are deleted so as to prevent crosslinking.
In vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to
produce fragments thereof, particularly, Fab fragments, can be accomplished
using routine techniques
known in the art.
Human and Humanized Antibodies
The anti-PR020080 antibodies of the invention may further comprise humanized
antibodies or
human antibodies. Humanized forms of non-human (e.g., murine) antibodies are
chimeric
immunoglobulins; immunoglobulin chains or fragments thereof (such as Fv, Fab,
Fab', F(ab')., or other
antigen-binding subsequences of antibodies) which contain minimal sequence
derived from non-human
immunoglobulin. Humanized antibodies include human immunoglobulins (recipient
antibody) in which
residues from a complementary determining region (CDR) of the recipient are
replaced by residues from a
CDR of a non-human species (donor antibody) such as mouse, rat or rabbit
having the desired specificity,
affinity and capacity. In some instances, Fv framework residues of the human
immunoglobulin are
replaced by corresponding non-human residues. Humanized antibodies may also
comprise residues which
are found neither in the recipient antibody nor in the imported CDR or
framework sequences. In general,
the humanized antibody will comprise substantially all of at least one, and
typically two, variable domains,
in which all or substantially all of the CDR regions correspond to those of a
non-human immunoglobulin
and all or substantially all of the FR regions are those of a human
immunoglobulin consensus sequence.
The humanized antibody optimally also will comprise at least a portion of an
immunoglobulin constant
region (Fc); typically that of a human immunoglobulin [Jones et al., Nature,
321:522-525 (1986);
Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct.
Biol., 2:593-596 (1992)].
Methods for humanizing non-human antibodies are well known in the art.
Generally, a
humanized antibody has one or more amino acid residues introduced into it from
a source which is non-
human. These non-human amino acid residues are often referred to as "import"
residues, which are
typically taken from an "import" variable domain. Humanization can be
essentially performed following
the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986);
Riechmann et al.,
Nature, _332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)],
by substituting rodent
CDRs or CDR sequences for the corresponding sequences of a human antibody.
Accordingly, such
"humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567),
wherein substantially less
than an intact human variable domain has been substituted by the corresponding
sequence from a non-
66
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
human species. In practice, humanized antibodies are typically human
antibodies in which some CDR
residues and possibly some FR residues are substituted by residues from
analogous sites in rodent
antibodies.
Human antibodies can also be produced using various techniques known in the
art, including
phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991);
Marks et al., J. Mol.
Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are
also available for the
preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies
and Cancer Therapy,
Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147 1 :86-95
(1991)]. Similarly, human
antibodies can be made by introducing of human immunoglobulin loci into
transgenic animals, e.g., mice
in which the endogenous immunoglobulin genes have been partially or completely
inactivated. Upon
challenge, human antibody production is observed, which closely resembles that
seen in humans in all
respects, including gene rearrangement, assembly, and antibody repertoire.
This approach is described,
for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;
5,633,425; 5,661,016,
and in the following scientific publications: Marks et al., Bio/Technology 10,
779-783 (1992); Lonberg et
al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild
et al., Nature
Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826
(1996); Lonberg and Huszar,
Intern. Rev. Immunol. 13 65-93 (1995).
The antibodies may also be affinity matured using known selection and/or
mutagenesis methods
as described above. Preferred affinity matured antibodies have an affinity
which is five times, more
preferably 10 times, even more preferably 20 or 30 times greater than the
starting antibody (generally
murine, humanized or human) from which the matured antibody is prepared.
4. Bispecific Antibodies
Bispecific antibodies are monoclonal, preferably human or humanized,
antibodies that have
binding specificities for at least two different antigens. In the present
case, one of the binding specificities
is for the PR020080, the other one is for any other antigen, and preferably
for a cell-surface protein or
receptor or receptor subunit.
Methods for making bispecific antibodies are known in the art. Traditionally,
the recombinant
production of bispecific antibodies is based on the co-expression of two
immunoglobulin heavy-
chain/light-chain pairs, where the two heavy chains have different
specificities [Milstein and Cuello,
Nature, 305:537-539 (1983)]. Because of the random assortment of
immunoglobulin heavy and light
chains, these hybridomas (quadromas) produce a potential mixture of ten
different antibody molecules, of
which only one has the correct bispecific structure. The purification of the
correct molecule is usually
accomplished by affinity chromatography steps. Similar procedures are
disclosed in WO 93/08829,
published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
67
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Antibody variable domains with the desired binding specificities (antibody-
antigen combining
sites) can be fused to immunoglobulin constant domain sequences. The fusion
preferably is with an
immunoglobulin heavy-chain constant domain, comprising at least part of the
hinge, CH2, and CH3
regions. It is preferred to have the first heavy-chain constant region (CHl)
containing the site necessary
for light-chain binding present in at least one of the fusions. DNAs encoding
the immunoglobulin heavy-
chain fusions and, if desired, the immunoglobulin light chain, are inserted
into separate expression
vectors, and are co-transfected into a suitable host organism. For further
details of generating bispecific
antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210
(1986).
According to another approach described in WO 96127011, the interface between
a pair of
antibody molecules can be engineered to maximize the percentage of
heterodimers which are recovered
from recombinant cell culture. The preferred interface comprises at least a
part of the CH3 region of an
antibody constant domain. In this method, one or more small amino acid side
chains from the interface of
the first antibody molecule are replaced with larger side chains (e.g.
tyrosine or tryptophan).
Compensatory "cavities" of identical or similar size to the large side chains)
are created on the interface
of the second antibody molecule by replacing large amino acid side chains with
smaller ones (e.g. alanine
or threonine). This provides a mechanism for increasing the yield of the
heterodimer over other unwanted
end-products such as homodimers.
Bispecific antibodies can be prepared as full length antibodies or antibody
fragments (e.g. F(ab')2
bispecific antibodies). Techniques for generating bispecific antibodies from
antibody fragments have been
described in the literature. For example, bispecific antibodies can be
prepared can be prepared using
chemical linkage. Brennan et al., Science 229:$1 (1985) describe a procedure
wherein intact antibodies
are proteolytically cleaved to generate F(ab')2 fragments. These fragments are
reduced in the presence of
the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and
prevent intermolecular
disulfide formation. The Fab' fragments generated are then converted to
thionitrobenzoate (TNB)
derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-
thiol by reduction with
mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB
derivative to form the
bispecific antibody. The bispecific antibodies produced can be used as agents
for the selective
immobilization of enzymes.
Fab' fragments may be directly recovered from E. coli and chemically coupled
to form bispecific
antibodies. Shalaby et al. , J. Exp. Med. 175:217-225 (1992) describe the
production of a fully humanized
bispecific antibody F(ab')2 molecule. Each Fab' fragment was separately
secreted from E. coli and
subjected to directed chemical coupling ira vitro to form the bispecific
antibody. The bispecific antibody
thus formed was able to bind to cells overexpressing the ErbB2 receptor and
normal human T cells, as
well as trigger the lytic activity of human cytotoxic lymphocytes against
human breast tumor targets.
Various technique for making and isolating bispecific antibody fragments
directly from
recombinant cell culture have also been described. For example, bispecific
antibodies have been produced
using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992).
The leucine zipper
peptides from the Fos and Jun proteins were linked to the Fab' portions of two
different antibodies by
68
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
gene fusion. The antibody homodimers were reduced at the hinge region to form
monomers and then
re-oxidized to form the antibody heterodimers. This method can also be
utilized for the production of
antibody homodimers. The "diabody" technology described by Hollinger et al. ,
Proc. Natl. Acad. Sci.
USA 90:6444-6448 (1993) has provided an alternative mechanism for making
bispecific antibody
fragments. The fragments comprise a heavy-chain variable domain (VH) connected
to a light-chain
variable domain (VL) by a linker which is too short to allow pairing between
the two domains on the same
chain. Accordingly, the VH and V~ domains of one fragment are forced to pair
with the complementary
VL and VH domains of another fragment, thereby forming two antigen-binding
sites. Another strategy for
making bispecific antibody fragments by the use of single-chain Fv (sFv)
dimers has also been reported.
See, Gruber et al., J. Immunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example,
trispecific antibodies can be
prepared. Tutt et al. , J. Immunol. 147:60 (1991).
Exemplary bispecific antibodies may bind to two different epitopes on a given
PR020080
polypeptide herein. Alternatively, an anti-PR020080 polypeptide arm may be
combined with an arm
which binds to a triggering molecule on a leukocyte such as a T-cell receptor
molecule (e.g. CD2, CD3,
CD28, or B7), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII
(CD32) and FcyRIII
(CD16) so as to focus cellular defense mechanisms to the cell expressing the
particular PR020080
polypeptide. Bispecific antibodies may also be used to localize cytotoxic
agents to cells which express a
particular PR020080 polypeptide. These antibodies possess a PR020080-binding
arm and an arm which
binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA,
DOTA, or TETA. Another
bispecific antibody of interest binds the PR020080 polypeptide and further
binds tissue factor (TF).
5. Heteroconiugate Antibodies
Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate
antibodies are composed of two covalently joined antibodies. Such antibodies
have, for example, been
proposed to target immune system cells to unwanted cells [U.S. Patent No.
4,676,980], and for treatment
of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated
that the antibodies may
be prepared i~a vitro using known methods in synthetic protein chemistry,
including those involving
crosslinking agents. For example, immunotoxins may be constructed using a
disulfide exchange reaction
or by forming a thioether bond. Examples of suitable reagents for this purpose
include iminothiolate and
methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent
No. 4,676,980.
6. Effector Function Engineering
It may be desirable to modify the antibody of the invention with respect to
effector function, so as
to enhance, e.g., the effectiveness of the antibody in treating cancer. For
example, cysteine residues)
may be introduced into the Fc region, thereby allowing interchain disulfide
bond formation in this region.
The homodimeric antibody thus generated may have improved internalization
capability and/or increased
complement-mediated cell killing and antibody-dependent cellular cytotoxicity
(ADCC). See Caron et al. ,
J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922
(1992). Homodimeric
69
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
antibodies with enhanced anti-tumor activity may also be prepared using
heterobifunctional cross-linkers as
described in Wolff et al. Cancer Research, 53: 2560-2565 (1993).
Alternatively, an antibody can be
engineered that has dual Fc regions and may thereby have enhanced complement
lysis and ADCC
capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3.: 219-230
(1989).
7. Immunoconiugates
The invention also pertains to immunoconjugates comprising an antibody
conjugated to a
cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an
enzymatically active toxin of bacterial,
fungal, plant, or animal origin, or fragments thereof), or a radioactive
isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have
been described
above. Enzymatically active toxins and fragments thereof that can be used
include diphtheria A chain,
nonbinding active fragments of diphtheria toxin, exotoxin A chain (from
Pseudo»aonas aeruginosa), ricin
A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurates fordii
proteins, dianthin proteins,
Phytolaca americafaa proteins (PAPI, PAPII, and PAP-S), momordica charantia
inhibitor, curcin, crotin,
sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin,
phenomycin, enomycin, and the
tricothecenes. A variety of radionuclides are available for the production of
radioconjugated antibodies.
Examples include z'zBi, '3iI, '3'In, 9oY, and'$6Re.
Conjugates of the antibody and cytotoxic agent are made using a variety of
bifunctional protein-
coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP),
iminothiolane (IT),
bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL),
active esters (such as
disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido
compounds (such as bis (p-
azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-
diazoniumbenzoyl)-
ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-
active fluorine compounds
(such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin
can be prepared as
described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-
isothiocyanatobenzyl-3-
methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating
agent for conjugation of
radionucleotide to the antibody. See W094/11026.
In another embodiment, the antibody may be conjugated to a "receptor" (such
streptavidin) for
utilization in tumor pretargeting wherein the antibody-receptor conjugate is
administered to the patient,
followed by removal of unbound conjugate from the circulation using a clearing
agent and then
administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic
agent (e.g., a radionucleotide).
8. Immunoliposomes
The antibodies disclosed herein may also be formulated as immunoliposomes.
Liposomes
containing the antibody are prepared by methods known in the art, such as
described in Epstein et al.,
Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad.
Sci. USA, 77: 4030
(1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced
circulation time are
disclosed in U.S. Patent No. 5,013,556.
Particularly useful liposomes can be generated by the reverse-phase
evaporation method
with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-
derivatized
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of
defined pore size to yield
liposomes with the desired diameter. Fab' fragments of the antibody of the
present invention can be
conjugated to the liposomes as described in Martin et al ., J. Biol. Chem.,
257: 286-288 (1982) via a
disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin)
is optionally contained
within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19):
1484 (1989).
M. Pharmaceutical Compositions
The active PR020080 molecules of the invention (e.g., PRO20080 polypeptides,
anti-PR020080
antibodies, and/or variants of each) as well as other molecules identified by
the screening assays disclosed
above, can be administered for the treatment of immune related diseases, in
the form of pharmaceutical
compositions.
Therapeutic formulations of the active PR020080 molecule, preferably a
polypeptide or antibody
of the invention, are prepared for storage by mixing the active molecule
having the desired degree of
purity with optional pharmaceutically acceptable carriers, excipients or
stabilizers (Retnington's
Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of
lyophilized formulations or
aqueous solutions. Acceptable carriers, excipients, or stabilizers are
nontoxic to recipients at the dosages
and concentrations employed, and include buffers such as phosphate, citrate,
and other organic acids;
antioxidants including ascorbic acid and methionine; preservatives (such as
octadecyldimethylbenzyl
ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol,
butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben;
catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about
10 residues) polypeptides;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic
polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine,
histidine, arginine, or lysine;
monosaccharides, disaccharides, and other carbohydrates including glucose,
mannose, or dextrins;
chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or
sorbitol; salt-forming
counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes);
and/or non-ionic surfactants
such as TWEENT"', PLURONICST"' or polyethylene glycol (PEG).
Compounds identified by the screening assays disclosed herein can be
formulated in an analogous
manner, using standard techniques well known in the art.
Lipofections or liposomes can also be used to deliver the PR020080 molecule
into cells. Where
antibody fragments are used, the smallest inhibitory fragment which
specifically binds to the binding
domain of the target protein is preferred. For example, based upon the
variable region sequences of an
antibody, peptide molecules can be designed which retain the ability to bind
the target protein sequence.
Such peptides can be synthesized chemically and/or produced by recombinant DNA
technology (see, e.g.,
Marasco et al., Proc. Natl. Acad. Sci. USA 90, 7889-7893 [1993]).
The formulation herein may also contain more than one active compound as
necessary for the
particular indication being treated, preferably those with complementary
activities that do not adversely
affect each other. Alternatively, or in addition, the composition may comprise
a cytotoxic agent, cytokine
or growth inhibitory agent. Such molecules are suitably present in combination
in amounts that are
71
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
effective for the purpose intended.
The active PR02008.0 molecules may also be entrapped in microcapsules
prepared, for example,
by coacervation techniques or by interfacial polymerization, for example,
hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively, in colloidal drug delivery
systems (for example, liposomes, albumin microspheres, microemulsions, nano-
particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed in
Rezningtorz's Pharmaceutical
Sciences 16th edition, Osol, A. Ed. (1980).
The formulations to be used for in vivo administration must be sterile. This
is readily
accomplished by filtration through sterile filtration membranes.
Sustained-release preparations or the PR020080 molecules may be prepared.
Suitable examples
of sustained-release preparations include semipermeable matrices of solid
hydrophobic polymers
containing the antibody, which matrices are in the form of shaped articles,
e.g., films, or microcapsules.
Examples of sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-
methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919),
copolymers of L-glutamic
acid and 7-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,
degradable lactic acid-glycolic acid
copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of
lactic acid-glycolic
acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
While polymers such as
ethylene-vinyl acetate and lactic acid-glycolic acid enable release of
molecules for over 100 days, certain
hydrogels release proteins for shorter time periods. When encapsulated
antibodies remain in the body for
a long time, they may denature or aggregate as a result of exposure to
moisture at 37°C, resulting in a loss
of biological activity and possible changes in immunogenicity. Rational
strategies can be devised for
stabilization depending on the mechanism involved. For example, if the
aggregation mechanism is
discovered to be intermolecular S-S bond formation through thio-disulfide
interchange, stabilization may
be achieved by modifying sulfhydryl residues, lyophilizing from acidic
solutions, controlling moisture
content, using appropriate additives, and developing specific polymer matrix
compositions.
N. Methods of Treatment
It is contemplated that the polypeptides, antibodies and other active
compounds of the present
invention may be used to treat various immune related diseases and conditions,
such as T cell mediated
diseases, including those characterized by infiltration of inflammatory cells
into a tissue, stimulation of T
cell proliferation, inhibition of T-cell proliferation, increased or decreased
vascular permeability or the
inhibition thereof.
Exemplary conditions or disorders to be treated with the polypeptides,
antibodies and other
compounds of the invention, include, but are not limited to systemic lupus
erythematosis, rheumatoid
arthritis, juvenile chronic arthritis, osteoarthritis, spondyloarthropathies,
systemic sclerosis (scleroderma),
idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's
syndrome, systemic
vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia,
paroxysmal nocturnal
hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic
purpura, immune-mediated
72
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis,
juvenile lymphocytic thyroiditis,
atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease
(glomerulonephritis,
tubulointerstitial nephritis), demyelinating diseases of the central and
peripheral nervous systems such as
multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barre
syndrome, and chronic
inflammatory demyelinating polyneuropathy, hepatobiliary diseases such as
infectious hepatitis (hepatitis
A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active
hepatitis, primary biliary
cirrhosis, granulomatous hepatitis, and sclerosing cholangitis, inflammatory
bowel disease (ulcerative
colitis: Crohn's disease), gluten-sensitive enteropathy, and Whipple's
disease, autoimmune or immune-
mediated skin diseases including bullous skin diseases, erythema multiforme
and contact dermatitis,
psoriasis, allergic diseases such as asthma, allergic rhinitis, atopic
dermatitis, food hypersensitivity and
urticaria, immunologic diseases of the lung such as eosinophilic pneumonias,
idiopathic pulmonary fibrosis
and hypersensitivity pneumonitis, transplantation associated diseases
including graft rejection and graft -
versus-host-disease.
In systemic lupus erythematosus, the central mediator of disease is the
production of auto-reactive
antibodies to self proteinsltissues and the. subsequent generation of immune-
mediated inflammation.
Antibodies either directly or indirectly mediate tissue injury. Though T
lymphocytes have not been shown
to be directly involved in tissue damage, T lymphocytes are required for the
development of auto-reactive
antibodies. The genesis of the disease is thus T lymphocyte dependent.
Multiple organs and systems are
affected clinically including kidney, lung, musculoskeletal system,
mucocutaneous, eye, central nervous
system, cardiovascular system, gastrointestinal tract, bone marrow and blood.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory
disease that mainly
involves the synovial membrane of multiple joints with resultant injury to the
articular cartilage. The
pathogenesis is T lymphocyte dependent and is associated with the production
of rheumatoid factors, auto-
antibodies directed against self IgG, with the resultant formation of immune
complexes that attain high
levels in joint fluid and blood. These complexes in the joint may induce the
marked infiltrate of
lymphocytes and monocytes into the synovium and subsequent marked synovial
changes; the joint
space/fluid if infiltrated by similar cells with the addition of numerous
neutrophils. Tissues affected are
primarily the joints, often in symmetrical pattern. However, extra-articular
disease also occurs in two
major forms. One form is the development of extra-articular lesions with
ongoing progressive joint
disease and typical lesions of pulmonary fibrosis, vasculitis, and cutaneous
ulcers. The second form of
extra-articular disease is the so called Felty's syndrome which occurs late in
the RA disease course,
sometimes after joint disease has become quiescent, and involves the presence
of neutropenia,
thrombocytopenia and splenomegaly. This can be accompanied by vasculitis in
multiple organs with
formations of infarcts, skin ulcers and gangrene. Patients often also develop
rheumatoid nodules in the
subcutis tissue overlying affected joints; the nodules late stage have
necrotic centers surrounded by a
mixed inflammatory cell infiltrate. Other manifestations which can occur in RA
include: pericarditis,
pleuritis, coronary arteritis, intestinal pneumonitis with pulmonary fibrosis,
keratoconjunctivitis sicca, and
rhematoid nodules.
73
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Juvenile chronic arthritis is a chronic idiopathic inflammatory disease which
begins often at less
than 16 years of age. Its phenotype has some similarities to RA; some patients
which are rhematoid factor
positive are classified as juvenile rheumatoid arthritis. The disease is sub-
classified into three major
categories: pauciarticular, polyarticular, and systemic. The arthritis can be
severe and is typically
destructive and leads to joint ankylosis and retarded growth. Other
manifestations can include chronic
anterior uveitis and systemic amyloidosis.
Spondyloarthropathies are a group of disorders with some common clinical
features and the
common association with the expression of HLA-B27 gene product. The disorders
include: ankylosing
sponylitis, Reiter's syndrome (reactive arthritis), arthritis associated with
inflammatory bowel disease,
spondylitis associated with psoriasis, juvenile onset spondyloarthropathy and
undifferentiated
spondyloarthropathy. Distinguishing features include sacroileitis with or
without spondylitis;
inflammatory asymmetric arthritis; association with HLA-B27 (a serologically
defined allele of the HLA-B
locus of class I MHC); ocular inflammation, and absence of autoantibodies
associated with other
rheumatoid disease. The cell most implicated as key to induction of the
disease is the CD8+ T
lymphocyte, a cell which targets antigen presented by class I MHC molecules.
CD8+ T cells may react
against the class I MHC allele HLA-B27 as if it were a foreign peptide
expressed by MHC class I
molecules. It has been hypothesized that an epitope of HLA-B27 may mimic a
bacterial or other microbial
antigenic epitope and thus induce a CD8+ T cells response.
Systemic sclerosis (scleroderma) has an unknown etiology. A hallmark of the
disease is
induration of the skin; likely this is induced by an active inflammatory
process. Scleroderma can be
localized or systemic; vascular lesions are common and endothelial cell injury
in the microvasculature is
an early and important event in the development of systemic sclerosis; the
vascular injury may be immune
mediated. An immunologic basis is implied by the presence of mononuclear cell
infiltrates in the
cutaneous lesions and the presence of anti-nuclear antibodies in many
patients. ICAM-1 is often
2-5 upregulated on the cell surface of fibroblasts in skin lesions suggesting
that T cell interaction with these
cells may have a role in the pathogenesis of the disease. Other organs
involved include: the
gastrointestinal tract: smooth muscle atrophy and fibrosis resulting in
abnormal peristalsis/motility;
kidney: concentric subendothelial intimal proliferation affecting small
arcuate and interlobular arteries with
resultant reduced renal cortical blood flow, results in proteinuria, azotemia
and hypertension; skeletal
muscle: atrophy, interstitial fibrosis; inflammation; lung: interstitial
pneumonitis and interstitial fibrosis;
and heart: contraction band necrosis, scarring/fibrosis.
Idiopathic inflammatory myopathies including dermatomyositis, polymyositis and
others are
disorders of chronic muscle inflammation of unknown etiology resulting in
muscle weakness. Muscle
injury/inflammation is often symmetric and progressive. Autoantibodies are
associated with most forms.
These myositis-specific autoantibodies are directed against and inhibit the
function of components, proteins
and RNA's, involved in protein synthesis.
Sjogren's syndrome is due to immune-mediated inflammation and subsequent
functional
destruction of the tear glands and salivary glands. The disease can be
associated with or accompanied by
74
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
inflammatory connective tissue diseases. The disease is associated with
autoantibody production against
Ro and La antigens, both of which are small RNA-protein complexes. Lesions
result in
keratoconjunctivitis sicca, xerostomia, with other manifestations or
associations including bilary cirrhosis,
peripheral or sensory neuropathy, and palpable purpura.
Systemic vasculitis are diseases in which the primary lesion is inflammation
and subsequent
damage to blood vessels which results in ischemia/necrosis/degeneration to
tissues supplied by the affected
vessels and eventual end-organ dysfunction in some cases. Vasculitides can
also occur as a secondary
lesion or sequelae to other immune-inflammatory mediated diseases such as
rheumatoid arthritis, systemic
sclerosis, etc. , particularly in diseases also associated with the formation
of immune complexes. Diseases
in the primary systemic vasculitis group include: systemic necrotizing
vasculitis: polyarteritis nodosa,
allergic angiitis and granulomatosis, polyangiitis; Wegener's granulomatosis;
lymphomatoid
granulomatosis; and giant cell arteritis. Miscellaneous vasculitides include:
mucocutaneous lymph node
syndrome (MLNS or Kawasaki's disease), isolated CNS vasculitis, Behet's
disease, thromboangiitis
obliterans (Buerger's disease) and cutaneous necrotizing venulitis. The
pathogenic mechanism of most of
the types of vasculitis listed is believed to be primarily due to the
deposition of immunoglobulin complexes
in the vessel wall and subsequent induction of an inflammatory response either
via ADCC, complement
activation, or both.
Sarcoidosis is a condition of unknown etiology which is characterized by the
presence of
epithelioid granulomas in nearly any tissue in the body; involvement of the
lung is most common. The
pathogenesis involves the persistence of activated macrophages and lymphoid
cells at sites of the disease
with subsequent chronic sequelae resultant from the release of locally and
systemically active products
released by these cell types.
Autoimmune hemolytic anemia including autoimmune hemolytic anemia, immune
pancytopenia,
and paroxysmal noctural hemoglobinuria is a result of production of antibodies
that react with antigens
expressed on the surface of red blood cells (and in some cases other blood
cells including platelets as well)
and is a reflection of the removal of those antibody coated cells via
complement mediated lysis and/or
ADCC/Fc-receptor-mediated mechanisms.
In autoimmune thrombocytopenia including thrombocytopenic purpura, and immune-
mediated
thrombocytopenia in other clinical settings, platelet destruction/removal
occurs as a result of either
antibody or complement attaching to platelets and subsequent removal by
complement lysis, ADCC or FC
receptor mediated mechanisms.
Thyroiditis including Grave's disease, Hashimoto's thyroiditis, juvenile
lymphocytic thyroiditis,
and atrophic thyroiditis, are the result of an autoimmune response against
thyroid antigens with production
of antibodies that react with proteins present in and often specific for the
thyroid gland. Experimental
models exist including spontaneous models: rats (BUF and BB rats) and chickens
(obese chicken strain);
inducible models: immunization of animals with either thyroglobulin, thyroid
microsomal antigen (thyroid
peroxidase).
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Type I diabetes mellitus or insulin-dependent diabetes is the autoimmune
destruction of pancreatic
islet (3 cells; this destruction is mediated by auto-antibodies and auto-
reactive T cells. Antibodies to
insulin or the insulin receptor can also produce the phenotype of insulin-non-
responsiveness.
Immune mediated renal diseases, including glomerulonephritis and
tubulointerstitial nephritis, are
the result of antibody or T lymphocyte mediated injury to renal tissue either
directly as a result of the
production of autoreactive antibodies or T cells against renal antigens or
indirectly as a result of the
deposition of antibodies and/or immune complexes in the kidney that are
reactive against other, non-renal
antigens. Thus other immune-mediated diseases that result in the formation of
immune-complexes can
also induce immune mediated renal disease as an indirect sequelae. Both direct
and indirect immune
mechanisms result in inflammatory response that produces/induces lesion
development in renal tissues
with resultant organ function impairment and in some cases progression to
renal failure. Both humoral
and cellular immune mechanisms can be involved in the pathogenesis of lesions.
Demyelinating diseases of the central and peripheral nervous systems,
including Multiple
Sclerosis; idiopathic demyelinating polyneuropathy or Guillain-Barre syndrome;
and Chronic
Inflammatory Demyelinating Polyneuropathy, are believed to have an autoimmune
basis and result in
nerve demyelination as a result of damage caused to oligodendrocytes or to
myelin directly. In MS there
is evidence to suggest that disease induction and progression is dependent on
T lymphocytes. Multiple
Sclerosis is a demyelinating disease that is T lymphocyte-dependent and has
either a relapsing-remitting
course or a chronic progressive course. The etiology is unknown; however,
viral infections, genetic
predisposition, environment, and autoimmunity all contribute. Lesions contain
infiltrates of predominantly
T lymphocyte mediated, microglial cells and infiltrating macrophages; CD4+ T
lymphocytes are the
predominant cell type at lesions. The mechanism of oligodendrocyte cell death
and subsequent
demyelination is not known but is likely T lymphocyte driven.
Inflammatory and Fibrotic Lung Disease, including Eosinophilic Pneumonias;
Idiopathic
Pulmonary Fibrosis, and Hypersensitivity Pneumonitis may involve a
disregulated immune-inflammatory
response. Inhibition of that response would be of therapeutic benefit.
Autoimmune or Immune-mediated Skin Disease including Bullous Skin Diseases,
Erythema
Multiforme, and Contact Dermatitis are mediated by auto-antibodies, the
genesis of which is T
lymphocyte-dependent.
Psoriasis is a T lymphocyte-mediated inflammatory disease. Lesions contain
infiltrates of T
lymphocytes, macrophages and antigen processing cells, and some neutrophils.
Allergic diseases, including asthma; allergic rhinitis; atopic dermatitis;
food hypersensitivity; and
urticaria are T lymphocyte dependent. These diseases are predominantly
mediated by T lymphocyte
induced inflammation, IgE mediated-inflammation or a combination of both.
Transplantation associated diseases, including Graft rejection and Graft-
Versus-Host-Disease
(GVHD) are T lymphocyte-dependent; inhibition of T lymphocyte function is
ameliorative.
Other diseases in which intervention of the immune and/or inflammatory
response have benefit are
infectious disease including but not limited to viral infection (including but
not limited to AIDS, hepatitis
76
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
A, B, C, D, E and herpes) bacterial infection, fungal infections, and
protozoal and parasitic infections
(molecules (or derivatives/agonists) which stimulate T cells can be utilized
therapeutically to enhance the
immune response to infectious agents), diseases of immunodeficiency
(molecules/derivatives/agonists)
which stimulate T cells can be utilized therapeutically to enhance the immune
response for conditions of
inherited, acquired, infectious induced (as in HIV infection), or iatrogenic
(i.e., as from chemotherapy)
immunodeficiency, and neoplasia.
It has been demonstrated that some human cancer patients develop an antibody
and/or T
lymphocyte response to antigens on neoplastic cells. It has also been shown in
animal models of neoplasia
that enhancement of the immune response can result in rejection or regression
of that particular neoplasm.
Molecules that enhance the T lymphocyte response have utility ira vivo in
enhancing the immune response
against neoplasia. Molecules which enhance the T lymphocyte proliferative
response (or small molecule
agonists or antibodies that affected the same receptor in an agonistic
fashion) can be used therapeutically to
treat cancer.
Additionally, inhibition of molecules with proinflammatory properties may have
therapeutic
benefit in reperfusion injury; stroke; myocardial infarction; atherosclerosis;
acute lung injury;
hemorrhagic shock; burn; sepsis/septic shock; acute tubular necrosis;
endometriosis; degenerative joint
disease and pancreatis.
The compounds of the present invention, e.g., polypeptides or antibodies, are
administered to a
mammal, preferably a human, in accord with known methods, such as intravenous
administration as a
bolus or by continuous infusion over a period of time, by intramuscular,
intraperitoneal,
intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal,
oral, topical, or inhalation
(intranasal, intrapulmonary) routes. Intravenous or inhaled administration of
polypeptides and antibodies
is preferred.
In immunoadjuvant therapy, other therapeutic regimens, such administration of
an anti-cancer
agent, may be combined with the administration of the proteins, antibodies or
compounds of the instant
invention. For example, the patient to be treated with a the immunoadjuvant of
the invention may also
receive an anti-cancer agent (chemotherapeutic agent) or radiation therapy.
Preparation and dosing
schedules for such chemotherapeutic agents may be used according to
manufacturers' instructions or as
determined empirically by the skilled practitioner. Preparation and dosing
schedules for such
chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry,
Williams & Wilkins,
Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow
administration of the
immunoadjuvant or may be given simultaneously therewith. Additionally, an anti-
estrogen compound
such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812)
may be given in dosages
known for such molecules.
It may be desirable to also administer antibodies against other immune disease
associated or
tumor associated antigens, such as antibodies which bind to CD20, CDlla, CD18,
ErbB2, EGFR, ErbB3,
ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition,
two or more antibodies
binding the same or two or more different antigens disclosed herein may be
coadministered to the patient.
77
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Sometimes, it may be beneficial to also administer one or more cytokines to
the patient.
For the treatment or reduction in the severity of immune related disease, the
appropriate dosage
of an a compound of the invention will depend on the type of disease to be
treated, as defined above, the
severity and course of the disease, whether the agent is administered for
preventive or therapeutic
purposes, previous therapy, the patient's clinical history and response to the
compound, and the discretion
of the attending physician. The compound is suitably administered to the
patient at one time or over a
series of treatments.
For example, depending on the type and severity of the disease, about 1 ~g/kg
to 15 mg/kg (e.g.,
0.1-20 mg/kg) of polypeptide or antibody is an initial candidate dosage for
administration to the patient,
whether, for example, by one or more separate administrations, or by
continuous infusion. A typical daily
dosage might range from about 1 pg/kg to 100 mg/kg or more, depending on the
factors mentioned above.
For repeated administrations over several days or longer, depending on the
condition, the treatment is
sustained until a desired suppression, of disease symptoms occurs. However,
other dosage regimens may
be useful. The progress of this therapy is easily monitored by conventional
techniques and assays.
O. Articles of Manufacture
In another embodiment of the invention, an article of manufacture containing
materials (e.g.,
comprising a PR020080 molecule) useful for the diagnosis or treatment of the
disorders, described above
is provided. The article of manufacture comprises a container and an
instruction. Suitable containers
include, for example, bottles, vials, syringes, and test tubes. The containers
may be formed from a
variety of materials such as glass or plastic. The container holds a
composition which is effective for
diagnosing or treating the condition and may have a sterile access port (for
example the container may be
an intravenous solution bag or a vial having a stopper pierceable by a
hypodermic injection needle). The
active agent in the composition is usually a polypeptide or an antibody of the
invention. An instruction or
label on, or associated with, the container indicates that the composition is
used for diagnosing or treating
the condition of choice. The article of manufacture may fuither comprise a
second container comprising a
pharmaceutically-acceptable buffer, such as phosphate-buffered saline,
Ringer's solution and dextrose
solution. It may further include other materials desirable from a commercial
and user standpoint,
including other buffers, diluents, filters, needles, syringes, and package
inserts with instructions for use.
P. Diagnosis and Prognosis of Immune Related Disease
Cell surface proteins, such as proteins which are overexpressed in certain
immune related
diseases, are excellent targets for drug candidates or disease treatment. The
same proteins along with
secreted proteins encoded by the genes amplified in immune related disease
states find additional use in the
diagnosis and prognosis of these diseases. For example, antibodies directed
against the protein products of
genes amplified in multiple sclerosis, rheumatoid arthritis, or another immune
related disease, can be used
as diagnostics or prognostics.
For example, antibodies, including antibody fragments, can be used to
qualitatively or
quantitatively detect the expression of proteins encoded by amplified or
overexpressed genes ("marker
gene products"). The antibody preferably is equipped with a detectable, e.g.,
fluorescent label, and
78
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
binding can be monitored by light microscopy, flow cytometry, fluorimetry, or
other techniques known in
the art. These techniques are particularly suitable, if the overexpressed gene
encodes a cell surface protein
Such binding assays are performed essentially as described above.
ha situ detection of antibody binding to the marker gene products can be
performed, for example,
by immunofluorescence or immunoelectron microscopy. For this purpose, a
histological specimen is
removed from the patient, and a labeled antibody is applied to it, preferably
by overlaying the antibody on
a biological sample. This procedure also allows for determining the
distribution of the marker gene
product in the tissue examined. It will be apparent for those skilled in the
art that a wide variety of .
histological methods are readily available for in situ detection.
The following examples are offered for illustrative purposes only, and are not
intended to limit
the scope of the present invention in any way.
All patent and literature references cited in the present specification are
hereby incorporated by
reference in their entirety.
EXAMPLES
Commercially available reagents referred to in the examples were used
according to
manufacturer's instructions unless otherwise indicated. The source of those
cells identified in the
following examples, and throughout the specification, by ATCC accession
numbers is the American Type
Culture Collection, Manassas, VA.
EXAMPLE 1: Isolation of cDNA Clones Encoding a Human PR020080
The extracellular domain (ECD) sequences (including the secretion signal
sequence, if any) from
about 950 known secreted proteins from the Swiss-Prot public database were
used to search sequence
databases. The databases included public databases (e.g., GenBank) In this
instance, genomic DNA
sequence from GenBank was analyzed using the gene preditiction program
GENSCAN, licenced from
- Stanford University. GENSCAN analysis predicts gene coding regions, creating
sequences which can be
subjected to the ECD search. The search was performed using the computer
program BLAST or BLAST2
[Altschul et al., Methods in Enzymology, 266:460-480 (1996)] as a comparison
of the ECD protein
sequences to a 6 frame translation of the sequences. Those comparisons
resulting in a BLAST score of 70 (or
in some cases, 90) or greater that did not encode known proteins were
clustered and assembled into
consensus DNA sequences with the program "phrap" (Phil Green, University of
Washington, Seattle,
Washington) if necessary.
A consensus sequence is herein designated DNA145436.
Based on the DNA145436 consensus sequence, oligonucleotides were synthesized:
1) to identify by
PCR a cDNA library that contained the sequence of interest, and 2) for use as
probes to isolate a clone of the
full-length coding sequence for PR020080. Forward and reverse PCR primers
generally range from 20 to
30 nucleotides and are often designed to give a PCR product of about 100-1000
by in length. The probe
sequences are typically 40-55 by in length. In some cases, additional
oligonucleotides are synthesized when
the consensus sequence is greater than about 1-l.Skbp. In order to screen
several libraries for a full-length
clone, DNA from the libraries was screened by PCR amplification, as per
Ausubel et al., Current Protocols
79
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
in Molecular Biology, supra, with the PCR primer pair. A positive library was
then used to isolate clones
encoding the gene of interest using the probe oligonucleotide and one of the
primer pairs.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-GAGAGAAGGTCAACTTCATCACTTGGCTTTTC-3' (SEQ ID N0:3)
reverse PCR primer 5'-CTGCAGGAAACTCCAGGGGAAGAGTTACT-3' (SEQ ID N0:4)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus
DNA145436 sequence which had the following nucleotide sequence
hybridization probe
5'-CTTCACCCAGTCCTACTCCCTGCAACTCAGCAACCTGAAGATGGAAGACA-3' (SEQ ID NO:S)
A pool of 50 different human cDNA libraries from various tissues was used in
cloning. The cDNA
libraries used to isolate the cDNA clones were constructed by standard methods
using commercially
available reagents such as those from Invitrogen, San Diego, CA. The cDNA was
primed with oligo dT
containing a NotI site, linked with blunt to SaII hemikinased adaptors,
cleaved with NotI, sized appropriately
by gel electrophoresis, and cloned in a defined orientation into a suitable
cloning vector (such as pRKB or
1 S pRKD; pRKSB is a precursor of pRKSD that does not contain the SfiI site;
see, Holmes et al., Science,
253:1278-1280 (1991)) in the unique XhoI and NotI sites.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for a
full-length PR020080 polypeptide (designated herein as DNA161000-2896 [Figure
1, SEQ ID NO: 1]) and
the derived protein sequence for that PR020080 polypeptide.
The full length clone identified above contained a single open reading frame
with an apparent
translational initiation site at nucleotide positions 62-64 and a stop signal
at nucleotide positions 1058-1060
(Figure 1, SEQ ID NO:1). The predicted polypeptide precursor is 332 amino
acids long, has a calculated
molecular weight of approximately 37345 daltons and an estimated pI of
approximately 6.72. Analysis of
the full-length PR020080 sequence shown in Figure 2 (SEQ ID N0:2) evidences
the presence of a variety of
important polypeptide domains as shown in Figure 2, wherein the locations
given for those important
polypeptide domains are approximate as described above. PR020080 amino acid
sequence has 22% identity
with CD84, 14% identity with SLAM and 11% identity with 2B4.
DNA161000-2896 was then deposited under the terms of the Budapest Treaty with
the American
Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA
(ATCC). Clone
DNA161000-2896 has been deposited with ATCC on April 18, 2000 and is assigned
ATCC deposit number
PTA-1731.
EXAMPLE 2:Expression of PR020080 in multiple human tissues.
Multiple tissue Northern Blots were obtained from Clontech (Palo Alto, CA).
These blots were
hybridized with a probe corresponding to the full length PR020080 cDNA made by
random primer
labeling with 3'-P-yATP label. Blots were washed 3X with 2XSSC/0.2%SDS and 1X
with
0.2XSSC/0.1 % SDS at 42 C. The blots were then exposed to X-OMAT film with
intensifying screens for
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
overnight. The result is shown in Figure 3. This shows that PR020080 receptor
is expressed highly in
spleen and lymph node, with lower level of PR020080 espression observed in
thymus and bone marrow,
with little expression in fetal liver. No expression was detected in brain,
heart, colon or lung.
EXAMPLE 3: Expression of PR020080 in multiple human cell lines.
Cell surface expression analysis of PR020080 was performed by washing
1X106cells in 1
FBS/PBS. An ALEXA-488 labeled monoclonal antibody raised against the
extracellular domain of
PR020080 was used to detect surface staining on cell lines at a concentration
of 1 ug per million cells.
Cells were then washed again and analyzed by flow cytometry. All of the T cell
derived lines such as
Jurkat, MOLT3 and MOLT4 were positive for cell surface staining of PR020080.
The B cell lines that
tested positive for PRO20080 expression were the Raji, Ramos and Daudi lines,
with no detection of
PRO20080 in the remainder of the B cell lines. This is shown in Figure 4.
EXAMPLE 4: Increased expression of PRO20080 upon stimulation.
Cell surface expression was detected by FAGS analysis on isolated human
peripheral T cells, as
shown in Figure 5. Human T cells were activated with plate-bound anti-CD3
antibody (coated at 0.1 uglml;
Pharmingen) and anti-CD28 antibody (coated at 1 ug/ml;Pharmingen). 0.5 x 106
cells were plated per well.
Both resting and activated T cells were then analyzed for expression of
PR020080 or CD69 at 24 and 48
hours by flow cytometry. PR020080 expression was detected using the ALEXA-488
labeled monoclonal
antibody raised against the extracellular domain of PRO20080 as described in
Example 3. CD69, an
activation marker, was detected using by flow cytometry using a FITC-labeled
antibody (Phanningen). Co-
stimulation of isolated T cells with anti-CD3 and anti-CD28 antibody led to
increased expression of
PR020080 on the cell surface as determined by FACS analysis at 24 hours (data
not shown) and even
greater expression at 48 hours post co-stimulation (Figure Sa). High
expression of PR020080 on the surface
of CD4+ CD45RO+ memory T cells without co-stimulation was also determined
(Figure Sb).
EXAMPLE 5: Homotypic binding of PR020080.
To deternine if PR020080 interacts with itself in a PR020080-PR020080
association similar to
SLAM, an ELISA assay was performed. Purified PR020080-Fc fusion protein was
coated onto a standard
Nunc Maxisorb ELISA plate at a concentration of 2 pg/ml and increasing
concentrations of biotinylated
PRO20080 were incubated and subsequently washed. Binding of the biotinylated
protein was detected using
a streptavidin-HRP conjugate. It was determined that the biotinlyated PR020080
can associate with the
bound PR020080 polypeptide and not with appropriate protein controls (Figure
6).
To determine if the ECD of PR020080 can interact with a wild type PR020080 on
the cell surface,
COS7 cells were transfected with wild type PR020080 or human CD4, which
contains an Ig domain, for
use as a control. Forty-eight hours after transfection, the transfected cells
washed and incubated with S~g/ml
purified PR020080 ECD-Fc fusion protein plus 5% normal goat serum. The treated
cells were washed and
fixed in 4% paraformadehyde for 15 minutes and then probed with a biotinlyated
goat anti-human Fc
antibody (Jackson Immunoreseach) at a dilution of 1:400. After a 30 minute
incubation period, the fixed
81
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
cells were washed and subsequently probed with a 1:400 dilution of Cy3-
conjugated streptavidin label
(Jackson Immunoresearch) for detection. Fluoresence was detected only in COS7
cells transfected with
PR020080, and not those COS7 cells transfected with CD 4, this demonstrates
that soluble PR020080 can
associate with cell-bound PRO20080 in a specific manner, since no staining is
observed on cells transfected
with CD4, a receptor also containing Ig domain repeats. This is shown in
Figure 7.
Lastly, a BIAcore~ assay was performed to determine if a His-tagged PR020080
would associate
with itself. The association rate can be determined by any method in which
formation of the complex may
be observed as a function of time. In the BIAcore~ analysis, in which one
measures the association of the
protein to an protein that has been immobilized on a biosensor surface
(reviewed by Rich & Myszka, Curr.
Opin. BioteclZnol. 11:54-61 (2000)). The homotypic interaction of His-tagged
PR020080 was calculated
using BIAcore evaluation software version 3, and found to be a weak
interaction, with a Kd of greater than
100 p,M. This was a specific interaction as the His-tagged PR020080 did not
associate with a CD40 control
protein. The Kd determined as determined by this assay is of the same order as
the homotypic interaction of
SLAM previously reported as 200 ~M [Mavaddat et al., (2000) J Biol Chem
275(36): 28100-28109 ].
Taken together, the conclusion from these assays is that like SLAM, PR020080
has self
interaction.
EXAMPLE 6: PRO20080-CD3 costimulation induces Tcell~roliferation and increased
INF-y production.
The crosslinking of SLAM and CD3 on T cells has a co-stimulatory effect, which
is to increase
proliferation of the T cells and the production of INF-y. To determine if
PR020080 has a similar effect,
human peripheral T cells were isolated and co-stimulated with an anti-PR020080
antibody and a suboptimal
dose of anti-CD3 antibody. Nunc Maxisorp 96-well plates were coated over night
with 0.1 ~,g ml anti-CD3
antibody (Pharmingen), 1 ~,g ml anti-CD28 (Pharmingen), or 1 ~,g ml anti-
PR020080 antibody generated
against the extracellular domain of PR020080. PR020080-FC fusion protein was
coated at 5 ug/ml.
Human CD4+ T cells were purified using anti-CD4 beads and AutoMacs sorting
from whole blood. For the
costimulation assay 0.5x106 T cells were plated per well in triplicate. On the
third day, post-costimulation,
supernatant was removed for cytokine analysis of IFN-'y or IL-4 (by ELISA or
Luminex-(Upstate
Biotechnology)) and the cells were pulsed for 16 hours with [3H]thymidine to
measure proliferation. This
co-stimulation induced a substantial increase in proliferation comparable with
with the increase in
proliferation induced by the co-stimulation of anti-CD3 and anti-CD28
treatment. Anti-PR020080 antibody
treatment alone did not induce proliferation. Anti-CD3 antibody treatment
alone also did not induce
proliferation. This is shown in Figure 8a.
INF-y production in the removed supernatant was measured, and was found to
have significantly
increased over untreated cells or cells treated with anti-PR020080 antibody or
anti-CD3 antibody alone.
The increase in INF-y production upon co-stimulation with anti-PR020080
antibody and anti-CD3 antibody
was comparable to the increase in INF-'y production produced by co-stimulation
with anti-CD3 antibody and
anti-CD28 antibody. Treatment with anti-PR020080 antibody alone did not induce
any detectable increase
in INF-~ production. This is shown in Figure 8b.
82
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Nonspecific induction of proliferation due to contaminants was ruled out with
the use of boiled
anti-PR020080 and PR020080 preps. No T cell proliferation was observed under
these conditions (data not
shown).
EXAMPLE 7: PR020080 interacts with SAP.
SLAM family members contain from two to four SAP binding motifs of the
consensus (TxYxxV/I),
where x can be any amino acid. SAP binds to non-phosphorylated and
phosphorylated forms of SLAM, but
greater amounts of SAP binding is seen when SLAM is phosphorylated. SLAM also
binds the intracellular
proteins SHP1 and SHP2, as well as binding SAP [Castro et al., (1999) J.
Immunol. 163(11): 5860-5870,
Lewis et al., (2001) Clin linmunol 100(1): 15-23, Shlapatska et al., (2001) J.
Immunol 166(9): 5480-5487].
PR020080 contains two SAP binding motifs in the intracellular domain of the
molecule (Figure 2), and to
determine if SAP, SHP1 and SHP2 bound to PR020080, 10' Jurkat T cells were
treated with pervanadate for
minutes at 37°C and lysed in RIPA buffer with 1%NP-40 and protease and
phosphatase inhibitors.
Lysates were pre-cleared with 10 pg/ml IgGI and protein G; then PRO20080 was
immunoprecipitated using
15 10 ~tg of a mixture of IgGl monoclonal antibodies raised against the
extracellular domain of PR020080. All
samples were then run on a 4-20% SDS-PAGE gel (Novagen Madison, WI).
Association of SAP was
detected by Western blotting using an antibody raised against full length SAP
in rabbit (Santa Cruz
Biotechnology Santa Cruz, CA). SAP was detected using 2~g1m1 antibody diluted
in 5% powdered milk.
These results of PR020080 Western blotting are shown in Figure 9a. There was
no PRO20080 association
with SAP in untreated cells. PRO20080 did associate with SAP ui pervanadate
treated cells, implying a
phosphorylation-dependant interaction. SHP1 and SHP2 are expressed in Jurkat
cells, but no interaction
with PR020080 was detected under any of the conditions tested. Therefore,
PR020080 interacts with SAP,
but not with SHP1 or SHP2, making the signal transduction pathway of PRO20080
differ signifcantly from
that of SLAM.
EXAMPLE 8: PR020080 phosphorylation upon co-stimulation
To examine the signaling events surrounding PR020080 during co-stimulation, a
phosphorylation
timecourse experiment was performed. For the Jurkat timcourse, cells were
first incubated with anti-CD3
and anti-PR020080 antibodies at 0.5 pg per 106 cells (Pharmingen). Cells were
then washed, let to rest in
PBS, then stimulated with goat anti-mouse Fc antibody (Jackson hnmunoresearch)
at 0.1 ~g per 106 cells to
crosslink the receptors. Cross linking times began with a minimum 30 seconds
to a maximum of 10
minutes. It was found that PR020080 was phosphorylated within 30 seconds
(Figure 9b).
Phosphorylation of PR020080 was also examined in isolated human T cells. Human
T cells were
isolated by AutoMACS sorting of CD4 positive cells. 400 million cells were
used per condition. In similar
conditions used for the Jurkat cells, PR020080 is phosphorylated upon CD3 and
PR020080 cross linking, as
shown by immunoprecipitation of PR020080 and subsequent western blotting with
an anti-phosphotyrosine
antibody. In detecting for SAP, it was found that SAP does not associate with
PRO20080 in untreated
human T cells, but does associate with phosphorylated PR020080. As in the
Jurkat cell line, SHP1 and
83
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
SHP2 do not associate with PR020080 even though both SHP1 and SHP2 are
expressed (Figure 9c). These
results suggest a SAP dependant, but SHP1/SHP2 independent pathway, different
from SLAM.
EXAMPLE 9: PR020080 and delayed type hypersensitive response.
As mentioned previously SLAM plays a role in Thl cell response. To determine
if PR020080
also has a role in Thl cell response, the murine homologue of PR020080 was
cloned, and used in in vivo
experiments to test for delayed type hypersenstivity (DTH). For mouse studies
CD4+ T cells were
isolated from the spleen by AutoMacs sorting, and l, 5, and 10 ug ml of murine
PR020080 was used for
stimulation. Anti-mouse CD3 antibody and anti-mouse CD28 antibody were used at
similar concentrations
as for the human assays (0.1 ug ml-1; 1 ug ml-l;Pharmingen). Cells were
stimulated for three days and a
fraction of the supernatant was removed from the wells to test for cytokine
expression and cells were
pulsed with [3H]thymidine in the final 16 hours of culture to determine
proliferation levels. Similar
results were found with co-stimulation involving murine PR020080-Fc fusion
protein and human
PR020080.
Mice were injected in the footpad with 100 ~g keyhole-limpet hemocyanin (KLH)
1:1 in CFA.
Mice were also injected IP every other day with 100 ~g murine PR020080-Fc or
saline. On day 9, draining
lymph nodes were collected from the mice and cells were incubated with KLH. On
the third day,
supernatant was removed for cytokine analysis and the cells were pulsed with
[3H]thymidine to measure
proliferation. This result is shown in Figure 10a (proliferation) and Figure
lOb (IFN-'y increase).
Lymphocytes from murine PR020080-Fc treated mice increased in proliferation in
response to KLH
challenge. IFN-'y production was also increased 2-4 fold.
The increase in IFN-y is proposed to modifiy T cell response to a Thl
response, and possibly DTH.
For DTH experiments, mice were injected with 100 ~g of KLH (1:l mixture with
CFA) in the base of the
tail. Mice were injected IP with 100 ~tg of the murine PR020080-Fc or saline
on day 0, 2, 5, 6, and 7. On
day 6 mice were injected with 150 ~g of KLH in the left ear and saline in the
right ear (25 ~tl volume). Ear
swelling was measured on day 8, 48 hours after ear injection. The difference
in size between the left and
right ear was plotted, and is shown in Figure 10c. These results suggest that
the murine PR020080 is
involved in DTH, a Thl response.
EXAMPLE 10: Preparation of Antibodies that Bind PR020080
This example illustrates preparation of monoclonal antibodies which can
specifically bind
PR020080. In this instance, antibodies were made to the ECD of PR020080, from
about amino acid 13
to about amino acid 228 of Figure 2 [SEQ ID N0:2].
Techniques for producing the monoclonal antibodies are known in the art and
are described, for
instance, in Goding, supra. Selection of the immunogen can be made by the
skilled artisan without undue
experimentation.
Mice, such as Balb/c, are immunized with the PR020080 immunogen emulsified in
complete
Freund's adjuvant and injected subcutaneously or intraperitoneally in an
amount from 1-100 micrograms.
84
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi
Immunochemical Research,
Hamilton, MT) and injected into the animal's hind foot pads. The immunized
mice are then boosted 10 to
12 days later with additional immunogen emulsified in the selected adjuvant.
Thereafter, for several
weeks, the mice may also be boosted with additional immunization injections.
Serum samples may be
periodically obtained from the mice by retro-orbital bleeding for testing in
ELISA assays to detect anti-
PR020080 antibodies.
After a suitable antibody titer has been detected, the animals "positive" for
antibodies can be
injected with a final intravenous injection of PR020080. Three to four days
later, the mice are sacrificed
and the spleen cells are harvested. The spleen cells are then fused (using 35
% polyethylene glycol) to a
selected murine myeloma cell line such as P3X63AgU.l, available from ATCC, No.
CRL 1597. The
fusions generate hybridoma cells which can then be plated in 96 well tissue
culture plates containing HAT
(hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of
non-fused cells, myeloma
hybrids, and spleen cell hybrids.
The hybridoma cells will be screened in an ELISA for reactivity against
PR020080.
Determination of "positive" hybridoma cells secreting the desired monoclonal
antibodies against
PR020080 is within the skill in the art.
The positive hybridoma cells can be injected intraperitoneally into syngeneic
Balb/c mice
to produce ascites containing the anti-PR020080 monoclonal antibodies.
Alternatively, the hybridoma
cells can be grown in tissue culture flasks or roller bottles. Purification of
the monoclonal antibodies
produced in the ascites can be accomplished using ammonium sulfate
precipitation, followed by gel
exclusion chromatography. Alternatively, affinity chromatography based upon
binding of antibody to
protein A or protein G can be employed. These antibodies were useful in the
identification of PR020080
in cell expression analysis, ELISA, and Western blotting.
EXAMPLE 11: Use of PR020080 as a hybridization probe
The following method describes use of a nucleotide sequence encoding PR020080
as a
hybridization probe.
DNA comprising the coding sequence of full-length or mature PR020080 as
disclosed herein is
employed as a probe to screen for homologous DNAs (such as those encoding
naturally-occurring variants
of PR020080) in human tissue cDNA libraries or human tissue genomic libraries.
Hybridization and washing of filters containing either library DNAs is
performed under the
following high stringency conditions. Hybridization of radiolabeled PR020080-
derived probe to the filters
is performed in a solution of 50% formamide, Sx SSC, 0.1 % SDS, 0.1 % sodium
pyrophosphate, 50 mM
sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at
42°C for 20 hours.
Washing of the filters is performed in an aqueous solution of 0. lx SSC and
0.1 % SDS at 42°C.
DNAs having a desired sequence identity with the DNA encoding full-length
native sequence
PR020080 can then be identified using standard techniques known in the art.
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
EXAMPLE 12: Expression of PR020080 in E. coli
This example illustrates preparation of an unglycosylated form of PR020080 by
recombinant
expression in E. coli.
The DNA sequence encoding PR020080 is initially amplified using selected PCR
primers. The
primers should contain restriction enzyme sites which correspond to the
restriction enzyme sites on the
selected expression vector. A variety of expression vectors may be employed.
An example of a suitable
vector is pBR322 (derived from E. coli; see Bolivar et al., Gene, 2:95 (1977))
which contains genes for
ampicillin and tetracycline resistance. The vector is digested with
restriction enzyme and
dephosphorylated. The PCR amplified sequences are then ligated into the
vector. The vector will
preferably include sequences which encode for an antibiotic resistance gene, a
trp promoter, a polyhis
leader (including the first six STII codons, polyhis sequence, and
enterokinase cleavage site), the
PR020080 coding region, lambda transcriptional terminator, and an argU gene.
The ligation mixture is then used to transform a selected E. coli strain using
the methods
described in Sambrook et al., supra. Transformants are identified by their
ability to grow on LB plates
and antibiotic resistant colonies are then selected. Plasmid DNA can be
isolated and confirmed by
restriction analysis and DNA sequencing.
Selected clones can be grown overnight in liquid culture medium such as LB
broth supplemented
with antibiotics. The overnight culture may subsequently be used to inoculate
a larger scale culture. The
cells are then grown to a desired optical density, during which the expression
promoter is turned on.
After culturing the cells for several more hours, the cells can be harvested
by centrifugation. The
cell pellet obtained by the centrifugation can be solubilized using various
agents known in the art, and the
solubilized PR020080 protein can then be purified using a metal chelating
column under conditions that
allow tight binding of the protein.
PR020080 may be expressed in E. coli in a poly-His tagged form, using the
following procedure.
The DNA encoding.PR020080 is initially amplified using selected PCR primers:
The primers will
contain restriction enzyme sites which correspond to the restriction enzyme
sites on the selected expression
vector, and other useful sequences providing for efficient and reliable
translation initiation, rapid
purification on a metal chelation column, and proteolytic removal with
enterokinase. The PCR-amplified,
poly-His tagged sequences are then ligated into an expression vector, which is
used to transform an E. coli
host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq).
Transformants are first
grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking
until an O.D.600 of 3-5 is reached.
Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57
g (NH~)ZS04, 0.71 g
sodium citrate~2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield
hycase SF in 500 mL
water, as well as 110 mM MPOS, pH 7.3, 0.55 % (w/v) glucose and 7 mM MgS04)
and grown for
approximately 20-30 hours at 30°C with shaking. Samples are removed to
verify expression by
SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells.
Cell pellets are frozen until
purification and refolding.
86
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in
10 volumes (w/v) in
7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium
tetrathionate is added to make
final concentrations of O.1M and 0.02 M, respectively, and the solution is
stirred overnight at 4°C. This
step results in a denatured protein with all cysteine residues blocked by
sulfitolization. The solution is
centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min. The
supernatant is diluted with 3-5
volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and
filtered through 0.22
micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen
Ni-NTA metal chelate column
equilibrated in the metal chelate column buffer. The column is washed with
additional buffer containing
50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with
buffer containing 250
mM imidazole. Fractions containing the desired protein are pooled and stored
at 4°C. Protein
concentration is estimated by its absorbance at 280 nm using the calculated
extinction coefficient based on
its amino acid sequence.
The proteins are refolded by diluting the sample slowly into freshly prepared
refolding buffer
consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCI, 2.5 M urea, 5 mM cysteine, 20
mM glycine and 1 mM
EDTA. Refolding volumes are chosen so that the final protein concentration is
between 50 to 100
micrograms/ml. The refolding solution is stirred gently at 4°C for 12-
36 hours. The refolding reaction is
quenched by the addition of TFA to a final concentration of 0.4% (pH of
approximately 3). Before
further purification of the protein, the solution is filtered through a 0.22
micron filter and acetonitrile is
added to 2-10% final concentration. The refolded protein is chromatographed on
a Poros Rl/H reversed
phase column using a mobile buffer of 0.1 % TFA with elution with a gradient
of acetonitrile from 10 to
80%~. Aliquots of fractions with A280 absorbance are analyzed on SDS
polyacrylamide gels and fractions
containing homogeneous refolded protein are pooled. Generally, the properly
refolded species of most
proteins are eluted at the lowest concentrations of acetonitrile since those
species are the most compact
with their hydrophobic interiors shielded from interaction with the reversed
phase resin. Aggregated
species are usually eluted at higher acetonitrile concentrations. In addition
to resolving misfolded forms of
proteins from the desired form, the reversed phase step also removes endotoxin
from the samples.
Fractions containing the desired folded PR020080 polypeptide are pooled and
the acetonitrile
removed using a gentle stream of nitrogen directed at the solution. Proteins
are formulated into 20 mM
Hepes, pH 6.8 with 0.14 M sodium chloride and 4 % mannitol by dialysis or by
gel filtration using G25
Superfine (Pharmacia) resins equilibrated in the formulation buffer and
sterile filtered.
Many of the PR020080 polypeptides disclosed herein were successfully expressed
as described
above.
EXAMPLE 13: Expression of PR020080 in mammalian cells
This example illustrates preparation of a potentially glycosylated form of
PR020080 by
recombinant expression in mammalian cells.
The vector, pRKS (see EP 307,247, published March 15, 1989), is employed as
the expression
vector. Optionally, the PR020080 DNA is ligated into pRKS with selected
restriction enzymes to allow
87
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
insertion of the PR020080 DNA using ligation methods such as described in
Sambrook et al., supra. The
resulting vector is called pRKS-PR020080.
In one embodiment, the selected host cells may be 293 cells. Human 293 cells
(ATCC CCL
1573) are grown.to confluence in tissue culture plates in medium such as DMEM
supplemented with fetal
calf serum and optionally, nutrient components and/or antibiotics. About 10
p,g pRKS-PR020080 DNA is
mixed with about 1 ~,g DNA encoding the VA RNA gene [Thimmappaya et al., Cell,
31:543 (1982)] and
dissolved in 500 ~,1 of 1 mM Tris-HCI, 0.1 mM EDTA, 0.227 M CaCl2. To this
mixture is added,
dropwise, 500 p1 of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaP04, and a
precipitate is
allowed to form for 10 minutes at 25°C. The precipitate is suspended
and added to the 293 cells and
allowed to settle for about four hours at 37°C. The culture medium is
aspirated off and 2 ml of 20%
glycerol in PBS is added for 30 seconds. The 293 cells are then washed with
serum free medium, fresh
medium is added and the cells are incubated for about 5 days.
Approximately 24 hours after the transfections, the culture medium is removed
and replaced with
culture medium (alone) or culture medium containing 200 ~,Ci/ml 35S-cysteine
and 200 ~,Ci/ml 35S-
methionine. After a 12 hour incubation, the conditioned medium is collected,
concentrated on a spin
filter, and loaded onto a 15 % SDS gel. The processed gel may be dried and
exposed'to film for a selected
period of time to reveal the presence of PR020080 polypeptide. The cultures
containing transfected cells
may undergo further incubation (in serum free medium) and the medium is tested
in selected bioassays.
In an alternative technique, PRO20080 may be introduced into 293 cells
transiently using the
dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci.,
12:7575 (1981). 293 cells
are grown to maximal density in a spinner flask and 700 ~,g pRKS-PR020080 DNA
is added. The cells
are first concentrated from the spinner flask by centrifugation and washed
with PBS. The DNA-dextran
precipitate is incubated on the cell pellet for four hours. The cells are
treated with 20% glycerol for 90
seconds, washed with tissue culture medium, and re-introduced into the spinner
flask containing tissue
culture medium, 5 p.g/ml bovine insulin and 0.1 ~g/ml bovine transferrin.
After about four days, the
conditioned media is centrifuged and filtered to remove cells and debris. The
sample containing expressed
PR020080 can then be concentrated and purified by any selected method, such as
dialysis and/or column
chromatography.
In another embodiment, PR020080 can be expressed in CHO cells. The pRI~S-
PR020080 can
be transfected into CHO cells using known reagents such as CaP04 or DEAE-
dextran. As described
above, the cell cultures can be incubated, and the medium replaced with
culture medium (alone) or
medium containing a radiolabel such as 35S-methionine. After determining the
presence of PR020080
polypeptide, the culture medium may be replaced with serum free medium.
Preferably, the cultures are
incubated for about 6 days, and then the conditioned medium is harvested. The
medium containing the
expressed PR020080 can then be concentrated and purified by any selected
method.
Epitope-tagged PR020080 may also be expressed in host CHO cells. The PR020080
may be
subcloned out of the pRKS vector. The subclone insert can undergo PCR to fuse
in frame with a selected
epitope tag such as a poly-his tag into a Baculovirus expression vector. The
poly-his tagged PR020080
88
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
insert can then be subcloned into a SV40 promoter/enhancer containing vector
containing a selection
marker such as DHFR for selection of stable clones. Finally, the CHO cells can
be transfected (as
described above) with the SV40 promoter/enhancer containing vector. Labeling
may be performed, as
described above, to verify expression. The culture medium containing the
expressed poly-His tagged
PR020080 can then be concentrated and purified by any selected method, such as
by Ni'+-chelate affinity
chromatography.
PR020080 may also be expressed in CHO and/or COS cells by a transient
expression procedure
or in CHO cells by another stable expression procedure.
Stable expression in CHO cells is performed using the following procedure. The
proteins are
expressed as an IgG construct (immunoadhesin), in which the coding sequences
for the soluble forms (e.g.
extracellular domains) of the respective proteins are fused to an IgGl
constant region sequence containing
the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.
Following PCR amplification, the respective DNAs are subcloned in a CHO
expression vector
using standard techniques as described in Ausubel et al., Current Protocols of
Molecular Biology, Unit
3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to
have compatible restriction
sites 5' and 3' of the DNA of interest to allow the convenient shuttling of
cDNA's. The vector used
expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9
(1774-1779 (1996), and
uses the SV40 early promoter/enhancer to drive expression of the cDNA of
interest and dihydrofolate
reductase (DHFR). DHFR expression permits selection for stable maintenance of
the plasmid following
transfection.
Twelve micrograms of the desired plasmid DNA is introduced into approximately
10 million
CHO cells using commercially available transfection reagents Superfect~
(Quiagen), Dosper or Fugene
(Boehringer Mannheim). The cells are grown as described in Lucas et al.,
supra. Approximately 3 x 10-'
cells are frozen in an ampule for further growth and production as described
below.
The ampules containing the plasmid DNA are thawed by placement into water bath
and mixed by
vortexing. The contents are pipetted into a centrifuge tube containing 10 mL
of media and centrifuged at
1000 rpm for 5 minutes. The supernatant is aspirated and the cells are
resuspended in 10 mL of selective
media (0.2 ~m filtered PS20 with 5% 0.2 pm diafiltered fetal bovine serum).
The cells are then aliquoted
into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the
cells are transferred into
a 250 mL spinner filled with 150 mL selective growth medium and incubated at
37°C. After another 2-3
days, 250 mL, 500 mL and 2000 mL spinners are seeded with 3 x 105 cells/mL.
The cell media is
exchanged with fresh media by centrifugation and resuspension in production
medium. Although any
suitable CHO media may be employed, a production medium described in U.S.
Patent No. 5,122,469,
issued June 16, 1992 may actually be used. A 3L production spinner is seeded
at 1.2 x 106 cells/mL. On
' day 0, pH is determined. On day 1, the spinner is sampled and sparging with
filtered air is commenced.
On day 2, the spinner is sampled, the temperature shifted to 33°C, and
30 mL of 500 glL glucose and 0.6
mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365
Medical Grade
Emulsion) taken. Throughout the production, the pH is adjusted as necessary to
keep it at around 7.2.
89
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
After 10 days, or until the viability dropped below 70% , the cell culture is
harvested by centrifugation and
filtering through a 0.22 pm filter. The filtrate was either stored at
4°C or immediately loaded onto
columns for purification.
For the poly-His tagged constructs, the proteins are purified using a Ni-NTA
column (Qiagen).
Before purification, imidazole is added to the conditioned media to a
concentration of 5 mM. The
conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM
Hepes, pH 7.4, buffer
containing 0.3 M NaCI and 5 mM imidazole at a flow rate of 4-5 ml/min. at
4°C. After loading, the
column is washed with additional equilibration buffer and the protein eluted
with equilibration buffer
containing 0.25 M imidazole. The highly purified protein is subsequently
desalted into a storage buffer
containing 10 mM Hepes, 0.14 M NaCI and 4 % mannitol, pH 6.8, with a 25 ml G25
Superfine
(Pharmacia) column and stored at -80°C.
Immunoadhesin (Fc-containing) constructs are purified from the conditioned
media as follows.
The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia)
which had been
equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column
is washed extensively
with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The
eluted protein is
immediately neutralized by -collecting 1 ml fractions into tubes containing
275 p1 of 1 M Tris buffer, pH 9.
The highly purified protein is subsequently desalted into storage buffer as
described above for the poly-
His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels
and by N-terminal amino
acid sequencing by Edman degradation.
Many of the PR020080 polypeptides disclosed herein were successfully expressed
as described
above.
EXAMPLE 14: Expression of PR020080 in Yeast
The following method describes recombinant expression of PR020080 in yeast.
First, yeast expression vectors are constructed for intracellular production
or secretion of
PR020080 from the ADH2/GAPDH promoter. DNA encoding PR020080 and the promoter
is inserted
into suitable restriction enzyme sites in the selected plasmid to direct
intracellular expression of
PR020080. For secretion, DNA encoding PR020080 can be cloned into the selected
plasmid, together
with DNA encoding the ADH2lGAPDH promoter, a native PR020080 signal peptide or
other mammalian
signal peptide, or, for example, a yeast alpha-factor or invertase secretory
signal/leader sequence, and
linker sequences (if needed) for expression of PR020080.
Yeast cells, such as yeast strain AB110, can then be transformed with the
expression plasmids
described above and cultured in selected fermentation media. The transformed
yeast supernatants can be
analyzed by precipitation with 10 % trichloroacetic acid and separation by SDS-
PAGE, followed by
staining of the gels with Coomassie Blue stain.
Recombinant PR020080 can subsequently be isolated and purified by removing the
yeast cells
from the fermentation medium by centrifugation and then concentrating the
medium using selected
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
cartridge filters. The concentrate containing PR020080 may further be purified
using selected column
chromatography resins.
Many of the PR020080 polypeptides disclosed herein were successfully expressed
as described
above.
EXAMPLE 15: Expression of PR020080 in Baculovirus-Infected Insect Cells
The following method describes recombinant expression of PR020080 in
Baculovirus-infected
insect cells.
The sequence coding for PR020080 is fused upstream of an epitope tag contained
within a
baculovirus expression vector. Such epitope tags include poly-his tags and
immunoglobulin tags (like Fc
regions of IgG). A variety of plasmids may be employed, including plasmids
derived from commercially
available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding
PR020080 or the desired
portion of the coding sequence of PR020080 such as the sequence encoding the
extracellular domain of a
transmembrane protein or the sequence encoding the mature protein if the
protein is extracellular is
amplified by PCR with primers complementary to the 5' and 3' regions. The 5'
primer may incorporate
flanking (selected) restriction enzyme sites. The product is then digested
with those selected restriction
enzymes and subcloned into the expression vector.
Recombinant baculovirus is generated by co-transfecting the above plasmid and
BaculoGoldTM
virus DNA (Pharmingen) into Spodoptera frugiperda ("Sf9") cells (ATCC CRL
1711) using lipofectin
(commercially available from GIBCO-BRL). After 4 - 5 days of incubation at
28°C, the released viruses
are harvested and used for further amplifications. Viral infection and protein
expression are performed as
described by O'Reilley et al., Baculovirus expression vectors: A Laboratory
Manual, Oxford: Oxford
University Press (1994).
Expressed poly-his tagged PR020080 can then be purified, for example, by Ni'+-
chelate affinity
chromatography as follows. Extracts are prepared from recombinant
virus=infected Sf9 cells as described
by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed,
resuspended in sonication
buffer (25 mL Hepes, pH 7.9; 12.5 mM MgClz; 0.1 mM EDTA; 10 % glycerol; 0.1 %
NP-40; 0.4 M
KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by
centrifugation, and the
supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM
NaCI, 10 % glycerol, pH 7.8)
and filtered through a 0.45 ~m filter. A Niz+-NTA agarose column (commercially
available from Qiagen)
is prepared with a bed volume of 5 mL, washed with 25 mL of water and
equilibrated with 25 mL of
loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL
per minute. The column is
washed to baseline A~BO with loading buffer, at which point fraction
collection is started. Next, the column
is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCI, 10 %
glycerol, pH 6.0), which
elutes nonspecifically bound protein. After reaching AZBObaseline again,~the
column is developed with a 0
to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions
are collected and analyzed
by SDS-PAGE and silver staining or Western blot with Ni2+-NTA-conjugated to
alkaline phosphatase
91
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
(Qiagen). Fractions containing the eluted Hislo-tagged PR020080 are pooled and
dialyzed against loading
buffer.
Alternatively, purification of the IgG tagged (or Fc tagged) PR020080 can be
performed using
known chromatography techniques, including for instance, Protein A or protein
G column
chromatography.
Many of the PR020080 polypeptides disclosed herein were successfully expressed
as described
above.
EXAMPLE 16: Purification of PR020080 Polypeptides Using Specific Antibodies
Native or recombinant PR020080 polypeptides may be purified by a variety of
standard
techniques in the art of protein purification. For example, pro-PR020080
polypeptide, mature PR020080
polypeptide, or pre-PR020080 polypeptide is purified by immunoaffinity
chromatography using antibodies
specific for the PR020080 polypeptide of interest. In general, an
immunoaffinity column is constructed
by covalently coupling the anti-PR020080 polypeptide antibody to an activated
chromatographic resin.
Polyclonal immunoglobulins are prepared from immune sera either by
precipitation with
ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB
Biotechnology,
Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse
ascites fluid by ammonium
sulfate precipitation or chromatography on immobilized Protein A. Partially
purified immunoglobulin is
covalently attached to a chromatographic resin such as CnBr-activated
SEPHAROSET°'' (Pharmacia LKB
Biotechnology). The antibody is coupled to the resin, the resin is blocked,
and the derivative resin is
washed according to the manufacturer's instructions.
Such an immunoaffinity column is utilized in the purification of PRO20080
polypeptide by
preparing a fraction from cells containing PR020080 polypeptide in a soluble
form. This preparation is
derived by solubilization of the whole cell or of a subcellular fraction
obtained via differential
centrifugation by the addition of detergent or by other methods well known in
the art. Alternatively,
soluble PR020080 polypeptide containing a signal sequence may be secreted in
useful quantity into the
medium in which the cells are grown.
A soluble PR020080 polypeptide-containing preparation is passed over the
immunoaffinity
column, and the column is washed under conditions that allow the preferential
absorbance of PR020080
polypeptide (e.g., high ionic strength buffers in the presence of detergent).
Then, the column is eluted
under conditions that disrupt antibody/PR020080 polypeptide binding (e.g., a
low pH buffer such as
approximately pH 2-3, or a high concentration of a chaotrope such as urea or
thiocyanate ion), and
PR020080 polypeptide is collected.
EXAMPLE 17: Drug Screening
This invention is particularly useful for screening compounds by using
PR020080 polypeptides or
binding fragment thereof in any of a variety of drug screening techniques. The
PR020080 polypeptide or
fragment employed in such a test may either be free in solution, affixed to a
solid support, borne on a cell
92
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
surface, or located intracellularly. One method of drug screening utilizes
eukaryotic or prokaryotic host
cells which are stably transformed with recombinant nucleic acids expressing
the PR020080 polypeptide
or fragment. Drugs are screened against such transformed cells in competitive
binding assays. Such cells,
either in viable or fixed form, can be used for standard binding assays. One
may measure, for example,
the formation of complexes between PR020080 polypeptide or a fragment and the
agent being tested.
Alternatively, one can examine the diminution in complex formation between the
PR020080 polypeptide
and its target cell or target receptors caused by the agent being tested.
Thus, the present invention provides methods of screening for drugs or any
other agents which
can affect a PR020080 polypeptide-associated disease or disorder. These
methods comprise contacting
such an agent with an PR020080 polypeptide or fragment thereof and assaying
(I) for the presence of a
complex between the agent and the PR020080 polypeptide or fragment, or (ii)
for the presence of a
complex between the PR020080 polypeptide or fragment and the cell, by methods
well known in the art.
In such competitive binding assays, the PR020080 polypeptide or fragment is
typically labeled. After
suitable incubation, free PR020080 polypeptide or fragment is separated from
that present in bound form,
and the amount of free or uncomplexed label is a measure of the ability of the
particular agent to bind to
PR020080 polypeptide or to interfere with the PR020080 polypeptide/cell
complex.
Another technique for drug screening provides high throughput screening for
compounds having
suitable binding affinity to a polypeptide and is described in detail in WO
84!03564, published on
September 13, 1984. Briefly stated, large numbers of different small peptide
test compounds are
synthesized on a solid substrate, such as plastic pins or some other surface.
As applied to a PR020080
polypeptide, the peptide test compounds are reacted with PR020080 polypeptide
and washed. Bound
PR020080 polypeptide is detected by methods well known in the art. Purified
PR020080 polypeptide can
also be coated directly onto plates for use in the aforementioned drug
screening techniques. In addition,
non-neutralizing antibodies can be used to capture the peptide and immobilize
it on the solid support.
This invention also contemplates the use of competitive drug screening assays -
in which
neutralizing antibodies capable of binding PR020080 polypeptide specifically
compete with a test
compound for binding to PR020080 polypeptide or fragments thereof. In this
manner, the antibodies can
be used to detect the presence of any peptide which shares one or more
antigenic determinants with
PR020080 polypeptide.
EXAMPLE 18: Rational Drug Design
The goal of rational drug design is to produce structural analogs of
biologically active polypeptide
of interest (i. e. , a PR020080 polypeptide) or of small molecules with which
they interact, e. g. , agonists,
antagonists, or inhibitors. Any of these examples can be used to fashion drugs
which are more active or
stable forms of the PR020080 polypeptide or which enhance or interfere with
the function of the
PR020080 polypeptide in vivo (c.f., Hodgson, Bio/Technology, 9: 19-21 (1991)).
In one approach, the three-dimensional structure of the PR020080 polypeptide,
or of a
PR020080 polypeptide-inhibitor complex, is determined by x-ray
crystallography, by computer modeling
93
CA 02458751 2004-02-25
WO 03/055440 PCT/US02/24252
or, most typically, by a combination of the two approaches. Both the shape and
charges of the PR020080
polypeptide must be ascertained to elucidate the structure and to determine
active sites) of the molecule.
Less often, useful information regarding the structure of the PR020080
polypeptide may be gained by
modeling based on the structure of homologous proteins. In both cases,
relevant structural information is
used to design analogous PR020080 polypeptide-like molecules or to identify
efficient inhibitors. Useful
examples of rational drug design may include molecules which have improved
activity or stability as
shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as
inhibitors, agonists, or
antagonists of native peptides as shown by Athauda et al., J. Biochem.,
113:742-746 (1993).
It is also possible to isolate a target-specific antibody, selected by
functional assay, as described
above, and then to solve its crystal structure. This approach, in principle,
yields a pharmacore upon
which subsequent drug design can be based. It is possible to bypass protein
crystallography altogether by
generating anti-idiotypic antibodies (anti-ids) to a functional,
pharmacologically active antibody. As a
mirror image of a mirror image, the binding site of the anti-ids would be
expected to be an analog of the
original receptor. The anti-id could then be used to identify and isolate
peptides from banks of chemically
or biologically produced peptides. The isolated peptides would then act as the
pharmacore.
By virtue of the present invention, sufficient amounts of the PR020080
polypeptide may be made
available to perform such analytical studies as X-ray crystallography. In
addition, knowledge of the
PR020080 polypeptide amino acid sequence provided herein will provide guidance
to those employing
computer modeling techniques in place of or in addition to x-ray
crystallography.
The foregoing written specification is considered to be sufficient to enable
one skilled in the art to
practice the invention. The present invention is not to be limited in scope by
the construct deposited, since
the deposited embodiment is intended as a single illustration of certain
aspects of the invention and any
constructs that are functionally equivalent are within the scope of this
invention. The deposit of material
herein does not constitute an admission that the written description herein
contained is inadequate to enable
the -practice of any aspect of the invention, including the best mode thereof,
wor is it to be- construed as
limiting the scope of the claims to the specific illustrations that it
represents. Indeed, various
modifications of the invention in addition to those shown and described herein
will become apparent to
those skilled in the art from the foregoing description and fall within the
scope of the appended claims.
94
